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SUMMARY 
Apolipoprotein E (apoE denotes protein; APOE denotes gene) is a lipid-transport 
protein abundantly expressed in the brain and strongly upregulated after acute brain 
injury. The APOE E4 allele is the major genetic risk factor for Alzheimer's disease (AD) 
and has been associated with poorer outcome after various types of acute brain injury, 
including traumatic brain injury and subarachnoid haemorrhage. However, the role of 
APOE genotype in focal ischaemic stroke is less clear. The mechanism(s) by which 
APOE genotype may modulate outcome after acute brain injury are also unclear at 
present. Accordingly, the studies described in this thesis were undertaken to further 
address these issues. 
Endocytic pathway alterations in human temporal lobe after global 
cerebral ischaemia and association with APOE genotype 
The endocytic pathway is integral to the intemalisation and intracellular trafficking of 
apoE. Marked upregulation and neuronal accumulation of apoE occur after cerebral 
ischaemia. Alterations in this pathway are therefore a potential mechanism that could 
contribute to APOE genotype effects in the injured brain. In the present study, endocytic 
pathway activity was assessed in post-mortem temporal lobe sections from patients who 
experienced an episode of global ischaemia (and controls) using antibodies to markers 
of endocytic pathway activity - rabaptin-5 (intemalisation) and rab4 (recycling). 
Significant increases in the degree of neuronal rabaptin-5 and rab4 immunoreactivity 
were observed after global ischaemia, indicative of enhanced endocytic pathway 
activity in response to ischaemia. In addition, endocytic pathway alterations after global 
ischaemia were APOE genotype-dependent. There was a significant interaction between 
the effects of APOE genotype and an episode of global ischaemia on the degree of 
neuronal rab4 immunoreactivity. This indicated an attenuated endocytic recycling 
response after global ischaemia in APOE E4 carriers compared to individuals without an 
APOE E4 allele. 
Characterisation and validation of the intraluminal filament model of focal 
cerebral ischaemia in C57BI/6J mice 
The intraluminal occlusion model of transient focal ischaemia was established and 
characterised in C57B1I6J mice in order to systematically investigate the role of APOE 
genotype and endocytosis in cerebral ischaemia. The consequences of increasing 
XXI 
duration (15,30 and 6Omin) of intraluminal occlusion on ischaemic damage (24h post-
occlusion), cerebral blood flow and blood pressure were determined. The volume of 
ischaemic damage increased significantly with increasing occlusion duration, in part 
due to recruitment of tissue outside middle cerebral artery territory. The severity of 
cerebral hypoperfusion was significantly greater in 9 of 12 brain regions examined after 
60min compared to 15min occlusion. Blood pressure during 60min occlusion remained 
stable for 25min after occlusion onset and declined thereafter. Cerebrovascular anatomy 
was examined and showed that a complete circle of Willis was present in only 10% of 
mice. A temporal decline in mean arterial blood pressure and increase in the severity 
of cerebral hypoperfusion with increasing occlusion duration likely underlie the high 
sensitivity of ischaemic damage to increasing occlusion duration. 
Association between APOE genotype and differences in outcome and 
endocytic pathway alterations after focal cerebral ischaemia in mice 
Characterisation of the intraluminal occlusion model enabled the effects of APOE 
genotype on outcome and endocytic pathway alterations to be investigated in APOE 
transgenic mice. Ischaemic damage, neurological deficit, and apoE and endocytic 
pathway alterations were assessed 24h after 15min focal ischaemia in mice expressing 
human APOE 83 or APOE 84. The volume of ischaemic damage and neurological 
deficit score were significantly greater in APOE 84 mice, indicating a poorer outcome 
associated with APOE 84. The volume of ischaemic damage correlated with 
neurological deficit. Focal ischaemia induced increased apoE immunoreactivity in areas 
of ischaemic damage in both APOE 83 and APOE 84 mice. The volume of apoE 
immunoreactivity correlated with the volume of ischaemic damage and was 
significantly greater in APOE 84 mice. Increased immunoreactivity of the endocytic 
markers, rabaptin-5 and rab4 were also observed in areas of ischaemic damage 
indicating elevated endocytic pathway activity in response to focal ischaemia. These 
alterations were APOE-genotype dependent. The degree of rab4 immunoreactivity was 
significantly greater in APOE 83 compared to APOE 84 mice suggesting an attenuated 
endocytic recycling response associated with the APOE 84 allele. APOE genotype-
dependent differences in endocytic pathway alterations could modulate the response to 
cerebral ischaemia by influencing the intracellular trafficking of apoE and its 
interactions with cellular elements. 
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Adenovirus-mediated gene transfer of APOE e3 markedly reduces 
ischaemic brain damage after focal cerebral ischaemia in mice 
A better outcome after focal ischaemia in APOE E3 mice (as determined in this thesis) is 
consistent with a number of previous studies showing favourable effects associated with 
the APOE E3 allele. Since exogenous administration of apoE has previously conferred 
neuroprotection after acute brain injury, increasing apoE3 levels to promote the 
beneficial effects of this isoform is a relevant strategy to improve outcome after focal 
ischaemia. In this study, a 2nd generation adenoviral vector containing the "beneficial" 
APOE E3 gene (Ad-APOE) was injected into the brain 3d prior to 60min focal 
ischaemia and outcome was determined 24h post-ischaemia. The volume of ischaemic 
damage was significantly reduced by 50% in Ad-APOE treated mice compared to mice 
treated with a control vector (Ad-GFP) or vehicle. There was a trend toward a lower 
neurological deficit score in Ad-APOE treated mice, although this did not reach 
statistical significance. ApoE immunohistochemistry and ELISA showed that levels of 
apoE were significantly increased in mice treated with Ad-APOE compared to a control 
vector (Ad-GFP) or vehicle. Thus, the neuroprotective effects achieved by adenoviral 
vector-mediated APOE E3 gene transfer may be mediated by elevated apoE3 levels and 
suggest that manipUlation of apoE-sensitive mechanisms could be a realistic therapeutic 
strategy in human stroke. 
The data presented in this thesis indicate an important role for APOE genotype in 
modulating outcome after ischaemic brain injury, further highlighting the favourable 
effects associated with the APOE E3 allele. APOE genotype-dependent alterations in the 
endocytic pathway are mechanisms which could contribute to differences in outcome. 
These data also highlight the neuroprotective effects achieved by manipulating apoE 
levels to promote the beneficial effects of apoE3. An apoE-based therapeutic strategy 
may be a potential approach for treatment of ischaemic brain injury in humans. 
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Chapter 1 
Introduction 
1.1 Cerebral ischaemia 
The structural and functional integrity of the brain requires a continuous and adequate 
supply of oxygen and metabolic substrate (glucose) to meet the high metabolic demands 
of brain tissue. Cerebral ischaemia refers to a condition where there is inadequate 
cerebral blood flow to meet these demands with the consequence that normal brain 
function is perturbed. Cerebrovascular disease resulting from cerebral ischaemia is the 
third leading cause of death in developed countries behind ischaemic heart disease and 
cancer (Dimagl et al., 1999). Cerebrovascular disease is also the most common cause of 
long-term neurological disability in the adult population (Wolfe, 2000). As a 
consequence, treatment of cerebrovascular disease consumes a large proportion of the 
economic resources of health-care systems (Terent et al., 1994; Rothwell, 2001). 
Furthermore, cerebral ischaemia is a major feature and cause of mortality and morbidity 
after traumatic brain injury resulting from head trauma (Graham et al., 1978; Graham et 
al., 1989), the leading cause of death under the age of 45 (Baethmann et al., 1998). 
Significantly, there is no current effective treatment for ischaemic brain damage that is 
in widespread use. Thus, in view of the prevalence of ischaemic brain damage in brain 
injury and disease and the severity and impact of its sequelae on society, further 
understanding of the aetiology and pathophysiology of cerebral ischaemia and 
development of novel treatments are imperative. 
There is increasing awareness of the important roles that genetic factors may play 
in modulating the risk of and outcome to cerebral ischaemia and their effects on the 
pathophysiology of ischaemic brain damage (Carr et al., 2002; Alberts, 2003). Strong 
clinical evidence indicates a role for polymorphism in the apolipoprotein E (APOE 
denotes gene; apoE denotes protein) gene in outcome from various types of acute brain 
injury, although results have been inconclusive with regard to ischaemic stroke. A 
major aim of this thesis was to further investigate the effects of APOE polymorphism in 
a model of focal ischaemia. A potential mechanism - endocytic pathway alterations -
by which APOE genotype may modulate the susceptibility of the brain to injury, was 
also investigated. In addition, the potential of exogenously administered apoE (via viral 
vector) to modulate ischaemic brain damage was determined. 
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1.1.1 Focal cerebral ischaemia 
Two major types of cerebral ischaemia, focal and global (see section 1.1.2), are 
recognised based on the anatomical distribution of the ischaemic insult. Focal cerebral 
ischaemia occurs when there is diminished cerebral blood flow to a discrete brain 
region. In humans, when the ischaemic insult is severe enough, focal (or global) 
neurological deficits present clinically, a condition referred to as "stroke" if such 
deficits persist for longer than 24h or lead to death and have no apparent cause other 
than a vascular one (as defined by WHO). The most rigorous studies have indicated 
stroke incidence rates of approximately 300 - 500 per 100,000 in white populations 
(Sudlow and Warlow, 1997). The incidence of stroke increases dramatically with age, 
with three-quarters of all first strokes occurring after the age of 65, at least in white 
populations (Sudlow and Warlow, 1997). Overall, approximately 30% of hospitalised 
patients die within one year of a stroke (Warlow et ai., 2003). 
1.1.1.1 Aetiology 
The underlying cause of focal cerebral ischaemia in stroke may be occlusive 
(thrombotic or embolic blockage of an artery) or haemorrhagic (bleeding from a 
ruptured artery) in origin. The majority (approximately 80% in white populations) of 
strokes result from thrombotic or embolic occlusion of an artery (for review see Kalimo 
et ai., 2002). The middle cerebral artery (MCA) is the most commonly occluded 
intracranial vessel (Derouesne et ai., 1993), which may be due to its relatively large size 
and proportion of blood flow and proximity to the internal carotid artery from which 
circulating emboli may pass into the MCA (McAuley, 1995). The territory supplied by 
the MCA includes motor and somatosensory cortex, the striatum and the internal 
capsule. Consequently, ischaemic damage is observed in these areas in a high 
proportion of strokes. The clinical importance of the MCA in human stroke is reflected 
by the development of numerous animal models of focal cerebral ischaemia that involve 
MCA occlusion (see section 1.1.4). 
Spontaneous intracranial haemorrhage is the underlying cause in approximately 
20% of first-time strokes (Warlow et ai., 2001). The two major types of intracranial 
haemorrhage are intracerebral and subarachnoid, which account for approximately 15% 
and 5% of strokes (in white popUlations) (Warlow et ai., 2001). Intracerebral 
haemorrhage (ICH) is associated with fonnation of an intraparenchymal haematoma 
that may result in raised intracranial pressure, displacement of deep brain structures and 
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loss of consciousness (Massaro et ai., 1991). Hypertension is the most important cause 
of ICH and is primarily associated with haemorrhages located deep within the brain 
(caudate nucleus, putamen, cerebellum, brainstem). Cerebral amyloid angiopathy 
(CAA), a condition involving deposition of the ~-amyloid protein in the walls of 
cerebral blood vessels, is also a major cause of ICH, particularly lobar haemorrhages 
located more superficially in the cerebral hemispheres (Massaro et ai., 1991). 
Subarachnoid haemorrhage (SAH) most frequently results from the rupture of a saccular 
aneurysm in a vessel on the brain surface leading to bleeding in to the subarachnoid 
space. Both SAH and ICH are associated with poorer clinical prognosis compared to 
occlusive stroke with mortality rates as high as 50% (Camarata, 1994). 
1. 1. 1.2 CBF thresholds in focal ischaemia 
Irrespective of the proximate cause of focal ischaemia, a characteristic topographical 
pattern develops consisting of a dense core region of hypoperfusion separated from 
normally perfused tissue by a zone of intermediate ischaemia, termed the ischaemic 
"penumbra" (Astrup et ai., 1981). This gradient of cerebral blood flow is associated 
with the development of irreversible damage in the ischaemic core and potentially 
reversible dysfunction in the surrounding tissue. Underlying this pattern is a series of 
critical thresholds of cerebral blood flow (CBP) at which various electrophysiological 
and biochemical alterations occur ultimately leading to irreversible injury. Experimental 
MCA occlusion in baboons and cats has shown that neuronal electrical function is 
affected when CBP falls below 40% (20mVlOOg/min) of the normal value and is 
completely lost when CBP is 30% of the normal level. (Branston et ai., 1974; Heiss et 
ai., 1976). At this level of perfusion, ionic homeostasis and structural integrity is 
maintained. Ionic pump failure and accompanying membrane depolarisation and 
potassium efflux do not occur until CBP is further reduced to approximately 15% (10-
12mVlOOg/min) of normal levels (Astrup et ai., 1977; Branston et ai., 1977). Ionic 
pump and membrane failure results in energy metabolism failure and irreversible 
neuronal injury unless adequate perfusion is restored. The concept of the ischaemic 
penumbra arose from the above studies and describes the zone oftissue surrounding the 
central core that is perfused at a level between the upper threshold of electrical failure 
and the lower threshold of energy failure and ionic pump failure (Astrup et ai., 1981). 
Cells in this zone are therefore considered to be functionally impaired but structurally 
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intact. The existence of a spectrum of cerebral hypoperfusion and the ischaemic 
penumbra has also been demonstrated in rodent models of MCA occlusion using 
autoradiographic techniques (Memezawa et az', 1992; Belayev et a/., 1997; Hata et a/., 
1998; Ginsberg, 2003) and in human stroke patients by the use of PET and CT scanning 
(Hakim et a/., 1989; Kaufmann et a/., 1999; Heiss et a/., 2001). 
1.1.1.3 Neuropathology 
Pathologically, focal ischaemia is characterised by damage to a discrete brain region, for 
example, the territory of the MCA in the event this artery is occluded (Figure 1). The 
extent of ischaemic pathology following a focal ischaemic insult is strongly dependent 
on both the severity and duration of hypoperfusion (Figure 2). Studies assessing both 
CBF deficits and the topography and severity of histopathology after MCA occlusion in 
primates, cats and rats have demonstrated correlations between the level of 
hypoperfusion and the degree of ischaemic pathology suggesting that ischaemic 
thresholds for infarction (necrosis of all tissue elements) also exist (Morawetz et a/., 
1979; Tamura et aJ., 1980; Jones et aJ., 1981; Heiss, 1983; Tyson et aJ., 1984; 
Nagasawa et a/., 1989). Systematic experiments using MCA occlusion in rats have 
shown that the infarcted core corresponds to tissue with CBF less than 20% of normal 
levels, whereas, in the surrounding penumbra as CBF rises the risk of infarction 
declines (Memezawa et a/., 1992; Belayev et a/., 1997; Zhao et a/., 1997) A similar 
relationship between CBF deficits and the risk of infarction has also been shown in 
human stroke patients (Kaufmann et a/., 1999; Heiss et ai., 2001). The nature and 
development of ischaemic damage is also strongly dependent on the duration of the 
ischaemic insult (Jones et ai., 1981; Kaplan et ai., 1991) such that short periods of 
severe ischaemia or longer durations of milder hypoperfusion are both capable of 
inducing irreversible damage or infarction (Figure 2). Pathologically, permanent 
occlusion or extensive durations of transient occlusion (6 - 8h) of the MeA are 
associated with necrosis of all tissue elements (neurons, glia, vascular cells), or 
infarction, in the ischaemic core. The core is frequently surrounded by a thin zone of 
tissue displaying scattered neuronal damage reflecting the penumbral zone of 
intermediate ischaemia (Nedergaard, 1988). In contrast, focal ischaemia of short 
duration and/or moderate severity may produce only areas of selective neuronal necrosis 
(incomplete infarction) or a combination of infarcted areas and areas of selective 
neuronal injury (DeGirolami et ai., 1984; Nedergaard, 1987). 
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Figure 1. Focal ischaemic brain damage 
Focal cerebral ischaemia typically produces damage in a discrete brain region . In this 
photomicrograph, the area of pallor (circumscribed area) represents the area of 
ischaemic damage which is confined to MCA territory. Photomicrograph shows a fresh-
frozen haematoxylin and eosin stained section from a rat brain 24h after electro-
coagulation of the MCA. Figure courtesy of Prof James McCulloch. 
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Figure 2. Influence of duration and severity of focal ischaemia on extent of 
damage 
Development of irreversible brain damage (infarction) is acutely related to the severity 
of reduction in cerebral blood flow and the duration of the hypoperfusion. Adapted from 
Jones et al. (1981), data are from MCA occlusion in non-human primates. 
6 
1.1.2 Global cerebral ischaemia 
1.1.2.1 Aetiology 
Global cerebral ischaemia occurs when the blood supply to the entire brain is 
interrupted or severely reduced. In humans, the clinical syndrome resulting from global 
ischaemia is termed hypoxic-ischaemic encephalopathy. This condition is most often 
the result of cardiac arrest and resultant failure of the systemic circulation. 
Approximately 10 - 20% of cardiac arrest patients show a recovery after resuscitation, 
however, coma or persistence in a vegetative state and subsequent death within a few 
weeks are the most likely outcomes (Roine et al., 1993; Bassetti et al., 1996). In 
survivors of cardiac arrest, the neurological sequelae of global cerebral ischaemia are a 
major cause of morbidity with neuropsychological deficits prominent (Roine et al., 
1993; Rempel-Clower et al., 1996). Other causes of global ischaemia include raised 
intracranial pressure as occurs following head trauma, severe arterial hypotension, 
carbon monoxide poisoning and heat stroke (cerebral hyperthermia). 
Global ischaemia, like focal, can be either transient or permanent. Transient global 
ischaemia has assumed greater clinical relevance since permanent global ischaemia is 
generally synonymous with death. Transient global ischaemia is associated with a 
characteristic pattern of ischemic damage in which selective and delayed neuronal death 
is observed in selectively vulnerable regions of the brain. 
1.1.2.2 Selective vulnerability and delayed neuronal damage 
Development of selective neuronal damage in specific neuroanatomical locations is a 
feature of transient global ischaemia in both humans and animal models. These 
selectively vulnerable regions include the hippocampus, cerebral cortex, striatum and 
thalamus (jor review see Auer and Sutherland, 2002). Hierarchies of vulnerability also 
exist within these susceptible regions, the precise pattern being dependent on the species 
and severity of ischaemia. For example, in the hippocampus, the pyramidal neurons of 
the CAl sector have been shown to be the cells most susceptible to a mild global 
ischaemic insult in humans (Auer and Sutherland, 2002), gerbils (Kirino, 1982; Kirino 
and Sano, 1984) and rats (Smith et al., 1984) (Figure 3). When the duration/severity of 
ischaemia is increased neuronal damage is also evident in the CA3 and CA4 sectors and 
even in the normally resistant dentate gyrus (Smith et al., 1984; Auer and Sutherland, 
2002). In contrast, in the mouse, neurons of the hippocampal CA2 sector and the 
caudate nucleus are most vulnerable to global ischaemia (Horsburgh et al., 1999b; Kelly 
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et at., 200lb). The mechanisms underlying selective vulnerability are incompletely 
understood. One possible explanation in the hippocampus is that the vulnerable CA 1 
pyramidal neurons have a relatively greater abundance of NMDA receptors than 
adjacent sectors suggesting that these neurons may be more susceptible to glutamate-
mediated excitotoxicity (Greenamyre et at., 1985; Monaghan and Cotman, 1985). 
Delayed neuronal death was described following observations in the hippocampus 
of rodents subjected to brief periods of global ischaemia (Ito et at., 1975; Kirino, 1982; 
Pulsinelli et at., 1982; Kirino and Sano, 1984; Smith et at., 1984). The principal 
observation was that hippocampal neurons displaying characteristic ischaemic 
morphology were largely absent a few hours after the ischaemic insult but substantially 
increased after 2 - 3 days (Kirino, 1982; Pulsinelli et at., 1982) (Figure 3). Delayed 
neuronal death is therefore thought to reflect neuronal degeneration that slowly matures 
hours to days after transient global ischaemia. Evidence of delayed neuronal damage in 
the hippocampus after global ischaemia (due to cardiac arrest) has also been observed in 
humans (Petito et at., 1987; Hom and Schlote, 1992). 
Caudate 
nucleus 
Hippocampus 
Sham Global ischaemia 
24h post-
ischaemia 
72h post-
ischaemia 
Figure 3. Selective and delayed neuronal damage after global ischaemia 
The caudate nucleus and hippocampal CA1 sector (arrows) are particularly vulnerable 
to neuronal damage after global ischaemia. Delayed neuronal damage (e.g. 72h post-
ischaemia) is a feature of global ischaemia, particularly in the hippocampus. Images, 
courtesy of Dr Karen Horsburgh, show tissue from rats after transient global ischaemia. 
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1.1.3 Involvement of cerebral ischaemia in traumatic brain injury 
Cerebral ischaemia is also a major sequel of head trauma and resultant traumatic brain 
injury (TBI). TBI is the leading cause of mortality in those aged less than 45 years and 
also causes severe morbidity (Baethmann et al., 1998). The prevalence of ischaemic 
brain damage after non-missile head injury was first recognised in the 1970s. In a 
comprehensive study involving 151 fatal head injuries, neuropathological evidence of 
ischaemic brain damage was observed in 138 (91 %) individuals (Graham et al., 1978). 
The basal ganglia and hippocampus were the most affected areas. In a follow-up study a 
decade later, a similar prevalence (88%) of ischaemic damage was reported despite 
improvements in management of head-injured patients (Graham et al., 1989). Studies 
assessing CBF after head injury have demonstrated that cerebral hypoperfusion is a 
feature of the acute (hours) phase after injury (Bouma et al., 1992; Sahuquillo et al., 
1993; Schroder et a!., 1995; Brown et al., 1998). CBF deficits may be focal or global in 
nature and levels below the threshold for infarction have been reported in the 4 - 6 
hours after injury (Bouma et al., 1992; Saluquillo et al., 1993; Schroder et al., 1996). 
Furthermore, correlations between the degree of CBF deficit and Glasgow Coma Score 
during the first 24 hours have been shown (Marion et al., 1991; Robertson et al., 1992; 
Kelly et a!., 1997). The clinical importance of cerebral ischaemia in TBI is highlighted 
by the indication that hypoxic/ischaemic brain damage is one of the principal factors 
governing outcome and the degree of morbidity after head injury (Graham et al., 2002). 
1.1.4 Animal models of cerebral ischaemia 
1. 1.4. 1 Importance and utility of animal models 
The development of animal models of cerebral ischaemia has been central to the 
elucidation of key features of cerebral ischaemia such as the concepts of the ischaemic 
penumbra and delayed neuronal damage described above. The utility of animal models 
of cerebral ischaemia (and models of other nervous system pathologies) is underscored 
by a number of factors. The capacity to directly investigate pathophysiological features 
underlying diseases of and injuries to the nervous system in humans is limited, most 
notably due to important ethical considerations. In addition, human disease is often 
sporadic, random and variable, factors that do not facilitate dissection of molecular and 
biochemical mechanisms of disease. Consequently, a number of animal models of brain 
injury and disease have been developed that offer greater reproducibility and control of 
confounding variables and therefore enable more systematic investigation of 
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pathophysiology and therapeutic strategies. With regard to cerebral ischaemia there are 
a number of specific advantages of animal models. These include the absence of co-
morbidity such as diabetes or hypotension and precise control over the location, 
duration and severity of the ischaemic insult, factors which may hamper interpretation 
of results in the clinical setting. Furthermore, in view of the development and increasing 
availability of genetically modified mice, the use of models of cerebral ischaemia in this 
species enables evaluation of the influence that single genes and their gene products 
may have in cerebral ischaemia. This powerful approach was exploited in this thesis to 
investigate the influence of polymorphism in the apolipoprotein E gene in cerebral 
ischaemia (chapter 5). 
Initial models of cerebral ischaemia were developed in large animal species 
(primates, cats, rabbits), the major advantage of which is their homology with humans, 
particularly with regard to the primate brain. However, due to considerable ethical 
concerns over use of sub-human primates in experimental research and their high costs, 
their use has declined and the majority of studies are now performed in rodents. Rodents 
are particularly suitable for study for a number of reasons including: (1) similarities 
between the anatomy of the intracranial circulation of rodents and man, (2) availability 
of detailed information on gross rodent brain anatomy and organisation of 
neurotransmitter systems, (3) relatively low maintenance and procedural costs on 
account of their small size. With specific regard to the mouse, the development of 
genetically modified strains is the major factor underlying their increasing use in 
cerebral ischaemia research (and other fields). Rodent models of both focal and global 
cerebral ischaemia have been successfully developed to simulate the corresponding 
clinical conditions of stroke and cardiac arrest. Throughout this thesis, a mouse model 
of focal cerebral ischaemia was used and therefore this section will focus on the 
development of the model and its important features. 
1.1.4.2 Rodent models of focal cerebral ischaemia 
MCA occlusion in the rat was first described in 1975 (Robinson et ai., 1975) using a 
trans-cranial approach to ligate the distal portion of the MCA and which produced a 
cortical lesion. Subsequent modifications of this technique enabled a striatal component 
to be incorporated into the ischaemic lesion (Albanese et ai., 1980; Tamura et ai., 
1981). The Tamura model has been central to the understanding and evaluation of 
various therapeutic agents such as glutamate receptor (NMDA) antagonists (park et ai., 
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1988c; Bielenberg and Beck, 1991}. With regard to human stroke, however, a major 
limitation of these models was the inability to induce recirculation through the occluded 
vessel, an event that occurs spontaneously in the majority of human strokes and, via 
thrombolytic agents, is a major clinical strategy for treating stroke patients (Ringelstein 
et ai., 1992). These factors instigated the development of models that permit a transient 
period of ischaemia followed by a period of reperfusion. The most extensively used 
model incorporating reperfusion is the intraluminal filament occlusion model. 
1. 1.4.3 Intraluminal filament occlusion model 
The intraluminal filament occlusion model of focal cerebral ischaemia was used 
throughout this thesis. Intraluminal occlusion involves the introduction of a filament of 
pre-determined diameter into the external or common carotid artery that is then 
advanced along the internal carotid artery until the filament tip is located in the 
proximal portion of the anterior cerebral artery and therefore blocking the origin of the 
MCA (section 2.3.2). Restoration of blood flow through the MCA is achieved by 
withdrawal of the filament and closure of the arteriotomy. Additional advantages of this 
model in comparison to the Tamura model include the avoidance of craniectomy and 
thermal and mechanical brain damage caused by electrocoagulation. Intraluminal 
filament occlusion was initially developed in rats using a silicon-treated (Koizumi et ai., 
1986) or heat-blunted (Longa et ai., 1989) filament tip to occlude the origin of the 
MCA. In common with other models of brain injury, adaptation of the intraluminal 
filament model for use in mice was prompted by the development and rapidly 
increasing availability of genetically modified mice. 
1. 1.4.4 Mouse strain differences in susceptibility to cerebral ischaemia 
The increasing use of different mouse strains has highlighted the effect of inter-strain 
differences in the sensitivity to cerebral ischaemia and is particularly relevant to 
intraluminal occlusion. Understanding the inherent features of the background strain of 
genetically modified mice is therefore an important element in ischaemia research. The 
C57B1I6J mouse is the most common background strain used to generate genetically 
modified mice. In this thesis, the transgenic mice expressing human APOE were 
developed on a C57B1I6J background. Studies have demonstrated an increased 
vulnerability of the C57B1I6J strain to focal and global ischaemia in comparison to other 
strains such as DBAl2, MFI and 129/Sv (Barone et a/., 1993; Connolly et a/., 1996; 
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Fujii et ai., 1997; Yang et ai., 1997a; Kitagawa et ai., 1998c; Kelly et ai., 2001b; Majid 
et al., 2001). The relative vulnerability of the C57B1J6J mouse has been ascribed to the 
absence of one or both posterior communicating arteries (PcomAs) (Fujii et al., 1997; 
Yang et al., 1997a; Kitagawa et al., 1998c; Kelly et ai., 2001b). These arteries connect 
the anterior and posterior portions of the circle of Willis with blood flow derived from 
the internal carotid and vertebral arteries respectively. The PcomA is important for 
perfusion of structures outside MCA territory (such as the hippocampus) during 
intraluminal filament occlusion. 
The topography and distribution of ischaemic damage following intraluminal 
occlusion in the mouse differs from that observed in rats and may be related to PcomA 
hypoplasticity. In the mouse, the ischaemic lesion lies more posteriorly in the 
hemisphere such that ischaemic damage has been consistently observed in the thalamus 
and hippocampus, structures not commonly affected in the rat (Belayev et al., 1999). 
Variability in the extent of ischaemic damage has been widely reported following 
transient intraluminal occlusion in both mice and rats (Connolly et al., 1996; Clark et 
al., 1997; Takano et ai., 1997) as has a relatively high mortality rate in comparison to 
permanent models of MCA occlusion (Koizumi et al., 1986; Longa et ai., 1989; 
Connolly et ai., 1996; Kitagawa et ai., 1998c). In this thesis, comprehensive 
characterisation of the intraluminal filament model was performed in the mouse in order 
to assess the variables described above and enable optimisation of the technique. 
1.1.5 Pathophysiology of ischaemic cell death 
1. 1.5. 1 Necrosis and apoptosis 
Cell death following ischaemic brain damage may involve both necrotic and apoptotic 
mechanisms with the predominating mode likely dependent on intrinsic (e.g. cell type) 
and extrinsic (e.g. nature and severity of insult) factors (Martin et ai., 1998; Snider et 
ai., 1999; Leker and Shohami, 2002). 
Necrotic cell death occurs only after an exogenous insult and is thought to represent 
the most prevalent fonn of ischaemic cell death (Lipton, 1999). Briefly, necrosis is 
characterised by pronounced darkening and shrinkage of the nucleus and cytoplasm 
with the cell often assuming a triangular shape (Brown and Brierley, 1972). 
Cytoplasmic changes include markedly swollen mitochondria, disruption of the Golgi 
and endoplasmic reticulum organisation and disappearance of polyribosomes (Brown 
and Brierley, 1972). The cytoplasm is strongly acidophilic, a defining feature of this 
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form of cell death, which can be identified under the light microscope with use of acidic 
dyes such as eosin. Morphological evidence of necrotic cell death has been widely 
described after focal ischaemia where it is thought to be the predominant form of cell 
death (DeGirolami et al., 1984; Lipton, 1999; Snider et aI, 1999) and has also been 
observed after global ischaemia in rodents (Kirino and Sano, 1984; Kirino et al., 1984; 
Petito and Pulsinelli, 1984). 
Apoptosis can occur under normal physiological conditions, in particular during 
development (Kerr et al., 1972; Johnson and Deckwerth, 1993), or be activated by 
various types of insult, including cerebral ischaemia (Snider et aI, 1999). In contrast to 
necrosis, apoptosis is primarily a nuclear event. Characteristic morphological features 
include the formation of regularly-shaped masses of chromatin within the nucleus and 
the formation of apoptotic bodies in the cytoplasm (Arends and Wyllie, 1991). Unlike 
necrosis, cytoplasmic organelles appear relatively normal and the cytoplasm does not 
become acidophilic (Arends and Wyllie, 1991; Martin et al., 1998). A strong indicator 
of apoptosis is the breakdown of DNA into nucleosomal fragments (DNA laddering) 
180 - 200 base pairs in length (Arends et al., 1990; Orrenius, 1995) that can be 
identified using the terminal deoxynucleosidyl transferase (TdT)-mediated biotinylated 
deoxyuridine triphosphate (dUTP) nick end labelling (TUNEL) technique (Gavrieli et 
al., 1992). This pattern of DNA fragmentation is not an explicit marker of apoptosis, 
however, since it may occur during necrosis and therefore ultrastructural confirmation is 
required. There is strong morphological (formation of spherical chromatin masses and 
apoptotic bodies) and biochemical (DNA fragmentation, caspase activation, cytochrome 
c release from mitochondria) evidence that apoptosis can occur after focal ischaemia, 
particularly in regions where the insult is less severe (e.g. penumbra) (Li et al., 1995a; 
Li et al., 1995b; Linnik et aI., 1995; Charriaut-Marlangue et al., 1996; Du et al., 1996). 
It has been proposed that the delayed neuronal damage observed after global ischaemia 
may reflect apoptosis (Nitatori et al., 1995). Although there is biochemical evidence to 
support this, morphological evidence of apoptosis after global ischaemia is weak (for 
review see Lipton, 1999). 
The initiating event in cerebral ischaemia that ultimately leads to ischaemic cell 
death is energy failure, which in turn activates a number of pathogenetic mechanisms 
that culminate in cell death (necrotic and/or apoptotic) (Figure 4). These include 
excitotoxicity, oxidative stress, inflammation and induction of pro-apoptotic factors that 
mediate damage through their impact on important subcellular components. 
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Figure 4. Simplified schema of pathophysiological mechanisms after 
ischaemic brain injury 
Energy failure and membrane depolarisation cause excessive glutamate release which 
triggers a number of pathological processess including excitotoxicity, oedema, free radical 
formation and oxidative stress, mitochondrial damage, apoptosis and inflammation. 
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1. 1.5.2 Glutamate and excitotoxicity 
Glutamate is generally accepted as being the major excitatory neurotransmitter in the 
brain (Monaghan et ai., 1989) and is integral to normal neuronal function. However, the 
neurotoxic potential of glutamate is well established and is thought to playa key role in 
the pathophysiology of ischaemic cell death (Olney, 1978). Microdialysis has shown 
that normal levels of extracellular glutamate in the brain are 1 - 5JlM (Butcher et ai., 
1990; Wahl et ai., 1994) but are substantially increased after focal (Butcher et ai., 1990; 
Wahl et ai., 1994) and global (Benveniste et ai., 1984) ischaemia. Elevated glutamate 
arises from energy depletion, loss of ionic homeostasis and resultant cellular 
depolarisation. Presynaptic voltage-dependent calcium channels are activated that in 
turn trigger glutamate release into the extracellular space. Other energy-dependent 
processes, notably neurotransmitter reuptake mechanisms are also impeded, which 
further elevates extracellular glutamate levels (Dimagl et ai., 1999). Elevated 
extracellular glutamate over-activates the ionotropic NMDA and AMP A receptors and 
leads to an excessive influx of Ca2+, Na+ and K+. A key event in excitotoxicity is the 
excessive influx of Ca2+ and ensuing calcium overload. Acting as a universal second 
messenger, an array of downstream processes is triggered by an increase in intracellular 
Ca2+ that can have detrimental effects on cellular integrity (Choi, 1988; Kristian and 
Siesjo, 1998; Arundine and Tymianski, 2003). These include direct activation of various 
enzymes such as proteases, phospholipases, and endonucleases that may result in 
structural damage to key cellular components (Leker and Shohami, 2002; Lo et ai., 
2003). Other important processes triggered by an increase in intracellular Ca2+ are 
oxidative stress and apoptotic pathways (see section 1.1.5.4). 
The most compelling evidence to support the role of glutamate-mediated 
excitotoxicity in ischaemic brain damage has arisen from numerous studies showing 
that ionotropic glutamate receptor antagonists are neuroprotective in experimental 
models of cerebral ischaemia (Simon et ai., 1984; Park et ai., 1988b; Park et ai., 1988c; 
McCulloch, 1992). 
1.1.5.3 Free radicals and oxidative stress 
Oxidative stress results when the generation of free radical species and their products 
exceeds intrinsic antioxidant capacity. Important free radicals include the reactive 
oxygen species (superoxide radical, hydroxyl radical, hydrogen peroxide), nitric oxide 
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and peroxynitrite. After brain injury, abnormally high production of free radicals 
overwhelms endogenous scavenging mechanisms (Lo et al., 2003). A multiplicity of 
mechanisms is involved in the genesis of these reactive oxygen and nitrogen species 
(Lipton, 1999; Lewen et al., 2000; Tyurin et al., 2000; Chan, 2001). Of particular 
importance is the elevation of intracellular Ca2+ resulting from glutamate receptor 
activation. Irrespective of their source, however, the toxicity of free radicals results 
from their modification of macromolecules, namely lipids, carbohydrates, proteins and 
nucleic acids that critically alter cellular function. The importance of oxidative stress 
following cerebral ischaemia has been highlighted by studies in genetically modified 
mice either over-expressing or deficient in antioxidant enzymes (Chan et al., 1995; 
Chan, 2001). Reduction of ischaemic damage after focal ischaemia has been 
demonstrated in mice over-expressing the copper, zinc superoxide dismutase (CuZn-
SOD) gene (Kinouchi et al., 1991; Noshita et al., 2002; Saito et al., 2003). An extensive 
number of studies have also shown that administration of agents with antioxidant 
properties (e.g. vitamin E, SOD enzymes, ebselen, tirilazad) confers neuroprotection in 
rodent models of cerebral ischaemia. 
1. 1.5.4 Induction of apoptotic pathways 
Glutamate receptor over-activation and calcium overload are key events following brain 
injury that can induce a number of pro-apoptotic pathways (Zipfel et al., 2000) 
including caspase activation and induction of pro-apoptotic members of the bcl family. 
Excessive production of free radicals is also an important mechanism leading to caspase 
activation via cytochrome c release from mitochondria (Skulachev, 1998; Sugawara et 
al., 2002). Pharmacological and genetic manipulation of molecules involved in 
apoptotic pathways has provided evidence for the importance of apoptotic cell death 
after ischaemic injury. Administration of small peptide inhibitors of caspases reduces 
the amount of tissue damage, TUNEL-positive staining and attenuates neurological 
deficit after experimental focal ischaemia (Hara et al., 1997; Mouw et al., 2002). 
Furthermore, transgenic and viral vector mediated overexpression of survival promoting 
members of the bcl-2 family, such as bcl-2 and bel-XL, have neuroprotective effects in 
models of cerebral ischaemia (Martinou et al., 1994; Kitagawa et al., 1998b; Kilic et al., 
2002; Zhao et al., 2003). 
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1.1.5.5 Inflammation 
Experimentally and clinically, an acute and prolonged inflammatory response follows 
cerebral ischaemia (Zhang and Stanimirovic, 2002; Allan and Rothwell, 2003). 
Production and activation of inflammatory mediators such as complement, adhesion 
molecules and cytokines - notably interleukin-1 and tumour necrosis factor-a - are 
substantially increased in injured cells as early as I hour after an ischaemic insult 
(Rothwell and Hopkins, 1995; Feuerstein et al., 1997; Feuerstein et al., 1998). These 
mediators promote inflammatory responses by stimulating expression of adhesion 
molecules that facilitate the migration of inflammatory cells such as neutrophils, 
macrophages and monocytes into the injured brain (del Zoppo et at., 2000). Resident 
brain microglia also contribute to the acute inflammatory response becoming activated 
within 4 - 6 hours after injury and producing a well developed microglial response by 
24 hours (Dimagl et at., 1999). Administration and viral vector-mediated 
overexpression of the interleukin-1 receptor antagonist has been shown to reduce 
ischaemic brain damage (Betz et at., 1995; Loddick and Rothwell, 1996; Yang et at., 
1997b; Yang et at., 1999; Tsai et at., 2003). 
1. 1.5.6 Endogenous protective mechanisms 
In addition to the above mediators of ischaemic damage, cerebral ischaemia also 
induces synthesis and activation of a variety of molecules that are potentially protective. 
Among these, evidence of protective effects is strongest for heat shock proteins and 
neurotrophic factors (Lipton, 1999; Leker and Shohami, 2002). 
Expression of the heat shock proteins HSP70 and HSP72 is induced after global 
ischaemia in rodents (Nowak, 1985; Dienel et at., 1986; Nowak, 1991; Simon et al., 
1991; Kawagoe et at., 1992; Liu et at., 1993; Nishino and Nowak, 2004). Studies 
examining HSP immunoreactivity have shown that increased HSP70 immunoreactivity 
is most prominent in less vulnerable regions (dentate gyrus, CA3) but minimal in the 
vulnerable CAl sector of the hippocampus (Vass et al., 1988; Kawagoe et al., 1992). 
After focal ischaemia, neurons in the core rarely display HSP70 immunoreactivity, 
whereas in the penumbra there is marked induction of HSP70 mRNA and neuronal 
HSP70 immunoreactivity suggesting that HSP70 may confer resistance to damage 
(Kinouchi et at., 1993; Li et ai, 1993). Over-expression of HSP by viral vectors or 
genetic manipulation confers neuroprotection in models of focal and global ischaemia 
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(Rajdev et aI., 2000; Kelly et ai., 2001a; Tsuchiya et ai., 2003b) while HSP knockouts 
display greater ischaemic damage (Lee et ai., 2001). 
Neurotrophic factors (NTFs) are vital for the survival and differentiation of 
normally developing neurons but are also thought to be integral to neuroprotective 
pathways under pathological conditions (Abe, 2000). Induction of several types of 
NTFs occurs in response to cerebral ischaemia, including nerve growth factor (NGF), 
brain derived neurotrophic factor (BDNF) and glial cell line derived neurotrophic factor 
(GDNF) (Abe, 2000; Leker and Shohami, 2002). Topical administration and viral 
vector-mediated overexpression of various NFTs have shown consistent effects in 
reducing the extent of damage after focal ischaemia (Abe et ai., 1997a; Hayashi et ai., 
1998; Kitagawa et al., 1998a; Kitagawa et al., 1999; Zhang et al., 1999; Wang et al., 
2000; Yagi et al., 2000; Hermann et al., 2001b; Zhang et al., 2001; Zhang et al., 2002). 
Apolipoprotein E is another molecule upregulated after acute brain injury that may 
contribute to endogenous protective mechanisms in the brain (jor reviews see Laskowitz 
et al., 1998; Horsburgh et al., 2000a). Furthermore, polymorphism in the 
apolipoprotein gene may be associated with disparities in the outcome/response to brain 
injury. Major components of this thesis were to further investigate this genetic influence 
and the neuroprotective potential of apolipoprotein E in cerebral ischaemia and as such 
the following sections focus on this molecule. 
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1.2 Apolipoprotein E (ApoE) 
1.2.1 Plasma apolipoproteins 
Apolipoprotein E (apoE denotes protein, APOE denotes gene) is one of numerous 
classes and sub-classes of apolipoproteins. Apolipoproteins comprise a group of 
molecules primarily synthesised in the liver that are intimately involved in directing 
plasma lipoprotein metabolism and maintaining cholesterol homeostasis. They are 
components of lipoprotein particles which transport and deliver lipids and cholesterol 
from one tissue or location to another (Borghini et at., 1995). Lipoprotein particles 
consist of a triglyceride and cholesteryl-ester core surrounded by a phospholipid and 
free cholesterol shell (Figure 5). Plasma lipoproteins can be separated into four major 
classes on account of their size and density: chylomicrons, very low-density lipoprotein 
(VLDL), low-density lipoprotein (LDL) and high-density lipoprotein (HDL). 
Apolipoproteins reside on the surface of these molecules where they perform several 
important functions that include stabilising the particles, serving as co-factors in 
enzymatic reactions (Fielding et at., 1972) and acting as ligands for lipoprotein 
receptors (Brown and Goldstein, 1986; Li et al., 1988). 
Phospholipids 
Triglyceride and 
cholesterol-ester core 
Free cholesterol 
Figure 5. Structure of a lipoprotein particle 
A cholesterol and phospholipid shell surrounds a triglyeride and cholesteryl-ester core. 
Apolipoproteins are located on the surface of the particle. Adapted from 
http://cwx.prenhall .com/horton/medialib/media_portfolio/16.html. 
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1.2.2 ApoE in plasma 
ApoE was discovered in 1973 as a protein constituent of triglyceride-rich plasma 
lipoproteins (Shore and Shore, 1973). In plasma, apoE is a component of several classes 
of lipoprotein particles including very low density lipoprotein (VLDL), chylomicron 
remnants and a subset of high density lipoprotein (HDL) (Mahley, 1988). ApoE 
associates with VLDL released from the liver and chylomicron remnants from the small 
intestine where it influences the hydrolysis of triglycerides and release of fatty acids 
from these particles for cellular uptake and energy metabolism (Mahley, 1988) As a 
constituent of VLDL apoE can direct triglycerides and cholesterol to extrahepatic sites 
whereas apoE associated with chylomicrons and their remnants delivers dietary 
triglycerides and cholesterol to the liver. In addition to promoting cellular uptake of 
cholesterol, apoE when associated with a subclass of HDL can support cholesterol 
efflux. This function of apoE is prominent in reverse cholesterol transport, a pathway 
that transports excess cellular cholesterol via apoE-containing HDL to the liver for 
excretion (Mahley and Innerarity, 1983; Huang et ai., 1994). 
1.2.3 ApoE in the nervous system 
Analysis of apoE mRNA expression in rats and marmosets revealed that the brain has 
the second highest level of apoE expression, containing approximately one third of the 
levels of apoE mRNA produced in the liver (Elshourbagy et ai., 1985). ApoE is also the 
most abundant apolipoprotein in the nervous system where a lipid transport function 
analogous to that in plasma has been proposed (Pitas et ai., 1987b; Poirier et ai., 1993a; 
Poirier, 1994; Poirier, 2000). Within the nervous system, apoE is located in two major 
environments, the brain parenchyma and the circulating cerebrospinal fluid (CSF). 
1.2.3.1 Localisation of apoE in "normal" brain parenchyma 
Several techniques have been used to investigate the regional distribution of apoE 
synthesis and to identify the specific cell types responsible for production of this protein 
in the uninjured brain. Using RNA dot blot hybridisation techniques in the rat and 
human brain, apoE mRNA was detected in several regions including the cerebellum, 
brain stem, medulla, pons and cerebral cortex (Elshourbagy et ai., 1985). A similarly 
extensive distribution of apoE transcripts was demonstrated in a comprehensive study 
utilising in situ hybridisation in the mouse brain; regions displaying apoE mRNA 
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included the choroid plexus and ependyma, cerebral cortex, thalamic nuclei, 
hypothalamus and hippocampus, particularly the molecular layer (Lorent et al., 1995). 
In general, it is thought that apoE is synthesised and secreted mostly by glial cells, 
particularly astrocytes (Boyles et al., 1985; Pitas et al., 1987a), although there is 
evidence of substantial inter-species variability in the cellular localisation of apoE. In 
the normal rodent brain, apoE is essentially restricted to glial cells. Intense apoE 
immunoreactivity has been shown in protoplasmic astrocytes of grey matter and fibrous 
astrocytes of white matter (Boyles et at., 1985). Other non-neuronal cells, such as 
microglia, oligodendrocytes and ependymal cells also stain positively for apoE. In the 
normal primate and human brains, however, there is evidence of apoE localisation to 
both glial cells and neurons (Han et al., 1994a; Han et al., 1994b; Metzger et al., 1996; 
Xu et aI., 1999). In the human brain, neuronal apoE immunoreactivity has been detected 
in pyramidal neurons of the cerebral cortex and hippocampus (Han et al., 1994b; Bao et 
aI., 1996). Furthermore, regionally specific neuronal APOE mRNA transcription has 
been revealed using in situ hybridisation (Xu et al., 1999). APOE mRNA-containing 
neurons were observed in the frontal cortex, CAl to CA4 regions of the hippocampus 
and the granule cell layer of the dentate gyrus but not in the cerebellar cortical neurons 
(Xu et al., 1999). In the same study, apoE immunohistochemical localisation paralleled 
the regional and cellular pattern of APOE mRNA transcription thus supporting a role for 
intraneuronal synthesis of apoE in the human brain. 
1.2.3.2 ApoE-containing lipoprotein particles in cerebrospinal fluid 
ApoE is also found in CSF associated with lipoprotein particles analogous to those 
circulating in plasma. CSF lipoprotein particles contain higher proportions of 
apolipoproteins than their counterparts in plasma and accordingly are of higher density 
and most closely resemble plasma HDL (Roheim et al., 1979; Pitas et al., 1987b). At 
least three major subpopulations ofCSF lipoprotein particles have been identified (pitas 
et al., 1987b; Borghini et al., 1995; Yamauchi et aI., 1999a; Koch et al., 2001). One is 
enriched in apoA-I and also contains significant quantities of apoE, apoD and apoJ, 
another is enriched in apoE and the third is less well defined and more heterogeneous in 
its composition (containing apoA-N, apoD, apoH, apoJ). The apoE-enriched particles 
are among the largest in CSF, with a diameter of approximately 151lm (pitas et al., 
1987b). These particles are similar to plasma HDL particles with regard to their density 
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and rich cholesteryl-ester content (Guyton et at., 1998). Significantly, the smaller 
particles containing apoA-I and apoA-IV are not thought to be synthesised within the 
CNS, but rather originate in plasma and are filtered across the blood-brain barrier 
(Elshourbagy et at., 1985; Karathanasis et at., 1986). In contrast, several lines of 
evidence suggest that apoE-containing lipoprotein particles are synthesised locally in 
the CNS and are most probably of astrocytic origin. Most convincing evidence that 
apoE is synthesised locally within the brain was revealed in patients undergoing liver 
transplantation where the plasma apoE phenotype changed to that of the donor whereas 
the apoE phenotype in CSF was unchanged (Linton et at., 1991). In addition, the 
sialylation pattern and molecular weight ofCSF-apoE is distinct from the corresponding 
plasma species. Furthennore, comparison of lipoprotein particles isolated from human 
CSF and from primary astrocyte cultures revealed that CSF lipoproteins contained 
several apolipoproteins, including apoE, apoA-I, apoA-II and apoJ, whereas astrocyte-
secreted lipoproteins contained only apoE and apoJ (LaDu et at., 1998). 
1.2.4 Molecular biology of apoE 
1.2.4.1 Genetic polymorphism 
Human apoE is a 34kDa glycoprotein composed of 299 amino acids in its mature fonn. 
Three isofonns of apoE are recognised in humans - apoE2, E3 and E4. This 
polymorphism is the result of three alleles at a single gene locus on chromosome 19. 
The corresponding alleles, APOE E2, E3 and E4, give rise to the three protein isofonns 
(Zannis et at., 1982). Although geographical and ethnic differences in relative allele 
frequencies have been identified (Gerdes et at., 1996; Schiele et ai., 2000), in all 
populations studied to date, the APOE E3 allele occurs with greatest frequency (-78%); 
also, in most cases the E4 allele (-14%) is more common than the E2 allele (-7%) 
(Davignon et ai., 1988). Thus, APOE genetic polymorphism results in six possible 
genotypes, three homozygous (E2/2, E3/3 and E4/4) and three heterozygous (E2/3, E2/4 
and E3/4). As a consequence of the variation in allelic frequency, the occurrence of the 
six APOE genotypes is approximately: E3/3 (55%), E3/4 (25%) and E2/3 (15%), with the 
remaining three genotypes (E2/2, E2/4, E4/4) occurring with a frequency of 1 - 2% each 
(Mahley and Rall, 2000). Significantly, up to one third of the population may therefore 
inherit at least one copy of the APOE E4 allele. 
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1.2.4.2 Structure of human apoE 
The apoE2, E3 and E4 isoforms differ sequentially by one unit of charge, a feature that 
has been demonstrated following isoelectric focussing (Utermann et at., 1977). ApoE4 
is the most cationic isoform, differing from apoE3 by one charge unit and from apoE2 
by two charge units. These charge differences are the result of single amino acid 
substitutions at two sites in the apoE polypeptide (Figure 6). ApoE2 has cysteine at 
residues 112 and 158, apoE3 has cysteine at residue 112 and arginine at residue 158 and 
apoE4 has arginine at both residues 112 and 158. These isoform-specific differences in 
primary structure have important effects on the tertiary structure and hence functional 
properties of each isoform. 
apoE2 
NH2 
apoE3 
NH2 
apoE4 
NH2 
112 158 
----Cys--: Cys 
:---Cys--: Arg 
----Arg--~ Arg 
signalling domain 
receptor-binding domain 
lipid-binding domain 
Figure 6. ApoE polymorphism 
eOOH 
eOOH 
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Polymorphism in apoE arises from amino acid substitutions at positions 112 and 158 of 
the protein. 
ApoE contains two independently folded domains each with distinct physical and 
functional properties which are linked by a region of random structure (Aggerbeck et 
at., 1988; Wetterau et ai., 1988; Weisgraber, 1994). The amino-terminal domain 
(residues 1-191) comprises five a-helices and contains the receptor-binding (residues 
134-150) and heparin (proteoglycan)-binding regions (Weisgraber, 1994). ApoE 
isoform polymorphisms at residues 112 and 158 produce subtle but important variations 
in the tertiary structure of the amino-terminal domain which in turn generate isoform-
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specific receptor binding activities (Zaiou et al., 2000; Lund-Katz et al., 2001). The 
lipid binding region of apoE (residues 244-272) is located within the carboxyl-terminal 
domain (residues 225-299) (Horie et ai., 1992). Polymorphisms at positions 112 and 
158, although within the amino-terminal domain, also produce isoform-specific 
differences in lipid-binding properties which are thought to be mediated by alterations 
in inter-domain interactions among the three apoE isoforms (Raffai et al., 2001). 
1.2.4.3 Structure of mouse apoE 
Mouse apoE, unlike in humans, does not display multiple isoforms. This feature is 
shared with other animals including all of the great apes, the closest living ancestors of 
humans (Hanlon and Rubinsztein, 1995). The mouse APOE gene encodes for arginine 
at the position corresponding to residue 112 in human apoE and therefore, mouse apoE 
is similar in primary structure to human apoE4 (Weisgraber, 1994). However, mouse 
apoE, in common with all other non-human apoE studied thus far, does not demonstrate 
the characteristic binding of human apoE4 to VLDL; mouse apoE preferentially binds 
to HDL. Underlying this feature is the presence of threonine at residue 61 in mouse 
apoE (in contrast to arginine at the corresponding position in humans) which diminishes 
the domain interactions responsible for the lipid-binding preferences of apoE4. Thus, 
mouse apoE, although related structurally to human apoE4 is more akin to apoE3 with 
regard to its functional properties (Strittmatter and Bova Hill, 2002). A key aspect of 
mice expressing only one apoE isoform is that, although general properties and 
functions of apoE can be investigated in wild-type mice, dissection of important 
differences that may exist in the behaviour of the human apoE isoforms is not possible. 
Accordingly, the development of transgenic mice expressing human APOE has been of 
huge importance to the investigation of isoform-specific differences in apoE that are 
pertinent to humans (section 1.4.3). 
1.2.5 ApoE receptors 
One of the most prominent functions of apoE is to serve as a ligand for receptors that 
mediate the cellular uptake of apoE and associated lipids. ApoE is a ligand for several 
structurally- and functionally-related cell surface receptors which are all members of the 
low-density lipoprotein (LDL) receptor family. In mammals, seven core members of 
this group have been identified each of which binds and internalises apoE-containing 
lipoproteins (Herz and Beffert, 2000). In the brain, the presence of three of these 
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receptors - LDL receptor, LDL receptor-related protein and the ApoER2 - has been 
most widely demonstrated. 
1.2.5.1 Low density lipoprotein receptor 
The LDL receptor was the first member of this group to be identified and elucidation of 
its role in lipid uptake was instrumental to understanding the mechanism of receptor-
mediated endocytosis (Brown and Goldstein, 1986). During this process, cell surface 
receptors recognise specific ligands in the circulation or extracellular space, bind them, 
and mediate their intemalisation via specialised regions of the plasma membrane called 
clathrin-coated pits (see aiso section 1.6.1). Humans and rabbits that are homozygous 
for spontaneous mutations that inactivate the LDL receptor display a grossly elevated 
plasma cholesterol level that leads to atherosclerosis and coronary artery disease early in 
life. These observations were explained by the inability to remove LDL from the 
circulation via receptor-mediated endocytosis in hepatocytes. Thus, the physiological 
role of the LDL receptor in the endocytosis of lipoproteins and lipid/cholesterol 
homeostasis provided a template that has been applied to other members of the LDL 
family of receptors subsequently discovered. 
The LDL receptor is expressed in tissues throughout the body, including the brain. 
In the brain, most evidence suggests that the LDL receptor is primarily found in glial 
cells. Astrocytic localisation has been demonstrated in rats, marmosets and humans 
using immunohistochemistry (pitas et ai., 1987b; Rebeck et ai., 1993). Further studies 
have also shown LDL receptor immunoreactivity in oligodendrocytes, microglia and 
brain capillary endothelial cells (Meresse et ai., 1989; Jordan et ai., 1991; Jung-Testas 
et ai., 1992; Dehouck et ai., 1994; Beffert et ai., 1998). Despite the presence of the LDL 
receptor in the brain, clinical and experimental evidence in humans and animals has thus 
far failed to uncover a critical role for this receptor in the nervous system (for review see 
Herz and Bock, 2002). For example, mice deficient for the LDL receptor do not appear 
to display neurological dysfunction (Ishibashi et ai., 1993) suggesting that other 
mechanisms or lipoprotein receptors can compensate in the absence of the LDL 
receptor. To date, no functions other than in lipoprotein metabolism have been shown 
for this receptor. 
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1.2.5.2 Low density lipoprotein receptor-related protein 
The LDL receptor-related protein (LRP) was the second member of the LDL-receptor 
family to be identified (Herz et al., 1988). Although located in tissues throughout the 
body, the LRP is most abundantly expressed in hepatocytes and neurons. In vitro studies 
have revealed that LRP binds apoE-containing lipoproteins and mediates their 
endocytosis in cultured cells (for review see Krieger and Herz, 1994). In the brain, LRP 
is highly expressed in neurons and is the principal receptor responsible for neuronal 
receptor-mediated endocytosis of apoE-containing lipoproteins. In the normal human 
brain, immunostaining was localised to neuronal cell bodies and proximal processes 
while other cell types were not positively stained (Wolf et al., 1992; Rebeck et al., 
1993). Widespread expression of LRP mRNA throughout the brain (hippocampus, 
cerebral cortex, cerebellum and brainstem) has been demonstrated (Bu et al., 1994, 
Lorent et al., 1995). Immunohistochemical analysis has also detected substantial LRP 
immunoreactivity in pyramidal and granule neurons of the hippocampal formation (Bu 
et al., 1994; Lorent et al., 1995). In contrast to the LDL receptor, there is accumulating 
evidence that LRP is not only involved in lipoprotein metabolism but also acts as a 
multifunctional signalling receptor that can bind a diverse range of ligands and 
participate in neuronal signal transduction pathways (Willnow et al., 1999; Herz and 
Strickland, 2001). The findings that conventional LRP-knockout mice die during 
gestation and display developmental abnormalities in the nervous system (Herz et al., 
1992) likely reflect the multi functionality of this receptor. 
1.2.5.3 ApoER2 
The structure of ApoER2 is strikingly similar to the LDL receptor and can bind apoE-
containing lipoproteins in vitro (for review see Herz, 2001b). Under normal conditions, 
ApoER2 expression is almost exclusively restricted to the brain and testes (Stockinger 
et al., 1998; Stockinger et al., 2000). In the brain, ApoER2 mRNA transcripts have been 
localised most strongly to the cerebellar cortex, choroid plexus, ependyma, 
hippocampus and olfactory bulb and to a lesser extent in the cerebral cortex (Kim et al., 
1996). In view of its homology to the LDL receptor and apoE-binding properties, a 
lipoprotein metabolism role was initially proposed for ApoER2. However, akin to LRP, 
there is increasing evidence that ApoER2 has important signalling functions, in 
particular as a key component of the Reelin signalling pathway that is involved in 
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neuronal migration during brain development (Hiesberger et al., 1999; Trommsdorff et 
al., 1999; Gotthardt et al., 2000). 
1.2.6 ApoE response to peripheral nerve injury - first indication of a role 
for apoE in nervous system pathology 
The relative abundance of apoE and the presence of apoE receptors illustrate that the 
nervous system contains the major components of a lipid/cholesterol transport system. 
An important function for apoE in the injured nervous system was first indicated in the 
1980s when a role for apoE was proposed in the redistribution of cholesterol among 
cells following peripheral nerve injury (Ignatius et al., 1987a). First, synthesis of a 
37kDa protein was found to be dramatically upregulated after rat peripheral nerve injury 
(Politis et al., 1983; Skene and Shooter, 1983; Muller et al., 1985; Muller et al., 1986). 
This protein was subsequently identified as apoE (Ignatius et al., 1986; Snipes et al., 
1986). After rat sciatic nerve crush injury, cells in the nerve sheath distal to the site of 
injury were shown to produce and secrete large quantities of apoE such that by 3 weeks 
post-injury apoE accumulated at the injury site where it accounted for approximately 2 
- 5% of the total soluble extracellular protein in the regenerating sciatic nerve sheath 
(Ignatius et al., 1986). Increasing levels of apoE after peripheral nerve injury were also 
shown to coincide with periods of axonal regeneration and peak levels were associated 
with the most active phase of axonal remyelination 3 weeks post-injury. Furthennore, 
axonal growth cones were enriched in LDL receptors during the period of axonal 
regeneration (Boyles et al., 1989). From these experiments it was proposed that apoE 
synthesised in the lesion scavenges lipids/cholesterol from degenerating nerves and 
redistributes them to the growth cones of regenerating axons where the apoE complexes 
are internalised for new membrane synthesis and remyelination (Ignatius et al., 1987b; 
Boyles et al., 1989). 
1.3 APOE polymorphism and human brain injury and disease 
Interest in the neurobiology of apoE was further stimulated with the seminal discoveries 
in 1993 that possession of the APOE &4 allele was associated with late-onset familial 
and sporadic Alzheimer's disease (AD) (Corder et ai., 1993; Poirier et ai., 1993b; 
Rebeck et ai., 1993; Saunders et ai., 1993; Strittmatter et ai., 1993). Subsequently, the 
effects of APOE polymorphism have been investigated in a multitude of brain disorders, 
most notably traumatic brain injury and cerebral ischaemia. 
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1.3.1 APOE polymorphism and Alzheimer's disease 
AD, originally described by Alois Alzheimer in 1907 (Alzheimer, 1907), is the most 
common age-related dementing illness, which at present is estimated to afflict 20 - 30 
million individuals worldwide (Selkoe and Schenk, 2003). Clinically, AD is 
characterised by progressive deterioration of cognitive function that ultimately leads to 
a profound dementia around a decade after onset of clinical symptoms. 
The APOE £4 allele was the second of four predisposing genetic factors for AD to 
be revealed. Mutations in the J3-amyloid precursor protein (APP) gene and the 
presenilin-l (PS 1) and presenilin-2 (PS2) genes have also been shown to be associated 
with familial AD (Levy et ai., 1990; Goate et a/., 1991; Murrell et a/., 1991; Hendriks et 
a/., 1992; Mullan et a/., 1992; Levy-Lahad et a/., 1995; Rogaev et a/., Sherrington et a/., 
1995). Following the linkage of late-onset familial AD to a region on chromosome 19 
containing the APOE locus (pericak-Vance et a/., 1991), inheritance of the APOE E4 
allele was shown to be associated with both late-onset familial (Corder et a/., 1993; 
Strittmatter et ai., 1993) and sporadic AD (poirier et ai., 1993; Rebeck et aI., 1993; 
Saunders et a/., 1993). The APOE E4 allele association with AD has now been 
corroborated in over 100 laboratories worldwide. Conversely, there is evidence to 
suggest that the APOE E2 allele may have a protective effect against AD (Corder et a/., 
1994). The APOE E4 allele is not a causative gene but rather acts as a susceptibility 
factor. It is thought to be the most important genetic risk factor for development of AD 
with up to 50% of all cases of AD estimated to involve the E4 allele as the principal 
genetic factor (Roses, 1996; Selkoe and Schenk, 2003). Inheritance of the APOE E4 
allele not only increases the risk for developing AD but also reduces the mean age of 
onset of the disease in a dose-dependent manner. Thus, individuals inheriting two 
copies of the E4 allele have an increased risk and earlier age of onset than individuals 
with one E4 allele (Saunders et ai., 1993). Likewise, individuals with one E4 allele have 
a greater risk and earlier onset of disease than those without an E4 allele (Corder et a/., 
1993). Moreover, the mean age of onset for individuals with the E4/E4 genotype is less 
than 70 years compared to over 90 years for individuals with the £2/E3 genotype 
(Corder et ai., 1993). In contrast, the progression of dementia and duration of survival 
after clinical onset is not influenced by APOE genotype (Corder et a/., 1995; Gomez-
Isla et a/., 1996). APOE genotype also appears to influence the age of onset of AD in 
early-onset families with APP mutations; individuals homozygous for APOE £4 with an 
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APP mutation experience an earlier onset of disease (St George-Hyslop et al., 1994; 
Nacmias et al., 1995). In contrast, a similar interaction of APOE genotype with age of 
onset is not generally evident in early-onset families with mutations in the PS 1 gene 
(Van Broeckhoven, 1995; Lendon et al., 1997; Houlden et al., 1998). However, in a 
kindred in which AD is caused by a PS 1 mutation, it has recently been shown that 
APOE £4 carriers were more likely to develop AD at an earlier age (Pastor et al., 2003). 
During the past five years, possible links between APOE promoter polymorphisms 
and the risk of AD have also been identified (Bullido et al., 1998; Lambert et al., 1998; 
Lambert et al., 2002). Promoter polymorphisms may influence AD risk by modulating 
APOE transcriptional activity (Artiga et al., 1998; Laws et aI., 2002; Laws et al., 2003). 
1.3.2 APOE polymorphism and traumatic brain injury 
Among patients who experience a similar severity of head injury there is heterogeneity 
in the quality of recovery only partially explained by prognostic factors, such as age and 
treatment (Jennett et al., 1979). This implies that additional factors, such as genetic 
make-up, may influence the response to TBI. 
The association of APOE genotype with outcome after TBI has been investigated 
by a number of groups (Teasdale et al., 1997; Friedman et al., 1999; Lichtman et aI., 
2000; Liberman et al., 2002; Chiang et al., 2003). In these studies, possession of the 
APOE £4 allele has been consistently associated with poorer outcome after TBI. In the 
first study to reveal this link, patients with at least one copy of the APOE E4 allele were 
more than twice as likely to have an unfavourable outcome (death, vegetative state or 
severe disability) 6 months after injury than their non-E4 counterparts (Teasdale et al., 
1997). An E4 allele dose effect was also indicated since all E4 homozygotes were 
severely disabled at 6 months post-injury compared to 30% of E4 heterozygotes and 
17% of those without an £4 allele. An increased risk of post-traumatic seizures has also 
been reported in APOE E4 individuals (Diaz-Arrastia et al., 2003). An association 
between APOE genotype and cognitive ability following TBI has also been shown. 
Patients possessing an APOE £4 allele demonstrated impaired learning and memory 
recall following TBI of similar severity. suggesting APOE-isoform dependent effects on 
hippocampal function after TBI (Crawford et al., 2002). Furthermore. in high-exposure 
boxers who have experienced repetitive blows to the head. possession of the APOE E4 
allele was associated with more pronounced neurological impairment (Jordan et al .• 
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1997). Similarly, in older American football players who have been exposed to repeated 
head trauma, APOE E4 carriers were significantly over-represented among players with 
lower cognitive perfonnance (Kutner et al., 2000). 
1.3.3 APOE polymorphism and cerebral ischaemia 
1.3.3.1 Ischaemic (occlusive) stroke 
Ischaemic stroke shares several risk factors with heart disease. The APOE E4 allele is 
associated with increased levels of low-density lipoprotein and cholesterol (Davignon et 
al., 1988; Larson et aI., 2000; Eichner et al., 2002), atherosclerosis (Hixson, 1991; 
Karvonen et al., 2002) and ischaemic heart disease (de Knijff and Havekes, 1996; 
Wilson et al., 1996; Frikke-Schmidt et al., 2000; Eichner et al., 2002) suggesting that 
APOE E4 may be a risk factor for ischaemic stroke. A number of case-control studies 
have shown over-representation of the APOE E4 allele in ischaemic stroke patients 
(Pedro-Botet et al., 1992; Margaglione et al., 1998; Peng et aI., 1999; Luthra et al., 
2002) and a meta-analysis reported a significant association between ischaemic stroke 
and the E4 allele (McCarron et al., 1999). Recently, the APOE E4 allele has been 
demonstrated to be a risk factor for recurrence of ischaemic stroke (Kim et al., 2003). 
However, other studies have also reported over-representation of the APOE E2 allele 
(Couderc et al., 1993) and neutral findings (Coria et al., 1995; MacLeod et al., 2001; 
Souza et al., 2003). 
In humans, the association of APOE genotype with outcome from ischaemic stroke 
is inconclusive. Initial studies assessing outcome after ischaemic stroke demonstrated 
that APOE E4 was not associated with a poor prognosis (McCarron et al., 1998; 
McCarron et al., 2000; MacLeod et al., 2001). Recently, however, the prevalence of 
aphasia after ischaemic stroke was demonstrated to be significantly greater in APOE E4 
patients (Treger et al., 2003). Furthennore, in a magnetic resonance imaging study, 
despite a smaller initial infarct in APOE E4 patients, expansion of infarct volume by day 
8 post-stroke was significantly greater in APOE E4 carriers (Liu et al., 2002). 
Conflicting results from clinical studies investigating outcome from ischaemic stroke 
may in part reflect the presence of potentially confounding factors (e.g. 
duration/severity of insult, pre-existing disease). Accordingly, the benefits of using 
experimental models of cerebral ischaemia, in which these confounding variables can be 
controlled, are underlined. 
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1.3.3.2 Haemorrhagic stroke 
There is accumulating evidence to suggest that APOE polymorphism is associated with 
outcome after intracerebral haemorrhage (ICH). A number of studies have revealed an 
association between possession of the APOE E4 allele and poorer outcome after ICH 
(Alberts et al., 1995; McCarron et al., 1998; McCarron et al., 1999), an effect thought 
to be independent of haematoma volume and severity of oedema. A recent prospective 
study reported that presence of the APOE E4 allele was linked to significantly reduced 
survival following ICH (McCarron et al., 2003). 
Cerebral amyloid angiopathy (CAA), a condition caused by deposition of the ~­
amyloid (A~) peptide in the walls of cerebral blood vessels, is an important cause of 
lobar ICH. Several studies have revealed that vascular A~ deposition is associated with 
the APOE £4 allele (Schmechel et a/., 1993; Greenberg et al., 1995; Olichney et al., 
1996; Premkumar et al., 1996; Yamada, 2002; Chalmers et al., 2003). Consistent with 
these findings, initial studies of CAA-related ICH demonstrated over-representation of 
the APOE E4 allele (Greenberg et al., 1995; Greenberg et al., 1996; Premkumar et al., 
1996). Subsequently, however, a high frequency of the APOE £2 allele was 
demonstrated in studies that accounted for concomitant AD (Nicoll et al., 1996; Nicoll 
et al., 1997; Greenberg et al., 1998). This led to the proposal that while APOE £4 may 
promote vascular A~ deposition, APOE E2 is a risk factor for rupture of amyloid-laden 
blood vessels (Nicoll et al., 1997). 
Consistent findings have emerged from studies in patients with subarachnoid 
haemorrhage (SAH). An association between the APOE £4 allele and risk of SAH was 
indicated (Kokubo et al., 2000; Leung et al., 2002). Poorer outcome after SAH in APOE 
£4 carriers has been demonstrated in several studies (Niskakangas et al., 2001; Leung et 
al., 2002; Tang et al., 2003), although a recent study did not find a link (Morris et al., 
2004). 
1.3.3.3 Global ischaemia 
Two studies in humans have examined the association of APOE genotype with outcome 
after cardiac arrest and have produced contrasting results. In the first study, patients 
with the APOE £3/3 genotype had a significantly higher survival rate at 6 months and 
more favourable neurological outcome compared to non-APOE £3/3 patients, 
suggesting a detrimental effect associated with the APOE £4 allele (Schiefermeier et al., 
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2000). However, in a recent study (Longstreth et ai., 2003), APOE genotype was not 
significantly related to survival or neurological outcome, although a larger and less 
homogeneous group was used in this study compared to that of Schiefermeier et ai. 
(2000). APOE genotype was also not associated with the extent of hippocampal 
neuronal damage in a cohort of patients who died following an episode of global 
ischaemia due to cardiac arrest and subsequent period of reperfusion (Horsburgh et ai., 
I 999a). 
1.3.4 Stroke and TBI as risk factors for dementia - association with APOE 
polymorphism 
1.3.4.1 Stroke 
Increasing evidence implicates ischaemic cerebrovascular disease as a major risk factor 
for dementia. Several studies have shown that the incidence of dementia is significantly 
higher in ischaemic stroke patients compared to controls (Tatemichi et ai., 1992; 
Tatemichi et ai., 1994; Censori et ai., 1996; Kokmen et ai., 1996; Henon et ai., 1997; 
Zhu et ai., 2000). A direct role for cerebrovascular disease in AD pathogenesis has also 
been proposed (Kalaria, 2000; de la Torre, 2002; Kalaria, 2002; de la Torre, 2004). At 
post-mortem, 60 - 90% of AD patients exhibit some form of cerebrovascular pathology 
and around one third display cerebral infarction (Gearing et ai., 1995a; Premkumar et 
ai., 1996). It has been suggested that stroke may be the major aetiological factor in a 
substantial number of AD patients (Kokmen et ai., 1996). The impact of cerebral 
infarction on AD was highlighted in a study of elderly nuns, since individuals with 
cerebral infarcts also showed more severe dementia (Snowdon et ai., 1997). A recent 
study showed the presence of cerebral infarction increased the odds of dementia by 2.8-
fold (Schneider et ai., 2004). Synergistic effects of APOE £4 and cerebrovascular 
disease on cognitive decline and dementia have been reported (Kalmijn et ai., 1996; 
Skoog et ai., 1998), although other studies have found only additive effects (Dik et ai., 
2000; Zhu et ai., 2000). The association between APOE polymorphism and vascular 
dementia is inconclusive, with several studies showing a higher frequency of the £4 
allele in vascular dementia patients compared to controls (Frisoni et ai., 1994a; Frisoni 
et ai., 1994b; Isoe et ai., 1996; Yang et ai., 2002) and others showing no association 
(Stengard et ai., 1995; Frank et ai., 2002; Traykov et ai., 2002). 
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1.3.4.2 Traumatic brain injury 
There is considerable evidence to suggest that a history of head injury is the most robust 
environmental risk factor for AD (Mortimer et al., 1985; Mortimer et al., 1991; Mayeux 
et al., 1993; Guo et al., 2000; Plassman et al., 2000; Fleminger et al., 2003). The risk of 
AD conferred by a previous head injury may also be modulated by APOE 
polymorphism. Mayeux et al. (1995) have shown that a history of previous head injury 
and possession of APOE &4 allele act synergistically to increase the risk of AD; the risk 
of AD was increased 10-fold when head injury and the &4 allele were both present 
compared with a two-fold increase in risk with presence of the E4 allele alone (Mayeux 
et al., 1995). Similarly, a survey of World War II veterans showed a trend toward a 
stronger association between TBI and AD in men with the APOE E4 allele (plassman et 
al., 2000). Other studies have demonstrated additive effects ofTBI and APOE E4 on AD 
risk (O'Meara et al., 1997; Guo et al., 2000; Jellinger et al., 2001). 
1.4 Role of apoE in brain injury - insight from animal models 
and APOE deficient and transgenic mice 
1.4.1 Cellular localisation of apoE after acute brain injury 
The discovery of associations between APOE polymorphism and the susceptibility and 
outcome to acute brain injury and neurodegenerative disease stimulated efforts to 
further understand the function(s) of apoE in the brain. Initial studies employing in vivo 
rodent models of acute brain injury were aimed at addressing fundamental issues 
regarding apoE in the injured brain, in particular to determine if alterations in cellular 
apoE localisation occurred after injury. 
In normal rodent brain, apoE immunoreactivity is localised to glial cells, 
predominantly astrocytes, and is not observed in neurons (Boyles et al., 1985; section 
1.2.3.1). However, following injury, marked changes in apoE localisation have been 
demonstrated. Increased neuronal apoE immunoreactivity after CNS injury was first 
shown in the selectively vulnerable hippocampus after cardiac arrest in the rat (Kida et 
al., 1995) and transient forebrain ischaemia in gerbils (Hall et al., 1995). In the same 
model, increased apoE mRNA levels were also observed after ischaemia (Ali et al., 
1996). In a rat model of transient global ischaemia, the temporal alterations in apoE 
after injury were investigated. In this study, apoE immunoreactivity was increased in 
astrocytes prior to evidence of neuronal damage and then subsequently localised to 
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ischaemic neurons, suggesting that neuronal accumulation of apoE was the result of 
uptake of astrocyte secreted apoE (Horsburgh and Nicoll, 1996). Neuronal apoE 
immunoreactivity and elevated levels of apoE were also observed after subdural 
haematoma in the rat (Horsburgh et a!., 1997) and transient global ischaemia in mice 
(Horsburgh et ai., 2000c). More recently, neuronal apoE immunoreactivity has been 
demonstrated in ischaemic neurons following focal cerebral ischaemia in the rat (Nishio 
et ai., 2003; Kamada et ai., 2003). Significantly, similar results have also been obtained 
in human post-mortem tissue where marked increases in apoE immunoreactivity in 
ischaemic neurons and elevated levels of apoE were found in patients who experienced 
an episode of global ischaemia (Horsburgh et at., 1999a) and in patients with cerebral 
infarction (Aoki et at., 2003). Together, these studies demonstrated that apoE levels are 
elevated in response to injury and indicate that localisation of apoE to neurons may 
enable modulation of pathophysiological processes in neurons. 
1.4.2 Studies in APOE deficient mice 
The development of APOE deficient mice (piedrahita et at., 1992) facilitated further 
investigation of the role of apoE in the brain. Studies using these mice have shown that 
apoE has neuroprotective effects against various types of acute brain injury. APOE 
deficient mice are more susceptible to the effects of focal ischaemia, showing a larger 
infarct volume than wild type mice (Laskowitz et ai., 1997). APOE deficient mice also 
display a poorer outcome (pathological and/or neurological) after global ischaemia 
(Horsburgh et at., 1999b; Sheng et at., 1999; Kitagawa et at., 2002a; Kitagawa et at., 
2002b), closed head injury (Chen et ai., 1997) and focal brain lesions (Masliah et at., 
1996). The neuroprotective role of apoE was further highlighted when it was shown that 
the increased susceptibility of APOE deficient mice to global ischaemia could be 
ameliorated by restoring apoE. Intraventricular infusion of a physiological concentration 
of human plasma-derived and lipid-conjugated apoE (of mixed isoform) significantly 
reduced ischaemic neuronal damage after global ischaemia to a level comparable to that 
observed in wild-type mice (Horsburgh et at., 2000b). 
1.4.3 APOE transgenic mice 
As described previously (section 1.2.4.3), rodents express only one form of apoE in 
contrast to the three isoforms found in humans. Generation of human APOE transgenic 
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mice has therefore been a vital development enabling direct and systematic in vivo 
investigation of the effects of human APOE in the brain. In combination with mouse 
models of brain injury, it is therefore possible to investigate the effects of human APOE 
polymorphism on the response to brain injury. Several populations of transgenic mice 
expressing the human APOE isoforms have been developed. 
1.4.3. 1 APOE transgenic mouse lines 
In this thesis, mice expressing human APOE E3 or APOE E4 under the control of human 
regulatory elements were used (Xu et al., 1996). The major utility of these mice is that 
they closely mirror the pattern of apoE expression in the human brain (i.e. glial and 
neuronal). Characterisation of these mouse lines showed that APOE gene transcription 
(analysed by northern blot) was evident in several organs, including the brain, kidney, 
heart and liver. Likewise, apoE protein expression was detected throughout the body, 
including the brain, liver, kidney, heart and serum. Levels of apoE protein content in 
different tissues were highly variable among transgenic lines depending on the number 
of gene copies that integrated into the genome. In the brain (and other tissues), apoE 
levels were comparable to endogenous mouse apoE levels in wild-type mice, therefore 
indicating physiologically relevant apoE expression in the brain. A key feature of these 
mice is that they display a human-like pattern of apoE immunostaining. ApoE 
immunoreactivity was localised to various cell types including astrocytes, microglia and 
ependymal cells. Notably, apoE immunoreactivity was also observed in subsets of 
neurons, particularly in the cerebral cortex, although to a lesser extent than glial 
immunoreactivity. In addition, another important feature of these mice is that plasma 
cholesterol levels approach that found in wild-type mice. Accordingly, of the several 
types of APOE transgenic mice developed, these mice likely provide the distribution of 
apoE expression most relevant to humans. Generation of these mice is described in 
detail in section 2.2.2. 
Transgenic mice expressing human APOE E3 and APOE £4 under the control of the 
astrocyte-specific glial fibrillary acidic protein (GFAP) promoter have been developed 
(Sun et al., 1998). The rationale for developing these mice was that astrocytes are the 
primary source of apoE in the human brain (Boyles et al., 1985; Pitas et al., 1987a; 
section 1.2.3.1) and so these mice would enable the in vivo study of human apoE 
isoforms expressed specifically by astrocytes. In these mice, apoE immunoreactivity 
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was localised to astrocytes and the neuropil with no clear immunostaining of neurons. 
This pattern of immunostaining was therefore similar to that observed for endogenous 
apoE in wild-type mice and rodents in general. ApoE levels in brain tissue samples from 
these mice (0.1 - O.3J.lglmg) were shown to be similar to levels in human brain tissue 
(0.4 - 0.5J..Lglmg), indicating physiologically relevant apoE expression in the brain. 
In contrast to the mice described above, other lines of APOE transgenic mice have 
been developed in which APOE expression is restricted to neurons (Buttini et al., 1999). 
The rationale for neuronal targeting of APOE expression was mainly based on 
observations that APOE mRNA and immunoreactivity could be detected in human brain 
(Han et al., 1994b; Metzger et af., 1996; Xu et al., 1999; section 1.2.3.1) and therefore 
may have critical effects in neurons. In these mice, expression of human APOE E3 and 
APOE E4 is driven by the neuron specific enolase (NSE) promoter. APOE expression 
was limited to neural tissue and testes of these mice. APOE mRNA and protein levels in 
brain tissue and CSF were shown to be comparable to those found in humans. ApoE 
immunoreactivity was localised exclusively to neurons, confirming the neuron-specific 
expression of apoE in these mice. Plasma cholesterol levels in these mice are similar to 
those found in APOE deficient mice (i.e. elevated in comparison to wild-type mice), 
reflecting the lack of apoE in plasma. 
The mouse lines described above were all generated by the pronuclear injection 
technique (Gordon et al., 1980; Gordon and Ruddle, 1983). Human APOE transgenic 
mice have also been generated by targeted replacement of the endogenous mouse APOE 
gene ("knock-in mice") (Sullivan et al., 1997; Sullivan et al., 1998; Knouff et al., 1999; 
Hamanaka et al., 2000), the major advantage of which is the ability to control the 
location of transgene integration. Since trans gene expression in these mice is under the 
control of endogenous promoters, the distribution and level of APOE expression in all 
tissues, including the brain, is generally similar to that observed in wild-type mice 
(Sullivan et al., 1997). 
1.4.3.2 Studies in APOE transgenic mice 
Studies in which animal models of acute brain injury have been applied in transgenic 
mice expressing human APOE isoforms have produced consistent findings showing 
poorer outcome associated with the APOE E4 allele. APOE E4 mice under the control of 
human regulatory sequences displayed significantly greater ischaemic neuronal damage 
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in the hippocampus after global ischaemia compared to APOE £3 mice (Horsburgh et 
ai., 2000c). In the same lines of mice, APOE E4 mice displayed a larger infarct volume 
than APOE £3 mice after transient focal ischaemia (Sheng et ai., 1998), although a 
major limitation of this study was that brain oedema was not controlled for during 
infarct quantification. Also in these transgenic lines, APOE E4 mice were more 
susceptible to the effects of closed head injury than APOE £3 mice (Sabo et ai., 2000). 
In mice expressing APOE under the control of the NSE promoter, APOE £3 mice were 
protected against excitotoxin-induced neurodegeneration whereas APOE £4 mice were 
not (Buttini et ai., 1999). Collectively, the results from experimental models add to and 
support the findings from the majority of clinical studies that indicate that the APOE £4 
allele is associated with poorer outcome after acute brain injury. However, in view of 
the inconclusive results in focal ischaemic stroke studies in humans, and the limitations 
of previous work using a model of focal ischaemia in APOE transgenic mice, it is 
evident that the effects of APOE genotype in focal ischaemia merit further systematic 
investigation. 
1.5 Mechanisms underlying APOE genotype effects 
The precise mechanism(s) underlying the APOE genotype-dependent differences in 
susceptibility and outcome to brain injury and disease are not fully understood. A 
number of mechanisms pertinent to acute brain injury have been investigated although 
the relative importance of each of these is unknown. 
1.5.1 ApoE and excitotoxicity 
Recent evidence suggests that apoE may be capable of attenuating glutamate receptor-
mediated excitotoxic damage and that there may be isoform-specific differences in this 
effect. Significantly, transgenic mice expressing apoE3 were shown to be protected 
from excitotoxin-induced neuronal damage whereas apoE4-expressing mice were not 
(Buttini et ai., 1999). In vitro, exposure of neuronal-glial primary cultures and a 
neuronal cell line to biologically relevant concentrations of recombinant apoE prior to 
NMDA exposure resulted in significant neuroprotection (Aono et ai., 2002). Peptides 
derived from the receptor-binding region of apoE were also demonstrated to exert a 
neuroprotective effect against NMDA-induced excitotoxicity (Aono et ai., 2003). 
Isoform-specific effects have also been demonstrated in vitro. ApoE3, but not apoE4, 
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was shown to prevent the neuronal calcium response and neuronal damage in response 
to NMDA receptor activation (Qiu et a/., 2003). These effects may not be due to direct 
NMDA receptor antagonism by apoE, but may be exerted through interactions with 
apoE cell surface receptors, such as LRP and apoER2 (Aono et a/., 2002). Ligand 
binding to LRP can modulate NMDA receptor-mediated calcium influx via putative 
interactions between LRP and the NMDA receptor (Bacskai et a/., 2000; Qiu et a/., 
2002; Qiu et a/., 2003). These interactions may be mediated by the postsynaptic 
scaffold protein, PSD-95 (Gotthardt et a/., 2000; Herz, 2001a). PSD-95 modifications 
after cerebral ischaemia have been described (Takagi et a/., 2000) and disruption of 
PSD-95-NMDA receptor interactions has been shown to suppress excitotoxicity and to 
improve neurological outcome and reduce the volume of ischaemic damage after focal 
cerebral ischaemia in the rat (Sattler et a/., 1999; Aarts et a/., 2002). 
1.5.2 ApoE and oxidative stress 
ApoE may possess antioxidant properties and protect against the effects of oxidative 
damage to neurons in an isoform-specific manner. In mice, APOE deficiency is 
associated with increased oxidative stress and an increase in the oxidant/antioxidant 
ratio in the brain (Ramassamy et a/., 2001; Shea et a/., 2002). Furthermore, elevated 4-
HNE immunoreactivity observed after global ischaemia in APOE-deficient mice 
compared to wild-type mice was ameliorated by intraventricular infusion of lipid-
conjugated apoE (Horsburgh et a/., 2000b). Similarly, pre-treatment of APOE-deficient 
mice with vitamin E, an antioxidant, markedly reduced neuronal damage after 
ischaemia (Kitagawa et a/., 2002b). There is also evidence of APOE genotype 
differences in the ability to modulate oxidative injury. In post-mortem AD brain, 
elevated levels of lipid peroxidation markers were associated with possession of the 
APOE E4 allele (Montine et a/., 1997; Ramassamy et a/., 2000; Tamaoka et a/., 2000). 
In vitro, apoE can protect neurons from hydrogen peroxide- and Ap-induced oxidative 
damage in an isoform-specific manner (E2 > E3 > E4) (Miyata and Smith, 1996; 
Lauderback et a/., 2002). It was also shown that apoE isoforms can bind with different 
affinities to 4-HNE (E2 > E3 > E4), suggesting isoform differences in the detoxifying 
abilities of apoE (Miyata and Smith, 1996; Pedersen et a/., 2000). 
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1.5.3 ApoE and cytoskeletal interactions 
An intact cytoskeleton is an important element In maintaining the structural and 
functional integrity of neurons. Disruption of cytoskeletal proteins occurs after various 
forms of acute brain injury, including cerebral ischaemia and TBI (Fitzpatrick et al., 
1996; Lipton, 1999). After brain injury, apoE is markedly elevated in neurons (section 
1.4.1), therefore providing the basis for interactions between apoE and cytoskeletal 
proteins. ApoE binding to microtubule associated proteins may promote cytoskeletal 
stability (Roses et al., 1996). In vitro, apoE3 binds with much greater affinity to the 
microtubule associated protein, tau, than apoE4 (Strittmatter et al., 1994a; Strittmatter et 
al., 1994b; Fleming et al., 1996). ApoE3 binding to tau may prevent its 
hyperphosphorylation and the formation of paired helical fragments. In support of this, 
expression of APOE E4 in transgenic mice and humans is associated with a greater load 
of hyperphosphorylated tau (Tesseur et al., 2000; Thaker et al., 2003). In addition to 
tau, apoE3 also shows greater affinity than apoE4 for binding to other microtubule 
associated proteins such as MAP2 (Huang et al., 1994a) and neurofilamant proteins 
(Fleming et ai., 1996). ApoE3 may therefore be the more effective isoform in 
promoting cytoskeletal stability. However, direct interactions between apoE and 
cytoskeletal components have been questioned since there is no conclusive evidence 
that intraneuronal apoE can escape the endosomal-Iysosomal compartments and enter 
the cytosol (DeMattos et ai., 1999). In this regard, apoE may modulate cytoskeletal 
function via a cell surface signalling pathway mediated by LRP or apoER2 (Herz and 
Beffert, 2000). 
1.5.4 Toxic effects of apoE 
The majority of proposed mechanisms underlying APOE genotype differences assume a 
positive role for apoE that reflects the relative failure of the apoE4 isoform in 
performing several functions i.e. that absence of apoE3 (or apoE2) is the most important 
factor. However, there is also evidence that apoE (and apoE fragments) have neurotoxic 
properties and that apoE4 may exert dominant effects over apoE3 in this regard. A toxic 
role for apoE was first suggested by the observation that synthetic apoE-related peptides 
induced degeneration of cultured sympathetic neurons (Crutcher et ai., 1994). Further 
work demonstrated greater neurotoxic effects of truncated and full-length forms of 
apoE4 compared to apoE3 (Marques et al., 1996; Marques et al., 1997). Toxic effects of 
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apoE may be mediated by disruption of intracellular calcium levels since elevated levels 
of intracellular calcium, resembling events in excitotoxicity, have been found in 
cultured neurons exposed to apoE (Tolar et ai., 1999; Veinbergs et ai., 2002) with 
apoE4 inducing greater increases in intracellular calcium than apoE3 (Veinbergs et ai., 
2002). Recently, it was shown that apoE can be cleaved to form bioactive carboxyl 
terminal fragments that induce formation of intracellular inclusions. In vitro, apoE4 was 
more susceptible to truncation and more readily induced formation of inclusions than 
apoE3 (Huang et ai., 2001). In mice expressing human apoE in neurons (NSE-apoE 
mice), apoE4 was more prone to truncation, and an excitotoxic challenge significantly 
increased apoE fragmentation in NSE-apoE4 but not NSE-apoE3 mice (Brecht et ai., 
2004). 
1.5.5 Plasma and brain apoE levels 
An alternative mechanism has been proposed for APOE genotype differences in 
susceptibility to brain injury that is independent of isoform-specific properties of apoE. 
It has been suggested that all apoE isoforms may have similar neuroprotective actions 
and that the crucial factor is the amount of apoE available, with greater levels being 
more beneficial (Poirier, 1994; Poirier, 2000). In humans, the level of plasma apoE is 
APOE genotype-related with APOE E4 carriers consistently shown to have significantly 
lower levels than E2 and E3 carriers (Slooter et ai., 1998; Schiele et ai., 2000; Panza et 
ai., 2003). There is also some evidence that plasma apoE levels in AD patients are 
lower in APOE E4 carriers (panza et ai., 2003). In addition, lower apoE levels in the 
brain parenchyma (Bertrand et ai., 1995; Beffert et ai., 1999) and in CSF (Yamauchi et 
ai., 1999b) have been reported in APOE E4 carriers with and without AD. Lower apoE 
levels in APOE E4 carriers has been suggested to underlie their increased susceptibility 
to AD and poorer recovery from injury (Bertrand et ai., 1995; Beffert et ai., 1999; 
Poirier, 2000). However, a number of other studies have reported conflicting findings, 
suggesting that APOE genotype is not associated with CSF or brain tissue apoE levels 
(LeFranc et ai., 1996; Pirttila et ai., 1996; Glockner et ai., 2002; Fukumoto et ai., 2003) 
or that significantly higher CSF apoE levels may be found in individuals (with and 
without AD) possessing the APOE E4 allele (Hesse et ai., 2000). 
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1.6 Endocytosis 
The endocytic pathway is integral to the intemalisation and intracellular trafficking of 
apoE. Since neuronal accumulation of apoE is a key feature in the response to ischaemic 
brain damage (section 1.4.1), alterations in this pathway are potential mechanisms that 
could contribute to APOE genotype effects in the injured brain. To date, however, there 
is limited information on endocytic pathway function in response to ischaemic damage. 
1.6.1 Endocytic pathway 
Endocytosis encompasses a number of highly evolved mechanisms used by mammalian 
cells to intemalise small molecules, macromolecules and various other particles (e.g. 
toxins). Phagocytosis ("cell eating"), pinocytosis ("cell drinking") and receptor-
mediated endocytosis all reflect specialised modes of endocytosis. Although all of these 
methods share common features, with regard to this thesis, all descriptions of 
endocytosis refer to receptor-mediated endocytosis. Endocytosis is a common feature of 
all nucleated vertebrate cells (MukheIjee et al., 1997) where it mediates the uptake and 
intracellular trafficking of nutrients, trophic factors and receptor-ligand complexes in a 
series of membranous compartments. In addition, in the CNS, neuronal endocytosis is 
intimately involved in events following neurotransmitter release, most notably the 
intemalisation and recycling of plasma membrane receptors and their ligands. 
Early, late and recycling endosomes comprise the group of membrane-bound 
compartments associated with endocytosis and together with lysosomes they form the 
central vacuolar system. Each of these compartments is morphologically and 
biochemically distinct with intra-membranous conditions optimised for the specific 
processes that are performed within each compartment; for example, the acidic 
environment of lysosomes is suited to the proteolytic actions that occur within these 
organelles. The importance of the endosomal-Iysosomal system is highlighted by the 
consequences of aberrant functioning of this pathway. Endocytic disturbances are 
believed to play important pathophysiological roles in atherosclerosis and diabetes 
(MukheIjee et al., 1997). Furthermore, there are around thirty inherited disorders 
involving defective handling of lysosomal enzymes that produce a severe phenotype 
characterised by cognitive impairment and widespread neurodegeneration (Nixon and 
Cataldo, 1995). 
41 
Upon intemalisation by clathrin-mediated endocytosis, molecules are delivered to 
the first major sorting station of the endocytic pathway, the early endosome (McCaffrey 
et al., 2001). From here, sequestered molecules have three major fates: recycling back 
to the plasma membrane in recycling endosomes; progression to the trans Golgi 
network for further sorting and distribution; or transport to late endosomes and 
lysosomes for proteolytic degradation (Figure 7). Endosomal trafficking along each of 
these distinct pathways is regulated by a number of proteins, such as the group of small 
GTPases known as the rab proteins. 
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Figure 7. Schematic overview of the endocytic pathway 
late 
endosome 
Internalisation occurs in clathrin-coated pits which bud from the plasma membrane to 
form clathrin-coated vesicles (CCVs). CCVs lose their clathrin coat and form early 
(sorting) endosomes. From early endosomes, internalised material may progress to 
late endosomes and Iysosomes for degradation, to recycling endosomes for transport 
to the plasma membrane or to the trans Golgi network for further sorting and 
distribution. 
1.6.2 Rab proteins 
1.6.2. 1 Rab proteins and regulation of endosomal trafficking 
The rab family of proteins is part of the Ras superfamily of small GTPases (Stenrnark 
and Olkkonen, 2001). Rab proteins are localised to the membranes of intracellular 
organelles such as endosomes, where they are thought to control vesicular docking and 
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fusion (Gonzalez et al., 1999). Of approximately 60 members of the rab family, 12 rab 
proteins have been localised to the endocytic pathway in mammalian cells (Rodman et 
al., 2000). Significantly, each of these proteins associates with particular organelles 
suggesting a degree of regulatory specificity (Figure 8). For example, rab5 is found on 
the membranes of early en do somes and is important for trafficking of material from 
internalised clathrin-coated pits to early endosomes (McLauchlan et ai., 1998; Rodman 
et aI., 2000). Rab4, in contrast, localises to recycling compartments where it is an 
important regulator of recycling activity (Daro et al., 1996). Rab7, in turn, plays a 
critical role in regulating trafficking from early to late endosomes and lysosomes (Feng 
et ai., 1995). In order for the rab proteins to exert their regulatory effects, they must 
interact with specific effector proteins. One such effector whose role has been well 
documented is rabaptin-5, a specific effector of rab5 that is integral to early endocytic 
trafficking (Stenrnark et al., 1995; Gournier et al., 1998; Gonzalez et ai., 1999). 
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Figure 8. Role of rab proteins in endocytosis 
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The rab proteins are small GTPases that regulate trafficking in specific stages of the 
endocytic pathway. Rab5 and its effector, rabaptin-5, are important for internalisation 
into clathrin-coated pits and fusion with early endosomes. Rab4 regulates the direct 
recycling pathway from early endosomes back to the plasma membrane. Rab7 
regulates transport from early to late endosomes and Iysosomes. 
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1.6.2.2 Utility of rab proteins and effectors as endocytic markers 
The specificity of rab proteins and their effectors for associating with and regulating 
distinct components of the endocytic pathway underlies their utility as tools to monitor 
activity in the various stages of endocytosis. Rab5 and rabaptin-5 are pertinent markers 
of intemalisation/early trafficking whereas the specificity of rab4 for recycling 
endosomes makes it an appropriate marker of recycling activity. Overexpression of 
rabaptin-5 stimulates endocytic uptake whereas immunodepletion of rabaptin-5 inhibits 
early endosome activity (Bucci et aI., 1992; de Hoop et al., 1994). Similarly, 
overexpression of rab4 promotes increased endosomal recycling (van der Sluijs et al., 
1992; Daro et al., 1996). The level of expression of these proteins is therefore thought 
to be an indicator of endocytic activity in the specific pathways they regulate. 
Moreover, elevations in immunoreactivity of these markers have been shown to reflect 
increased numbers of endosomes which is indicative of enhanced activity in the relevant 
pathways (Cataldo et al., 1997; Cataldo et al., 2000). 
1.6.3 Trafficking of apoE through the endocytic pathway 
Although the intracellular trafficking of apoE is poorly understood, the use of in vitro 
studies has revealed some important details. Support for LRP representing the major 
receptor mediating neuronal apoE endocytosis has arisen from studies using molecules 
that prevent binding of apoE to LRP, such as receptor associated protein (RAP) and 
lactoferrin. Blocking LRP in this way eliminated neuronal apoE staining in cultured 
neurons incubated with exogenous apoE (Williams et al., 1998) and also abolished the 
neurotrophic effects of exogenous apoE added to adult mouse cortical neuron cultures 
(Nathan et al., 2002). Further experiments tracking the progress of apoE through the 
endocytic system have revealed isoform-specific variations in trafficking. Although 
trafficking of both apoE3 and apoE4 through early endosomes was demonstrated, 
apoE4 progressed to late endosomes and lysosomes whereas apoE3 did not, possibly 
following a recycling pathway instead (DeKroon and Armati, 2001). 
1.6.4 ApoE receptors, endocytosis and signal transduction 
There is accumulating evidence that the function of the LDL family of receptors, and in 
particular LRP, may not be restricted to the binding and internalisation of lipoproteins 
(Willnow et al., 1999; Herz and Beffert, 2000; Herz and Strickland, 2001; Nykjaer and 
Willnow, 2002). The initial identification ofLRP as a receptor for the protease inhibitor 
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<l2-macroglobulin (Kristensen et al., 1990; Strickland et al., 1990) has led to the 
subsequent discovery of over 30 ligands that recognise LRP, including proteases, 
protease inhibitors and matrix metalloproteinases (Herz and Strickland, 2001). A role 
for LRP in signal transduction was implied by the presence of two copies of the NPxY 
motif in the cytoplasmic tail of LRP. Only one motif is required for mediating 
endocytosis suggesting that interactions with cytosolic proteins other than the endocytic 
machinery may be possible (Chen et al., 1990; Willnow et al., 1999). Two cytoplasmic 
adaptor proteins, disabled-l (Dab-I) and FE65, which interact with NPxY motifs in the 
LRP receptor via phosphotyrosine-binding (PTB) domains have been identified 
(Trommsdorff et al., 1998; Gotthardt et al., 2000). The intracellular effects mediated by 
these interactions are currently unknown although studies using Dab-l mutant mice 
suggest a critical role for Dab-l in the Reelin signalling pathway (Howell et al., 1997). 
Significantly, association of FE65 with the cytoplasmic tail of ~-amyloid precursor 
protein (APP) has been demonstrated (Bressler et al., 1996; Zambrano et al., 1997; 
Kinoshita et al., 2001), which enables interaction of LRP and APP via this adaptor 
protein. Additional interactions between LRP and ~-APP via extracellular Kunitz-type 
protease inhibitor (K-PI) domains have also been shown (Kinoshita et al., 2001). 
Together, these findings have important implications for AD pathogenesis, since they 
suggest mechanisms by which LRP may influence APP processing. (Ulery et aI., 2000; 
Pietrzik et al., 2002). Notably, binding of apoE to LRP can modulate the interactions of 
LRP with APP and blocking LRP with RAP diminishes A~ production (Ulery et al., 
2000). 
In view of the integral role ofNPxY domain interactions in endocytic intemalisation 
and putative signalling pathways it is conceivable that there may be interplay between 
the two processes. Receptor-mediated endocytosis is a well established way of down-
regulating extracellular signals and it has been proposed that assembly of receptors in 
clathrin-coated pits during endocytosis may displace adaptor proteins and therefore 
switch off cytosolic signalling capabilities (Willnow et al., 1999). 
1.6.5 Endocytic alterations in Alzheimer's disease 
To date, there has been little investigation of endocytic pathway function in the injured 
brain. However, there has been increasing interest in the neuronal endosomal-Iysosomal 
system in view of its possible importance in AD pathogenesis. Several proteins strongly 
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implicated in AD pathophysiology, such as apoE, APP, A~ and LRP are all trafficked 
through the endocytic pathway and therefore the endocytic pathway, and early 
endosome in particular, is a key point of convergence for these molecules. The 
endocytic pathway is fundamental to apoE and LRP trafficking. In addition, there is 
evidence that APP can be processed through the endosomal-Iysosomal system (Haass et 
af., 1992; Golde et al., 1992; Koo et aI., 1996; Yamazaki et aI., 1996). Furthermore, 
proteolytic production of A~ may occur in the early endosome shortly after 
intemalisation of APP from the cell surface (Koo et al., 1994; Refolo et al., 1995). 
Initial studies in AD post-mortem brain revealed up-regulation of neuronal lysosomal 
activity in affected regions (Cataldo et al., 1995; Cataldo, et al., 1996). Subsequently, 
increased endocytic activity was also shown in post-mortem AD brain which the 
authors speculate may induce elevated APP intemalisation and A~ production through 
increased protease delivery (Cataldo et al., 1997). Enhanced endocytic uptake and 
recycling may represent alterations occurring during the early stages of AD SInce 
increased numbers of abnormally enlarged early and recycling endosomes were 
observed in post-mortem brain from individuals at pre-clinical stages of AD and in 
patients with Down syndrome (Cataldo et al., 2000). Furthermore, possession of the 
APOE E4 allele was associated with more pronounced endocytic alterations in this 
study, suggesting that isoform-differences in endocytic activity may exist that could 
influence the processing and interactions of several putative aetiological factors in AD. 
To date, the response of the endocytic pathway after cerebral ischaemia has not 
been investigated. 
1.7 Modulation of apoE levels by APOE gene transfer 
1.7.1 APOE as a candidate for gene transfer to the brain 
ApoE is markedly upregulated after ischaemic brain injury and APOE deficient mice 
display a poorer outcome after cerebral ischaemia (section 1.4). These results suggest 
that the availability of apoE is a key factor that helps to protect the brain after injury. 
This is supported by the demonstration that restoring CSF apoE levels in APOE 
deficient mice ameliorates ischaemic damage after global ischaemia (Horsburgh et al., 
2000b). In this study, a physiological concentration (5J.1g/ml) of lipid-conjugated apoE 
was administered by intraventricular infusion and reduced the extent of ischaemic 
damage in APOE deficient mice to a level comparable with that in saline-treated wild-
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type mice. In addition, there was a trend toward reduced ischaemic damage in wild-type 
mice infused with apoE. These data indicate that augmenting endogenous apoE levels 
could have beneficial effects on the response of the brain to injury. 
Aside from direct administration of apoE, another approach to achieve this is by 
viral-vector mediated gene transfer of APOE. A number of studies have shown that viral 
vectors can be used to transfer a specific gene into the brain and mediate expression of 
the gene product and thus modulate levels of the targeted protein. Advantages of a viral 
vector-mediated gene transfer strategy to the brain include the potential for prolonged 
production of the protein and the ability to induce localised alterations in protein levels. 
Viral vector-mediated transfer of genes encoding various classes of protein (e.g. 
neurotrophic factors, anti-apoptotic proteins, anti-inflammatory mediators) have 
previously been demonstrated to have neuroprotective effects in models of cerebral 
ischaemia (jor review see Ooboshi et ai., 2003). To date, however, the efficacy of 
APOE gene transfer has not been investigated. 
1.7.2 Viruses as vectors for gene transfer 
A prerequisite for successful gene transfer is the efficient delivery of the appropriate 
therapeutic gene to the appropriate target tissue. Two major classes of vector system -
viral and non-viral- have been developed that can mediate effective gene transfer to the 
eNS in vivo. Non-viral approaches include the use of DNA conjugates and cationic 
liposomes to deliver genetic material (Shi and Pardridge, 2000; Zhang et ai., 2003). 
Viral vectors, however, possess a number of properties that render them particularly 
suitable for gene transfer and are currently the most extensively used tools for in vivo 
gene delivery to the eNS. 
Viruses are microscopic particles (10 - 50nm in diameter) composed of nucleic acid 
(DNA or RNA) enclosed in a protein coat (capsid) and in certain cases a membranous 
envelope. The key attribute of a virus that underlies its utility as a gene transfer vector is 
its inherent ability to infect and transfer genetic material to host cells. Viruses are 
therefore highly evolved natural vectors for the transfer of foreign genetic information 
into cells. Other properties of viral vectors that are advantageous include: the relative 
ease of engineering viruses to include genes of interest; increased selectivity for specific 
cell types (e.g. dividing/non-dividing) or tissue (e.g. brain) in comparison to non-viral 
vectors; and in general greater efficiency of gene transfer and stability of the foreign 
gene once inside the host cell. Limitations of viral vectors include the limited size of 
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DNA that can be transferred and the stimulation of deleterious immunological and/or 
inflammatory responses. 
In order for viruses to be suitable for use as gene transfer vectors, they must be 
modified to render them replication defective and thus prevent proliferation of new viral 
particles and cell destruction in host tissue. Attenuation of replicative ability is achieved 
by removal of certain sections of the viral genome that are responsible for viral 
replication. Genetic manipulation of viral vectors is thus designed to retain virus 
infective ability but not replicative ability. Deletion of sections of the viral genome also 
provides a site in which the gene of interest can be inserted. A further aim of genetic 
modification of viral vectors is to minimise the immune/inflammatory response 
triggered by viral gene expression which may be achieved by removal of additional 
regions ofthe viral genome. 
To date, five major classes of virus have been used extensively as viral vectors: (1) 
retroviruses, (2) herpes simplex viruses, (3) adenoviruses, (4) adeno-associated viruses 
and (5) lentiviruses. Each type of virus has its own unique properties such as the 
amount of DNA that can be packaged, cell tropism, efficiency and stability of transgene 
expression and the host immune response triggered. The most appropriate type of viral 
vector is therefore dependent upon a number of factors, most notably the gene of 
interest and the features of the target tissue/cell-type. In this thesis, an adenoviral vector 
was used to transfer genetic material to the brain and therefore the following section 
will focus on the characteristic features and utility of adenovirus as a viral vector. 
1.7.3 Adenoviral vectors 
Adenoviruses are linear double-stranded DNA viruses containing a genome 30 - 35kb 
in size that, in native form, can be pathogenic in humans causing intestinal, upper 
respiratory and eye infections (Kennedy et aI., 1997; Robbins et ai., 1998). Over 50 
human adenoviral serotypes have been identified; serotypes 2 and 5 have been most 
commonly used to generate vectors. These are also the most common serotypes to 
which humans have been exposed and therefore pre-existing immunity may be present, 
a factor that may influence the efficacy of subsequent adenoviral vector administration 
in humans. Adenovirus serotypes 2 and 5 enter host cells through binding to the 
coxsackievirus-adenovirus receptor and reach the nucleus via nuclear pores where the 
genome remains episomal (does not integrate into the host cell genome). Four different 
early viral genes (El, E2, E3 and E4) that are important for viral replication are 
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expressed following infection. Initial construction of attenuated adenoviral vectors (first 
generations vectors) involved deletion of the E 1 gene, expression of which is required 
for induction of the E2, E3 and E4 genes and viral replication. Deletion of the El gene 
therefore produces a replication defective vector and provides a site for insertion of the 
therapeutic gene(s) of interest. Favourable characteristics of adenoviral vectors include 
their relatively large packaging capacity, relative ease of growth to high titres (up to 1 X 
1013 virus particles/ml) and the ability to transduce an extensive range of cell types 
(dividing and non-dividing) with high efficiency, an important characteristic for gene 
transfer to the eNS (Akli et a/., 1993; Robbins et al., 1998; Zou et al., 2000; Kay et al., 
2001) 
However, despite reports of sustained transgene expression for months following 
injection of adenovirus vectors into brain parenchyma (Byrnes et al., 1996; Kajiwara et 
al., 1997), it is widely acknowledged that a major limitation of these first generation 
vectors is their triggering of inflammatory and immune responses that can substantially 
, 
diminish transgene expression over time (Byrnes et al., 1995; Byrnes et al., 1996; 
Tripathy et al., 1996; Wood et a/., 1996; Kajiwara et al., 1997; Kajiwara et al., 2000). 
Immunogenicity of first generation vectors has been attributed to "leaky" expression of 
viral genes. For this reason, efforts were made to construct a less immunogenic 
adenovirus vector by deletion of additional regions of the viral genome such as the E3 
and E4 genes. The result has been development of second generation vectors variously 
called "gutless", "helper-dependent" or "high-capacity" adenovirus vectors that are 
almost devoid of viral genome (Amalfitano et al., 1998; Morsy et al., 1998; Gorziglia et 
al., 1999). Attenuated immune responses and prolonged trans gene expression have been 
demonstrated following both peripheral and intracerebral administration of these gutless 
adenovirus vectors in comparison to conventional first generation vectors (Morral et al., 
1998; O'Neal et al., 1998; Thomas et al., 2000; Zou et al., 2000; Kochanek et al., 
2001b; Thomas et al., 2001). 
1.7.4 Adenoviral transduction and transgene expression in the brain 
The cellular tropism of viral vector transduction and transgene expression in the brain is 
influenced by a number of factors. These include the type of virus, the cellular 
distribution of proteins required for entry of viral particles into host cells and the 
features of the promoter and associated regulatory elements driving transgene 
expression. Since adenovirus is capable of infecting post-mitotic cells, transduction of 
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neurons is feasible. Widespread distribution of the coxsackievirus-adenovirus receptor 
also facilitates entry of adenovirus into most cell types in the brain, including neurons 
and glia (Glover et at., 2002). In general, therefore, adenoviral vectors transduce both 
neurons and non-neuronal cells (astrocytes, oligodendrocytes, microglia and endothelial 
cells), although transduction of non-neuronal cells probably occurs with greater 
efficiency (Kugler et at., 2001). However, studies investigating the expression of 
reporter genes such as green fluorescent protein (GFP) and ~-galactosidase (~-gal) have 
shown that the type of promoter strongly influences the cellular specificity of adenoviral 
transgene expression. The human cytomegalovirus (CMV) promoter is widely used to 
drive trans gene expression in adenoviral vectors. A predominantly glial pattern of 
trans gene expression has been reported with this promoter both in vivo and in vitro 
(Hermann et at., 2001b; Kugler et at., 2001; Kugler et at., 2003). In the absence of glia, 
however, strong trans gene expression has been demonstrated in hippocampal neurons 
suggesting that non-neuronal transduction and/or trans gene expression may actively 
suppress CMV promoter activity in neurons perhaps via a cytokine-mediated 
mechanism (Kugler et at., 2001; Kugler et at., 2003). Attempts have been made to 
achieve neuron-restricted trans gene expression through various methods including 
modification of the viral particle (Biermann et at., 2001) and use of cell-specific 
promoters such as the neuron-specific enolase promoter (Navarro et al., 1999; Kugler et 
at., 2001). However, recent evidence suggests that the human synapsin 1 gene promoter 
may offer the most efficient and prolonged neuron-specific transgene expression in vivo 
(Kugler et at., 2001; Glover et al., 2003; Kugler et at., 2003). 
1.7.5 Adenoviral vector-mediated gene transfer and cerebral ischaemia 
Reflecting their utility for CNS gene transfer, adenoviral vectors (mostly first 
generation) have been used in the majority of studies investigating the efficacy of gene 
transfer strategies in cerebral ischaemia. Delivery of adenoviral vectors containing a 
variety of ''therapeutic'' genes have been shown, to protect against ischaemic brain 
damage (Ooboshi et al., 2003). These include genes encoding neurotrophic factors 
(Kitagawa et aI., 1999; Yagi et al., 2000; Hermann et al., 2001 b; Zhang et al., 2002), 
anti-apoptotic proteins (Kilic et al., 2002) and anti-inflammatory mediators (Betz et al., 
1995; Yang et al., 1997b; Yang et al., 1999). These data indicate that adenoviral vector-
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mediated delivery is a feasible strategy for investigating the effects of APOE gene 
transfer in cerebral ischaemia. 
1.8 Hypotheses and aims of thesis 
In view of previous work described in this introduction, the overall objective of this 
thesis was to further investigate the role of APOE in cerebral ischaemia. To achieve this 
objective, three main hypotheses were tested: 
1. APOE e4 is associated with poorer outcome after transient focal ischaemia 
2. APOE genotype-dependent alterations in the endocytic pathway occur after 
cerebral ischaemia 
3. Adenoviral vector-mediated gene transfer of APOE reduces ischaemic brain 
damage after transient focal ischaemia 
To test the above hypotheses, a number of aims were established which were to: 
1. Determine, in human post-mortem temporal lobe tissue, if APOE genotype-
dependent alterations in the endocytic pathway occur after global ischaemia 
2. Establish and characterise the intraluminal filament model of transient focal 
ischaemia in the mouse 
3. Determine if APOE genotype is associated with differences in outcome after 
transient focal ischaemia in the mouse 
4. Determine if APOE genotype-dependent alterations in apoE and the endocytic 
pathway occur after transient focal ischaemia in the mouse 
5. Determine if intracerebral adenoviral vector-mediated gene transfer of APOE IS 
neuroprotective in a mouse model of transient focal ischaemia 
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Chapter 2 
Materials and Methods 
2.1 Human post-mortem brain tissue 
All experiments using human post-mortem tissue were approved by the ethics 
committee of the Southern General Hospital, Glasgow. 
2.1.1 Tissue processing and selection 
Paraffin-embedded sections of medial temporal lobe from patients who died after an 
episode of global ischaemia due to cardio-respiratory arrest and control patients (see 
below) were selected from the archives of the Department of Neuropathology, Southern 
General Hospital, Glasgow. Archival tissue was derived from material originally 
referred to the Department of Neuropathology from 1984 - 1996 for standard 
neuropathological examination. Tissue used in this thesis was from a systematically 
selected cohort of patients with detailed case histories identified by Prof James Nicoll 
and Dr Karen Horsburgh for a previous study (see below). 
Whole brains were immersion-fixed in 10% fonnal saline for up to 3 weeks. Brains 
were then cut in a standard fashion for neuropathological examination; lcm coronal 
slices of the cerebral hemispheres, lcm slices of the cerebellar hemispheres at right 
angles to the surface markings of the folia and 0.5cm horizontal slices of the brainstem 
were cut. After general observations were made, regions of interest (including the 
medial temporal lobe) were identified and blocks were dissected from the cerebral 
hemispheres for paraffm processing and embedding. Thereafter, 8J.1Ill sections were cut 
and mounted on poly-L-Iysine coated glass slides. Sections were routinely stained with 
haematoxylin and eosin and luxol fast blue/cresyl violet for histological examination. 
For a previous study (Horsburgh et al., 1999a), histological examination of medial 
temporal lobe sections from patients who died after cardio-respiratory arrest and from 
patients who died from other causes was perfonned by Prof James Nicoll and Dr Karen 
Horsburgh to identify suitable global ischaemia case and control material. For control 
material, case and post-mortem reports were consulted and tissue from patients without 
clinical or neuropathological evidence of neurological/psychiatric impainnent or 
cardiovascular disease was selected. For global ischaemia material, case and post-
mortem reports were consulted and patients who had experienced cardio-respiratory 
arrest with subsequent resuscitation and a defined period ofreperfusion (survival) were 
identified. Tissue used in this thesis was from this carefully selected cohort of cardio-
respiratory arrest and control individuals (see Appendix C for clinical details). 
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2.1.2 APOE genotyping 
This procedure was perfonned by Mrs Janice Stewart at the Department of 
Neuropathology, Southern General Hospital. APOE genotype was detennined using a 
polymerase chain reaction (PCR) method that was optimised for archival formalin-fixed 
paraffin-embedded tissue and has been described previously (Nicoll et ai., 1997). 
For each case, one 8JlIl1 tissue section was placed in a sterile Eppendorf tube and 
1ml xylene was added. Tubes were vortexed for 1min and then centrifuged at 
13,OOOrpm for 5min. Xylene was decanted, 1ml ethanol was added and tubes were 
vortexed for 1min and then centrifuged at 13,OOOrpm for 5min. Ethanol was decanted 
and 1ml fresh ethanol was added and vortexing and centrifuging was repeated. Ethanol 
was decanted and residual ethanol was removed by placing tubes on a dry heat block 
(55 - 60°C) for 1h. 
The dried tissue sample was resuspended in a proteinase K digest reaction mix 
containing 4,.d proteinase K (200J-lg/ml), 20J-ll PCR buffer (perkin Elmer Amplitaq Gold 
containing 15mM MgCh) and 176J-l1 water (Sigma). The solutions were overlaid with 5 
- 6 drops of mineral oil (Sigma) and incubated at 56°C (waterbath) overnight. Samples 
were then incubated at 95°C for lOmin to inactivate proteinase K. Samples containing 
target DNA were stored at -20°C or -80°C until PCR amplification. 
PCR reactions took place in a total volume of l5J-l1 comprising 14.21l1 master mix 
and O.8J-ll target DNA solution. Master mix contained 9.025J-ll Analar water, 1.5J-l1 PCR 
buffer (Amplitaq Gold), 1.5J-l1 dNTP solution (containing 2mM each of dATP, dCTP, 
dGTP and dTTP), 1. 5 III dimethyl sulphoxide (DMSO), and 0.3J-l1 of each primer 
(10IlM). Left and right primers were described previously (Wenham et ai., 1991). 
Sequences are as follows: 
Left 5' -ACAGAATTCGCCCCGGCCTGGTACACTGCCA-3' 
Right 5'-TCCAAGGAGCTGCAGGCGGCGCA-3' 
14.2J-ll master mix was pipetted into an Eppendorftube and was overlaid with one drop 
mineral oil and then O.81ll target DNA solution was added. Tubes were then transferred 
to a thennal cycler (Techne Genius) which was programmed to cycle through a series of 
temperature changes as follows: 
1. 35°C (to preheat lid) 
2. 94°C - 9min (to denature target DNA and activate DNA polymerase) 
then 40 cycles of 
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3. 94°C - Imin (to denature target DNA) 
4. 65°C - Imin (to anneal primers) 
5. 72°C - 2min (to extend DNA) 
Hhal Restriction endonuclease (1.21l1) was added to 15111 ofPCR reaction product 
and incubated at 37°C overnight. The Hhal restriction endonuclease cleaves at GCGC 
sites in the DNA sequence, which corresponds to arginine residues in the protein 
sequence. ApoE isoform differences in amino acid sequence result from substitutions at 
positions 112 and 158 of the 299 amino acid protein (see section 1.2.4.2). Hhal 
digestion of the target DNA will therefore produce fragments of varying lengths 
depending on APOE isoform. These fragments can be separated and identified by gel 
electrophoresis. 
A 10% polyacrilamide gel was used. 4111 of gel loading solution was added to 15111 
of PCR product and mixed thoroughly before samples were loaded into the gel wells. A 
DNA ladder was also prepared: 0.51l1 Hinf I marker was added to 24111 distilled water 
and then 4111 of gel loading solution was added and mixed thoroughly before loading on 
to the gel. The gel was run at 20Ovolts/0.06amps for approximately 4Omin. Gels were 
then removed from the assembly, stained with ethidium bromide solution (IOmglml) for 
4min, viewed on an ultraviolet light box and photographed. 
2.2 Mice 
Upon arrival, all mice were housed in an animal housing facility. At both the Wellcome 
Surgical Institute (WSI), University of Glasgow, and Division of Neuroscience, 
University of Edinburgh, mice were housed in barrier-controlled units screened every 3 
months for pathogens. Units were on a 12h light/dark cycle with regulated environment 
(temperature, humidity). All mice were given access to food and water ad libitum upon 
arrival in each facility. A summary of mouse numbers used in each study is given in 
Appendix B. 
2.2.1 C57BI/6J mice 
C57B1I6J mice were obtained from Charles-River, UK. C57B1I6J is the most widely 
used inbred strain and most commonly used background strain for generation of 
transgenic mice (including APOE transgenic mice used in this thesis). An inbred strain 
is defined as one which has been maintained by sibling (brother x sister) matings for 20 
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or more consecutive generations. Aside from sex difference, mice from an inbred strain 
are as genetically alike as possible, being homozygous at virtually all loci. 
2.2.2 APOE transgenic mice 
2.2.2.1 Production of transgenic mice by pronuclear injection 
There are essentially three methods of generating transgenic mice: (1) retroviral 
integration of foreign DNA into an early developing embryo; (2) direct microinjection 
of foreign DNA into the pronucleus of a newly fertilised egg; (3) genetic manipulation 
of embryonic stem cells. The APOE transgenic mice used in this thesis were generated 
using the pronuclear injection technique (Xu et al., 1996). 
The technique of producing transgenic mice by pronuclear microinjection of DNA 
was pioneered over 20 years ago (Gordon et al., 1980; Gordon and Ruddle, 1983) and 
has since become the most extensively used technique. A major advantage of this 
technique is that large fragments of DNA can be injected into the pronucleus, thus 
allowing complete genes and their regulatory elements to integrate into the genome 
(Evans, 1994). This technique is also remarkably efficient; approximately 80% of 
founder mice are true transgenics (every cell contains the integrated transgene), 
indicating that DNA integration occurred at the one-cell embryo stage (Brinster et al., 
1985; Evans, 1994). A disadvantage of this technique, however, is that foreign DNA 
typically integrates into the genome by non-homologous recombination and therefore 
can integrate randomly at mUltiple sites and cause DNA rearrangement (Reventos and 
Gordon, 1990). The site of integration in the genome can affect transgene expression, 
so that different founder mice with different integration sites often demonstrate different 
levels of expression (Evans, 1994). 
2.2.2.2 Generation of transgenic mice expressing human APOE 
APOE transgenic mice were obtained through collaboration with Dr Allen Roses 
(GlaxoSmithKline, USA). APOE £3 and £4 transgenic mice expressing human APOE 
under control of human regulatory sequences were used. These lines were initially 
produced and characterised at Duke University, USA, and have been described in detail 
previously (Xu et al., 1996). APOE knockout mice were generated by inactivating the 
endogenous APOE gene by gene targeting in embryonic stem cells (piedrahita et al., 
1992). Cosmid libraries were constructed from lymphoblasts of humans who were 
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verified to be homozygous carriers for the APOE E3 and E4 alleles. Fragments 
containing human regulatory sequences and the coding sequences for human APOE (E3 
and E4) were isolated, purified and injected into single-celled embryos from 
homozygous APOE-deficient mice and transferred to female recipients (a cross of 
C57B1I6J x DBAl2J) to produce founder transgenic mice. Founder mice were backbred 
to APOE knockout mice to generate animals hemizygous for human APOE trans genes 
and homozygous for inactivated mouse APOE gene. Animals were bred to 
homozygosity for human APOE transgenes and backbred into APOE knockout strains to 
remove the genetic influence of DBAl2J background strains. The presence of human 
APOE was confirmed by polymerase chain reaction (PCR). The mice were backcrossed 
at least six times to C57B1I6J mice in the USA before transport to the UK and thereafter 
several backcrosses to C57B1I6J mice were made at GlaxoSmithKline, UK. For the 
APOE transgenic study in this thesis, the APOE E3-437 and APOE £4-81 lines were 
used which carry two copies of the respective transgenes. These lines were best matched 
for apoE levels from the original lines bred. The mice were transferred from 
GlaxoSmithKline, UK to the Wellcome Surgical Institute, where surgical procedures 
were performed. 
2.2.2.3 APOE genotyping 
Tail tissue samples were used to confirm the APOE genotype of mice bred in-house. 
Each mouse was briefly anaesthetised with 3% halothane in a mixture of 30% oxygen 
and 70% nitrous oxide. A tail-tip tissue sample was collected by removing a small 
portion from the tail-end using aseptic technique. The tail was cauterised to prevent 
bleeding and the mouse was returned to its cage. Tissue was placed in a sterile 
DNAIRNA-free eppendorftube containing ethanol and stored at 4°C. Tail samples were 
transported at 4°C to the Southern General Hospital where APOE genotype was 
determined by Mrs Janice Stewart. After decanting ethanol, samples were dried and 
DNA extracted as described previously (section 2.1.2) except a proteinase K 
concentration of lOOJ.l.g/ml was used. PCR and gel electrophoresis (Figure 9) was 
performed as previously described (section 2.1.2) 
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Figure 9. Genotyping of APOE transgenic mice 
91bp 
72bp 
48bp 
33bp 
10% polyacrilamide gel stained with ethidium bromide showing the specific DNA 
fragments associated with the APOE E3 and E4 genotype. Image courtesy of Mrs 
Janice Stewart. 
2.3 Surgical procedures 
All animal procedures were carried out under appropriate Home Office Personal 
(60/8182) and Project Licences (60/2023, 6012942, 60/3043) and adhered to regulations 
as specified in the Animals (Scientific Procedures) Act (1986). Upon arrival in the 
animal unit, a period of at least one week elapsed prior to surgical procedures to allow 
acclimatisation. Adult male mice were used for all surgical procedures. 
2.3.1 Stereotaxic injection 
Stereotaxic injections were performed by Dr Karen Horsburgh at the Division of 
Neuroscience, University of Edinburgh. Each mouse was placed in a perspex chamber 
and anaesthesia was induced with 3% halothane in a mixture of 30% oxygen and 70% 
nitrous oxide. Each mouse was then placed onto a stereotaxic frame and mechanically 
ventilated (125 breaths per minute). Anaesthesia was maintained with approximately 
2% halothane in the same mixture of oxygen and nitrous oxide for the duration of 
surgery. A skin incision was made above the parietal skull and a burr hole was carefully 
drilled through the bone overlying the parietal cortex. Stereotaxic infusions (0.51-11 over 
5min) were made in the dorsolateral caudate nucleus (2.5nun lateral to midline at 
bregma level and 3mm from the cortical surface) (Figure 10). After infusion, the needle 
was left in place for 10min to prevent diffusion along the needle tract. The needle was 
then withdrawn and the wound sutured. Anaesthesia was discontinued and mice were 
allowed to regain consciousness before being transferred to a temperature-controlled 
(30°C) incubator for 2h. Subsequently, mice were returned to the animal recovery room 
58 
where they were housed singly and given free access to food and water. Soft food was 
provided during recovery to aid post-surgery feeding. Throughout the recovery period, 
the condition of the mice was regularly monitored (at least twice daily) and recorded on 
an animal recovery form. 
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Figure 10. Location of stereotaxic injections 
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Injections were made in the dorsolateral caudate nucleus (2.5mm lateral to midline at 
bregma level and 3mm from the cortical surface). 
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2.3.2 Intraluminal filament occlusion 
Two models of intraluminal occlusion were used in this thesis. A sustained anaesthesia 
(during occlusion) model was fully characterised and used in studies (chapters 4 and 5) 
performed at the Wellcome Surgical Institute, Glasgow. A recovery (during occlusion) 
from anaesthesia model was used in the viral vector study (chapter 6) performed at the 
Division of Neuroscience, Edinburgh. 
2.3.2. 1 Sustained anaesthesia model 
Intraluminal filament occlusion in the mouse had not previously been performed at the 
Wellcome Surgical Institute and therefore, development of and gaining competence in 
the surgical technique was necessary prior to use of the model in studies described in 
this thesis. During the initial development of the technique, competence was gained in 
general surgical protocols, such as inducing/maintaining an appropriate level of 
anaesthesia, aseptic technique, control of body temperature and suturing. The technique 
first described by Longa et al. (1989) was used as the basis for optimising the surgical 
approach. At the outset, a number of technical issues were addressed, for example, the 
most appropriate approach for tissue dissection and exposure of the carotid vessels and 
the approximate distance to insert the filament. It was particularly important to establish 
the most appropriate size of occluding filament to use (see section 4.3.1.1) as previous 
studies reported the use of both a 5-0 and 6-0 heat-blunted filament. Accordingly, this 
preliminary work led to the intraluminal occlusion technique described below being 
established. 
Each mouse was placed in a Perspex chamber and anaesthesia was induced with 3% 
halothane in a mixture of 30% oxygen and 70% nitrous oxide. The mouse was then 
transferred to the operating surface where anaesthesia was maintained for the duration 
of surgery with 1.5% halothane in the same mixture delivered by a face mask. Core 
temperature was monitored with a rectal probe and maintained at 37 ± 0.5 °C using a 
heat lamp. 
Intraluminal filament occlusion was produced using a modification of the method 
previously described by Longa et al. (1989). A midline neck incision was made and the 
left submandibular gland freed and retracted cranially. The left carotid bifurcation was 
exposed and connective tissue surrounding the common carotid artery (CCA), external 
carotid artery (ECA), internal carotid artery (ICA) and occipital artery was cleared. 
60 
Particular care was taken to ensure that the vagus nerve was not disturbed. The occipital 
artery, superior thyroid artery and maxillary artery were electro-coagulated then 
divided. The ECA was ligated with 6-0 silk thread. 6-0 silk thread was looped loosely 
around the ICA proximal to the bifurcation with the pterygopalatine artery and 6-0 
thread was also tied loosely around the ECA proximal to the ligature. The ECA was 
electro-coagulated distal to the ligature. A microvascular aneurysm clip was temporarily 
placed on the CCA to establish proximal control and tension was applied to the loose 
thread around the ICA to establish distal control. An arteriotomy was made in the ECA 
proximal to the ligature and distal to the loosely tied thread and then a 5-0 nylon 
monofilament (heat-blunted rounded tip; diameter 185J.lIl1) was inserted into the ECA 
and advanced to the carotid bifurcation. The loosely tied thread around the ECA was 
tightened to hold the filament in place. Tension on the thread around the proximal ICA 
was relieved and the ECA was divided and the stump brought in line with the ICA. The 
filament was advanced along the ICA (9 - llmm distal to the carotid bifurcation) until 
the tip was positioned in the proximal part of the anterior cerebral artery (ACA) and 
therefore occluding the origin of the MCA (Figure 11). Sham occlusion was identical to 
that described above except that immediately following placement in the proximal ACA 
the filament was immediately withdrawn until the tip was positioned in the ECA. 
In experiments requiring 24h reperfusion-recovery, the filament was withdrawn 
after the desired duration of occlusion to allow reperfusion through the previously 
occluded MCA. In mice undergoing sham occlusion, the filament was withdrawn from 
the ECA. The ECA stump was electro-coagulated proximal to the arteriotomy to 
prevent bleeding upon removal of the filament. The neck wound was then closed and 
sutured with 6-0 silk thread and 1 ml sterile saline was administered by subcutaneous 
injection. Anaesthesia was discontinued and mice were allowed to regain consciousness 
(assisted by administration of oxygen via face mask) before being transferred to a 
temperature-controlled (30°C) incubator for 2h. Subsequently, mice were returned to 
their cages in the animal unit for the remainder of the recovery period where they were 
housed singly and given free access to food and water. Soft food was provided during 
recovery to aid post-surgery feeding. Throughout the recovery period, the condition of 
the mice was regularly monitored (at least 3 times daily) and recorded on an animal 
recovery form. 
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5-0 nylon monofilament 
(heat-blunted rounded tip; 
diameter 185f-U11) 
VA VA 
Figure 11. Intraluminal filament occlusion - surgical approach 
A 5-0 filament was introduced into the ECA and advanced along the ICA 9 - 11 mm 
distal to the carotid bifurcation. ACA - anterior cerebral artery; MCA - middle cerebral 
artery; ICA - internal carotid artery; PCA - posterior cerebral artery; SCA - superior 
cerebellar artery; SA - basilar artery; VA - vertebral artery. Figure adapted from 
Kitagawa et al. I 1998c. 
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2.3.2.2 Recovery from anaesthesia model 
This model was previously characterised and perfonned by Dr Ailsa McGregor. 
Induction and maintenance of anaesthesia and monitoring of core temperature was 
achieved as described for the sustained anaesthesia model. The surgical approach was 
also similar to that described for the sustained anaesthesia model except for a few key 
differences. Following exposure and electro-coagulation of carotid vessels, an 
arteriotomy was made immediately proximal to the carotid bifurcation. An 8-0 filament 
(Ethilon), the tip (3 - 4mm) of which was coated with silicon paste was then advanced 
along the ICA until resistance was felt, indicating that the tip was positioned in the 
proximal part of the ACA and therefore occluding the origin of the MCA. Following 
filament placement, the neck wound was temporarily sutured and the mouse was 
recovered from anaesthesia. The mouse was then placed in an incubator (30°C) for the 
duration of occlusion. After the desired duration of occlusion, the mouse was re-
anaesthetised as before and the filament was withdrawn to induce reperfusion. The neck 
wound was then closed and sutured and the mouse regained consciousness before being 
placed in an incubator for 2h and then returned to its cage for the remainder of the 
recovery period as described for the previous model. 
The main consequence of recovering mice from anaesthesia during occlusion is 
likely to be on blood pressure and hence cerebral blood flow during occlusion. In the 
recovery from anaesthesia model, blood pressure is likely to be more stable than in the 
sustained anaesthesia model since mice are conscious during occlusion. 
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2.3.3 Monitoring of mean arterial blood pressure 
Each mouse was placed in a supine position and an incision was made in the left 
femoral region. Connective tissue was removed to expose the femoral artery, vein and 
nerve. The femoral nerve was then carefully cleared from the artery and vein to provide 
unrestricted access to the artery. A 6-0 silk thread was tied tightly around the femoral 
artery and vein to establish distal control. Another 6-0 silk thread was then loosely tied 
around the femoral artery and vein close to the midline and tension applied to establish 
proximal control. Any small branches of the femoral artery which could cause potential 
bleeding were electro-coagulated. An arteriotomy was made in the femoral artery (in 
opposite side to vein) as near to the ligature as possible. A nylon cannula (internal 
diameter 0.5Omm; external diameter 0.63mm) was then inserted into the femoral artery 
through the arteriotomy and glued in place. Tension was relaxed on the proximal 
ligature to restore blood flow through the femoral artery. The cannula was then 
attached to a blood pressure monitoring line and connected to a pressure transducer. 
Mean arterial blood pressure was monitored using a computer system receiving input 
from the pressure transducer. 
2.3.4 Examination of cerebrovascular anatomy 
The major arteries and branches of the circle of Willis were examined. Each mouse was 
placed in a Perspex chamber and anaesthesia was induced with 3% halothane in a 
mixture of 30% oxygen and 70% nitrous oxide. The mouse was then transferred to the 
operating surface where anaesthesia was maintained for the duration of surgery with 
1.5% halothane in the same mixture delivered by a face mask. A sternotomy was 
performed to completely expose the heart. Approximately 20ml 0.9% saline was 
perfused through the vasculature via the left ventricle with an incision made in the right 
atrium to provide an outlet for perfused blood. A loss of colour in the liver, lungs and 
extremities and absence of blood from the exiting perfusate was used to indicate 
adequate removal of blood from the tissues. This was followed by perfusion of 5 - IOml 
of carbon blue ink through the vasculature to aid visualisation of the major arteries. A 
change in colour of the extremities was used as an indicator to terminate perfusion. 
Following perfusion, the mouse was decapitated and the brain removed from the skull. 
Cerebrovascular anatomy was examined under a dissecting microscope and the presence 
or absence of posterior communicating arteries was recorded. 
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2.4 Assessment of neurological deficit 
After 24h reperfusion and immediately prior to perfusion fixation, the neurological 
status of each mouse was assessed using a modification of the system described by 
Bederson et al. (1986). Neurological deficit was assessed according to a neurological 
grading score of increasing severity: 0 = no observable neurological deficit; 1 = failure 
to extend forelimb to grip cage-top; 2 = spontaneous circling; 3 = leaning/falling; 4 = no 
spontaneous movement. 
2.5 Perfusion fixation 
Mice were deeply anaesthetised with 3 - 4% halothane in a mixture of 30% oxygen and 
70% nitrous oxide and a sternotomy was performed to completely expose the heart. 
Approximately 20ml 0.9% saline was perfused through the vasculature via the left 
ventricle with an incision made in the right atrium to provide an outlet for perfused 
blood. A loss of colour in the liver, lungs and extremities and absence of blood from the 
exiting perfusate was used to indicate adequate removal of blood from the tissues. This 
was followed by perfusion of approximately 20ml of 4% paraformaldehyde (PAM) 
solution through the vasculature. Rigidity of the extremities was indicative of successful 
fixation. Following fixation, the mice were decapitated. If fixation was considered 
successful, the brain was left in the skull and immersed in PAM for 24h. The brain was 
then removed from the skull and immersed in PAM for a further 24h after which 
paraformaldehyde was replaced with phosphate buffer solution. If fixation was not 
considered satisfactory, the brain was immediately removed from the skull and 
immersed in PAM for 48h followed by immersion in phosphate buffer. 
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2.6 Paraffin processing, embedding and cutting 
2.6.1 Paraffin processing 
2.6.1. 1 Processing of whole brains 
Paraformaldehyde-fixed brains were processed either as whole brains (Well come 
Surgical Institute, Glasgow) or as 4mm slices (Division of Neuroscience, Edinburgh). 
Whole brain processing was used in initial experiments involving intraluminal 
occlusion to enable serial sections to be cut through the entire brain and the relative 
positions of the eight coronal levels used for volumetric measurement to be assessed. 
Individual brains were placed in labelled embedding cassettes and processed in an 
automated processor using a protocol previously optimised for whole mouse brain 
processing as outlined in Table 1. After processing, brains were embedded in fresh 
paraffin, cooled and allowed to set prior to cutting. 
Table 1. Paraffin processing protocol for whole brains 
Station Solution Temp. (OC) Duration (h) 
1 70% ethanol 30 2 
2 80% ethanol 30 2 
3 95% ethanol 30 2 
4 100% ethanol 1 30 2 
5 100% ethanol 2 30 2 
6 100% ethanol 3 30 2 
7 100% ethanol 4 30 2 
8 xylene/100% ethanol 30 2 
9 xylene 1 30 2 
10 xylene 2 30 2 
11 paraffin 1 65 2 
12 paraffin 2 65 2 
13 paraffin 3 65 2 
Brains were placed inside plastic processing cassettes and processed on a 26h cycle 
(13 stations x 2h each). 
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2.6.1.2 Processing of brain slices 
An alternative method was used to process brains at the Division of Neuroscience, 
Edinburgh. Paraformaldehyde-fixed brains were placed into a mouse brain matrix and 
cut into two coronal blocks (4mm thick). Individual blocks were placed in labelled 
embedding cassettes, washed in running water and then cassettes were placed in a series 
of wide-bodied measuring jars containing the following solutions: 
1. 70% ethanol- 2 x 30min 
2. 90% ethanol - 2 x 30min 
3. 100% ethanol- 2 x 30min 
4. xylene - 2 x 30min 
5. paraffm (65°C) - 2 x 30min 
6. paraffin (65°C) - overnight 
After processing, brain slices were embedded in fresh paraffin, cooled and allowed to 
set prior to cutting. 
2.6.2 Cutting 
Serial sections (6J.lm) were cut from paraffin-embedded whole brains or slices on a 
microtome. Particular care was taken to ensure sections were cut with satisfactory inter-
hemispheric symmetry and ventro-dorsal alignment. Sections were stretched by surface 
tension on a water bath (approximately 40°C) and mounted on poly-L-Iysine coated 
glass slides. Slides were dried on a hot-plate and then stored at room temperature in 
protective cases until required for staining. 
2.7 Histological staining 
Histological staining was used to enable observation of the general features of brain 
tissue (e.g. artefact, haemorrhage), examination of cell morphology and the 
identification of areas of ischaemic damage (section 2.8.2). 
2.7.1 Haematoxylin and eosin 
Haematoxylin and eosin (H & E) staining enables the assessment of the quality of tissue 
fixation/processing and identification of any artefact present. H & E is also an excellent 
stain for visualisation of cellular morphology and therefore differentiation of nonnal 
and ischaemic neurons is possible on the basis of morphological differences (section 
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2.8.2). Haematoxylin stains negatively-charged nucleic acids blue and is therefore 
primarily a nuclear stain, whereas eosin is a pink/red dye that stains acidophilic 
elements such as the cellular cytoplasm. 
Paraffin-embedded sections (6J.Ull) were de-waxed in an oven at 6SoC for 20min and 
in xylene (lOmin)lHistoclear (2 x lOmin) and then dehydrated in a series of alcohols: 
100% (2 x Smin) ~ 90% (2min) ~ 70% (2min) before briefly rinsing in running water. 
Sections were immersed in haematoxylin for 30s - 3min depending on intensity 
required, rinsed briefly in running water and then differentiated in acid alcohol (lOs) 
followed by a further rinse in running water (2min) and immersion in Scots Tap Water 
Solution (2min). Sections were then rinsed in running water (2min) before immersion in 
eosin (4min) and a further rinse in running water. Sections were then taken through a 
series of alcohols: 70% (2min) ~ 90% (2min) ~ 100% (2 x 5min). Finally, sections 
were cleared in xylenelHistoclear and covered with glass cover-slips. 
2.7.2 Thionin 
Thionin is a deep blue Nissl dye and therefore imparts a deep blue colour to basophilic 
components of the cell, particularly the nucleus, nucleoli and Nissl bodies found in the 
rough endoplasmic reticulum of the cytoplasm. Thionin staining demonstrates the 
grouping of nerve cell bodies into nuclei or layers, and gives information on the size of 
cell bodies and density of cell packing. Areas of ischaemic damage appear as areas of 
pallor on thionin stained tissue due to the shrinkage of the cell body and nucleus in 
ischaemic neurons. 
Paraffin-embedded sections (6J.lm) were de-waxed in an oven at 65°C for 20min and 
in xylene (1Omin)lHistoclear (2 x 10min) and then dehydrated in a series of alcohols: 
100% (2 x Smin) ~ 90% (2min) ~ 70% (2min) before briefly rinsing in running water. 
Sections were immersed in thionin for 20min and differentiated in 1% acetic acid (lOs). 
Sections were then taken through a series of alcohols: 70% (2min) ~ 90% (2min) ~ 
100% (2 x Smin). Finally, sections were cleared in xyleneIHistoclear and covered with 
glass cover-slips. 
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2.8 Volumetric measurement of ischaemic damage 
Volumetric measurement of ischaemic damage was carried out using a modification of a 
previously established technique that was developed and characterised in the laboratory 
for volumetric measurement of ischaemic damage after electro-coagulation of the MCA 
in rats (Osborne et al., 1987). The major principles of this technique are (1) the use of 
thin coronal sections cut from paraffin-embedded brain, (2) histological staining of 
sections at anatomically defined stereotaxic levels through the brain, (3) transcription of 
areas of ischaemic damage on to scale diagrams representing the stereotaxic levels, (4) 
measurement and integration of areas of damage to calculate the volume of damage. 
Since intraluminal occlusion in the mouse was the model of focal ischaemia used in this 
thesis some modifications were necessary, most notably the use of scale diagrams 
derived from a stereotaxic mouse atlas. 
2.8.1 Selection of sections at eight coronal levels 
Eight coronal levels were selected from the stereotaxic mouse (C57B1I6J) atlas ofHof et 
al. (2000) (1.6, 1.1, 0.2, -0.5, -1.1, -2.1, -3.6, -4.4mm with respect to bregma) (Figure 
12). These levels were chosen based on the previous report by Osborne et al. (1987) 
demonstrating that area measurements at eight coronal levels were adequate to 
accurately calculate the volume ofischaemic damage. Sections (6J.Ull) corresponding to 
the eight coronal levels were selected and stained with H & E. Distinct neuroanatomical 
landmarks defined which sections were chosen for each level (Table 2). 
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Figure 12. Coronal levels for quantification of ischaemic damage 
Sections corresponding to the eight coronal levels were selected for haematoxylin and 
eosin staining . Areas of ischaemic damage were delineated at each coronal level and 
integrated with the distance between levels to calculate a volume of ischaemic 
damage. Diagrams of coronal levels are from the stereotaxic atlas of Hof et a/. t (2000). 
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Table 2. Coronal levels and their neuroanatomical landmarks 
Stereotaxic co-
Coronal level ordinates (relative to 
bregma) (mm) 
1 1.6 
2 1.1 
3 0.2 
4 -0.5 
5 -1 .1 
6 -2.1 
7 -3.6 
8 -4.4 
Neuroanatomicallandmarks 
End of forceps anterior 
Nucleus accumbens; corpus callosum almost 
continuous at mid-line 
Lateral septal nucleus; caudate large and round; 
anterior commissure as band 
Globus pallidus large and round; minimal septal 
nucleus; lateral and third ventricles continuous 
Anterior hippocampus; anterior thalamus 
Medial habenula; lateral habenula 
Temporal and full hippocampus; substantia nigra 
(pars compacta) 
Peri-aqueductal grey matter, no hippocampus; 
subiculum; superior colliculus 
The eight coronal levels were selected from the stereotaxic atlas of Hof et al. (2000). Each level is 
associated with distinct neuroanatomicallandmarks which were used to select sections corresponding 
to each level. 
2.8.2 Identification of areas of ischaemic damage 
Areas of ischaemic damage were readily identifiable on H & E stained sections on 
account of characteristic cell morphology and tissue changes (Figure 13). Notably, 
areas of ischaemic damage contain neurons that typically display a shrunken and 
triangular cell body and nucleus and intensely eosinophillic cytoplasm. Pallor and 
vacuolation of the neuropil are also observed in areas of ischaemic damage. In contrast, 
undamaged tissue is composed of compact neuropil and contains neurons that typically 
display a large, round nucleus and cell body. Accordingly, boundaries between areas of 
ischaemic damage and morphologically normal tissue could be delineated. 
Ipsilateral to occlusion Contralateral to occlusion 
Figure 13. Identification of areas of ischaemic damage 
Areas of ischaemic damage (a,c) are characterised by shrunken, eosinophillic neurons 
surrounded by a vacuolated neuropil. In contrast, undamaged tissue (b,d) is composed 
of compact neuropil and contains neurons with large, round cell bodies and thin 
cytoplasm. Scale bar (a,b), 25f..lm; (c,d), 101-.lm. 
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2.8.3 Calculation of volume of ischaemic damage 
Scale diagrams representing the eight coronal levels were reproduced from the 
stereotaxic atlas ofHof et al. (2000) at 35% original size (x9 actual size of mouse brain) 
and arranged on an A4 sheet. A master copy was kept from which all copies were made 
using the same photocopier to ensure reproducibility. Areas of ischaemic damage were 
identified as described above and delineated on to the scale diagrams representing the 
eight coronal levels. The scale diagrams were placed on a light box, covered with a 
Perspex block to prevent paper curl and then digitised on an MelD image analysis 
system. The scale diagrams were superimposed on a stereotaxic grid which enabled 
direct calibration of distance from the digitised images and therefore accounted for the 
magnification of the scale diagrams from true brain size. For each brain, the area of the 
hemisphere at coronal level 3 (0.2mm rostral to bregma) was measured to verify 
reproducibility of scale diagram photocopying and image analyser set-up. The areas of 
ischaemic damage were then transcribed and measured at each coronal level. 
Approximation of the total volume (mm3) of hemispheric ischaemic damage was 
achieved by integration of areas (mm2) with the distance (mm) between each coronal 
level. The end points for integration were 2.9mm (rostral limit) and -4.9mm (caudal 
limit) with respect to bregma. This was calculated using the GrapbPad Prism software 
package which computes the area under a curve representing the area of ischaemic 
damage at each coronal level. 
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2.9 Immunohistochemistry 
2.9.1 Antibodies 
Initial characterisation of primary antibodies was perfonned to detennine the 
concentrations which produced optimal immunostaining in different tissues as outlined 
in Table 3. The species that the primary antibody was raised in detennined the type of 
secondary antibody used which in turn detennined the species of nonnal sera used in 
blocking solution to prevent non-specific binding of the secondary antibody (Table 3). 
For each antibody, control for the specificity of immunostaining was achieved by 
omission of primary antibody. 
2.9.2 Avidin-biotin (ABC) method of immunohistochemistry 
The "ABC" method of immunohistochemistry was used for all peroxidase-based 
staining procedures (Hsu et al., 1981) (Figure 14). The extremely high affinity binding 
of avidin to biotin underlies this method. (1) The first step of the procedure is to 
incubate the section with primary antibody raised against the antigenic site(s) of 
interest. (2) A biotin-conjugated secondary antibody is then added which binds to the 
primary antibody and introduces many biotin molecules localised to the site of the 
antigen. (3a) An enzyme complex is fonned consisting of avidin and the biotinylated 
enzyme peroxidase (Vectastain ABC kit). (4a) This complex is added to the section 
where it binds to the biotin on the secondary antibody localised at the antigenic site(s) 
thus amplifying the original signal. The final stage is the addition of an enzyme 
substrate (diaminobenzidine) which the peroxidase converts to a readily visible brown 
deposit that can be viewed using conventional light microscopy. Advantages of using 
this protocol include increased sensitivity and lower background staining. To amplify 
the signal further, a Vectastain ABC Elite kit can be used to fonn the avidin-
biotinylated peroxidase complex. The Elite complex provides a stronger signal since the 
biotinylated peroxidase enzyme contains a greater number of peroxidase molecules. 
The high affinity binding of avidin and biotin also underlies the method used for 
fluorescent immunohistochemistry. However, at step (3) (Figure 14), an avidin-
conjugated fluorochrome (3b) is added so that fluorochrome is localised at the antigenic 
site( s) through binding of avidin to the biotin on the secondary antibody (4b). The 
fluorochrome can then be visualised using a fluorescent microscope. 
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Table 3. Primary antibodies, optimised conecntrations and their corresponding secondary antibodies and blocking serum 
Concentration 
Primary Supplier Species Mouse Secondary Species Normal serum in Antibody raised in Human antibody raised in blocking solution 
DAB Fluorescence DAB 
ApoE Chemicon Goat 1 :5000 1 :1000 Anti-goat Horse NHS 
GFAP Chemicon Mouse 1 :100 Anti-mouse Horse NHS 
Neu-N Chemicon Mouse 1 :100 Anti-mouse Horse NHS 
Rabaptin-5 Santa Cruz Goat 1 :100E 1:50 1:50E Anti-goat Horse NHS 
Rab4 Santa Cruz Rabbit 1:200E 1:50 1:50E Anti-rabbit Goat NGS 
The concentration of each primary antibody was optimised for the specific staining method (peroxidase-DAB or fluorescence) and the type of 
tissue (mouse or human). A specific species of blocking serum was used for each primary (and corersponding secondary) antibody to prevent 
non-specific binding of the secondary antibody. E, Vectastain Elite ABC kit used; NHS, normal horse serum; NGS, normal goat serum. 
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Figure 14. "ABC" immunohistochemistry method 
(1) Tissue is incubated with primary antibody which binds to the antigen of interest. (2) 
A biotinylated secondary antibody is added which binds to the primary antibody. (3a) 
An avidin-biotinylated peroxidase complex is formed and added to the section where 
(4a) the avidin binds to the biotinylated secondary antibody. A chromogenic enzyme 
substrate (e.g. DAB) is then added that is converted to a readily visible deposit by the 
peroxidase. (3b) The procedure is similar for fluorescent immunostaining except an 
avidin-conjugated fluorochrome (e.g. fluorescein) is added which binds to the 
secondary antibody (4b). 
76 
2.9.3 Peroxidase single-labelling immunohistochemistry 
Day 1. 6~m thick paraffin-embedded sections were dewaxed in an oven at 60-70°C for 
30min and in xylenelHistoclear (2 x 10min) followed by dehydration in absolute 
alcohol (2 x 10min). Endogenous peroxidase was eliminated by incubating the sections 
in 0.5% H20 2 in methanol for 30min. Sections were washed in running water for 30min 
and phosphate-buffered saline (PBS) (2 x 5min). Non-specific binding sites were 
blocked with 10% normal serum and 0.5% bovine serum albumin in PBS for lh. 
Sections were then incubated with primary antibody in blocking solution overnight at 
4°C. 
Day 2. After washing in PBS (2 x 5min) sections were incubated with biotinylated 
secondary antibody (Vector Laboratories, UK) in PBS (1 : 1 00) for 1 h and washed again 
in PBS (2 x 5min). Sections were then incubated with an avidin-biotinylated enzyme 
complex solution (Vectastain ABC Standard/Elite kit, Vector) for lh. After further 
washes in PBS (2 x 5min), colour was developed by incubating sections in a 3'3'-
diaminobenzidine tetrahydrochloride solution (Vector) for 1 h. The colour reaction was 
terminated after 3min by washing sections in running water. Sections were then 
dehydrated in a graded series of alcohols, cleared in xylenelHistoclear and cover-slipped 
with DPX. 
2.9.4 Fluorescent double-labelling immunohistochemistry 
Day 1. 61lm thick paraffin-embedded sections were dewaxed in an oven at 60-70°C for 
30min and in xylenelHistoclear (2 x 10min) followed by dehydration in absolute 
alcohol (2 x 10min). Sections were then rinsed in phosphate-buffered saline (PBS) (2 x 
10min) and non-specific binding sites were blocked with 10% normal serum and 0.5% 
bovine serum albumin in PBS for 1h. Sections were incubated with primary antibody 
overnight at 4°C. 
Day 2. After washing in PBS (2 x 5min) sections were incubated with biotinylated 
secondary antibody in PBS (1: 100) for 1 h and washed again in PBS (2 x 5min). 
Sections were then incubated with fluorochrome-conjugated avidin D (Vector) (1 :100 in 
PBS) for lh. For the previous stage and for the remainder of the protocol sections were 
covered with aluminium foil to prevent bleaching of the fluorochrome. Sections were 
further washed in PBS (2 x 10min) before non-specific binding sites were blocked with 
10% normal serum (relevant for species biotinylated secondary antibody is raised in) 
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and 0.5% bovine serum albumin in PBS for 1h. Blocker was drained off and sections 
were incubated with the second primary antibody overnight at 4°C. 
Day 3. After washing in PBS (2 x 5min) sections were incubated with biotinylated 
secondary antibody in PBS (1:100) for 1h and washed again in PBS (2 x 5min). 
Sections were then incubated with fluorochrome-conjugated avidin D (1: 1 00 in PBS) 
for 1h. The fluorochrome chosen at this stage possessed different excitation and 
emission wavelengths than the fluorochrome used to label the first primary antibody. 
For example, if fluorescein was used to label the first primary antibody, Texas red was 
used as the fluorochrome to label the second primary antibody. This produces the 
double-labelling effect whereby sites localised with each primary antibody emit a 
different wavelength and hence colour of light when viewed with a fluorescent 
microscope. Sections were then thoroughly washed in PBS (3 x 5min), cover-slipped 
with non-fading aqueous mounting medium and stored in the dark at 4°C. 
2.9.5 GFP fluorescence 
In tissue containing green fluorescent protein (GFP) derived from adenoviral vector 
injection, 6Jlm paraffm-embedded sections were de-waxed in xylene (2 x 10min) and 
cover-slipped with non-fading aqueous mounting medium. 
2.9.6 Quantification of immunostaining 
2.9.6.1 Volumetric measurement of immunoreactivity 
The volume of immunoreactivity was quantified similarly to volumetric assessment of 
ischaemic neuronal damage (section 2.8.3). Clearly defined areas of immunoreactivity 
with identifiable boundaries were delineated on to scale diagrams (x9 actual size) from 
the stereotaxic mouse atlas of Hof et al. (2000), representing the eight coronal levels 
previously described (section 2.8.1). Scale diagrams were then digitised on an MCID 
image analysis system and approximation of the total volume of immunoreactivity was 
achieved by integration of areas with the distance between each coronal level. 
2.9.6.2 Semi-quantitative assessment of immunoreactivity 
The degree of immunoreactivity in a defined region was classified using a scoring 
system as follows: 0 = no cellular staining; 1 = <35% cells stained; 2 = 35% - 70% cells 
stained; 3 = >70% cells stained. 
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2.10 Measurement of apoE levels 
An enzyme-linked imrnunosorbent assay (ELISA) technique was used to detennine the 
brain tissue levels of apoE following stereotaxic injections of adenoviral vector or 
vehicle. This assay is based on the antibody sandwich principle (Figure 15). First, a 
capture antibody raised against the protein of interest is bound to a microtiter plate to 
create the solid phase. Samples and standards are then incubated with the solid phase 
antibody, which captures the protein. A detection antibody is then added that recognises 
a different epitope of the protein and completes the sandwich. Addition of a conjugated 
secondary antibody (e.g. HRP-conjugated) is then followed by incubation with a 
substrate solution such that colour develops in proportion to the amount of bound 
protein. Colour development is then stopped and the intensity of the colour is measured. 
The major advantage of the sandwich ELISA technique is its high sensitivity to detect 
even very low levels of protein. 
Procedures using tissue from adenoviral-treated mice were perfonned in a fume 
hood. 1 % Virkon and 100% alcohol were available to hand at all times. 
2.10.1 Tissue harvesting 
Each mouse was deeply anaesthetised with 3 - 4% halothane in a mixture of 30% 
oxygen and 70% nitrous oxide and a sternotomy was perfonned to completely expose 
the heart. Approximately 20ml of cold (4DC) 0.9% saline was perfused through the 
vasculature via the left ventricle with an incision made in the right atrium to provide an 
outlet for perfused blood. A loss of colour in the liver, lungs and extremities and 
absence of blood from the exiting perfusate was used to indicate adequate removal of 
blood from the tissues. The brain was removed from the skull, placed in a mouse brain 
matrix and a 3mrn coronal slice oftissue was cut containing the bilateral injection tracts. 
In the 3mrn slice, tissue surrounding each injection tract was then dissected out on ice 
and each tissue sample was then frozen in liquid nitrogen and stored at -80DC until 
homogenisation. 
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2.10.2 Sample homogenisation and protein extraction 
This procedure was perfonned by Dr Sandra Magnoni. Tissue samples were removed 
from -80°C storage, weighed and immediately placed on ice. Tissue samples were 
homogenised in 5x volume (i.e. 5ml per Ig tissue) ice-cold homogenisation buffer 
(25mM Tris pH 7.4, 3mM MgCh, 100mM NaCl,20% CHAPS with Imglml each of 
leupeptin, pepstatin A and aprotinin and 100mM PMSF) using a glass-on-glass 
homogeniser (Iml, Wheaton). Homogenised samples were stored on ice for 1 hour 
before centrifuging at 13000rpm for 5min. Supernatant was carefully removed and 
transferred to a fresh Eppendorfbefore proceeding to protein assay. 
2.10.3 Protein assay 
The bicinchoninic acid (BCA) protein assay was used to detennine total protein 
concentration in each sample (Smith et al., 1985). A BCA Protein Assay Reagent Kit 
was used (Pierce Biotechnology). This assay is based on divalent copper ion (Cu2+) 
fonning complexes with peptide bonds in which it is reduced to the monovalent ion 
(Cu+) under alkaline conditions. Monovalent copper ion reacts with BCA reagent to 
produce a purple-coloured reaction product that exhibits a strong absorbance at a 
wavelength of 56211m. The major advantages of the BCA assay are its stability over a 
broad range of protein concentrations (20J.1g1ml - 2000J.1g1ml) and its compatibility with 
a wide range of buffer reagents (e.g. detergents). 
Bovine serum albumin (BSA) was used as the standard against which the 
concentration of protein in each sample was detennined. A series of dilutions of BSA 
standard (50J.1g1ml - 1000J.1g1ml diluted in homogenisation buffer) was used to generate 
the standard curve. Samples were diluted (1 :40 in homogenisation buffer) and vortexed. 
50J.11 of standards and samples were then aliquoted in duplicate. BCA working reagent 
(pierce Biotechnology) was prepared by mixing 50 parts reagent A (containing BCA) 
with 1 part reagent B (containing cupric sulphate). Iml of BCA working reagent was 
added to standards and samples (1:20 sample:BCA reagent ratio) and incubated for 
30min at 37°C. After cooling to room temperature, the absorbance of standards and 
samples was measured on a spectrophotometer (Amersharn Ultraspec 31 00 pro) at a 
wavelength of 56211m. All readings were made within 1000n of each other to prevent 
error due to continuing colour development. 
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To determine the protein concentration of each sample, a standard curve was 
prepared by plotting the mean absorbance at 562nm of each BSA standard against its 
concentration. The standard curve was used to determine the protein concentration of 
each unknown sample. As each sample was run in duplicate, the protein concentration 
for each sample was calculated by determining the protein concentration of each 
replicate from the standard curve and computing the mean of the duplicates. 
2.10.4 ELISA 
This procedure was performed by Mr Andrew Wong. A 96-well plate (Nunc Maxisorp) 
was first coated (100JlUwell) with the capture antibody (rabbit anti-human 
apolipoprotein E (1:5000), Dako, diluted in 16mM carbonate/34mM bicarbonate buffer 
pH 9.6) and incubated overnight (>17h) at 4°C. Following washes (x3) with phosphate 
buffered saline (PBS), blocking solution (2% bovine serum albumin (BSA) in PBS) was 
added (150 Jlllwell) and the plate incubated for Ih at 37°C. After 3 washes in 1% PBS-
Tween 20 (PBST), apoE standard (recombinant human apolipoprotein E3, Chemicon) 
was diluted (0.25nglml- 40nglml in sample diluent [1 % BSA in PBS] and added to five 
columns of wells (100Jlllwell). Frozen samples were thawed on ice, diluted in sample 
diluent and plated in triplicate (100Jlllwell). The plate was then sealed and incubated for 
2h at 37°C. The detection antibody (goat polyclonal anti-apolipoprotein E, Chemicon, 
1 :2000 in sample diluent) was added (100Jlllwell) after further washes in PBST (x3) and 
the plate incubated for Ih at 37°C. Washes in PBST (x3) were then followed by addition 
(100Jlllwell) of horse radish peroxidase conjugated secondary antibody (rabbit anti-goat 
HRP conjugated IgG, Dako, 1 :5000 in sample diluent) and the plate incubated for Ih at 
37°C. After washes in PBST (x4) and PBS (x2), the chromogen 0-
phenylenediaminedihydrohcloride (OPD) was added (100f.lllwell) at room temperature. 
The colour reaction was terminated after IOmin by addition of 1M sulphuric acid 
(100Jlllwell). Absorbance was read at a wavelength of 492TJm on a plate reader. 
To calculate the apoE concentrations in each of the samples a standard curve was 
generated by plotting the absorbance of each apoE standard against its concentration. 
The apoE concentration of the unknown samples was then derived from the standard 
curve. As each sample was run in triplicate, the apoE concentration for each sample was 
calculated from the three replicates by determining the apoE concentration of each 
replicate from the standard curve and computing the mean of these values. Knowledge 
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of the total protein concentration of the sample (determined in protein assay above) then 
enabled apoE concentration for each sample to be expressed as ng apoE/mg total 
protein. 
2.11 Measurement of local cerebral blood flow 
2.11.1 Utility of 14C-iodoantipyrine as a radioactive tracer 
Carbon-14 labelled iodoantipyrine (14C_IAP) was used as a radioactive tracer. There are 
several properties of this particular isotope which confer its suitability for use in 
measuring cerebral blood flow: 
1. high lipid solubility - facilitates diffusion across blood brain barrier 
2. blood-tissue partition co-efficient is uniform throughout the brain 
3. slowly metabolised by the liver (6% per hour) therefore remains stable over 
the experimental period 
4. solubility in blood does not vary with the haematocrit 
5. non-volatile 
6. 14C has a very long half-life (5730 years) - facilitates preparation of 
permanentautoradiograms 
7. commercially available 
2.11.2 Administration of 14C_IAP 
14C_IAP was administered by intraperitoneal injection. Intraperitoneal administration of 
14C_IAP results in a linear increase in the arterial concentration of 14C_IAP with time, at 
least until 2min after injection (Maeda et ai., 2000) (Figure 16). This represents an 
excellent ramp delivery of tracer and therefore eliminates the unwanted effects of 
equilibration of rapidly perfused tissue with the blood compartment. In consideration of 
the above, 15JlCi 14C_IAP in 0.15ml physiological saline was injected into the 
intraperitoneal cavity and allowed to circulate for 2min. The injection was given in the 
right side of the supine mouse to minimise the risk of puncturing the bladder and a 
gauze pad was placed under the mouse to aid uptake of isotope into the peritoneal 
vessels and prevent reflux through the injection site. Heart rate and respiratory rate were 
monitored closely immediately prior to 14C_IAP administration since the degree of 
sympathetic activity is likely to influence the dynamics of isotope uptake. 
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Figure 16. Representative time course of arterial 14C radioactivity after 
intraperitoneal injection of 14C-IAP 
Intraperitoneal injection of 15J.1Ci 14C_IAP results in a linear increase in 14C radioactivity 
in arterial blood at least until 2min after administration of the tracer. Adapted from 
Maeda et al., 2000. 
2.11.3 Measurement of terminal heart blood sample 14C_IAP concentration 
Exactly 2min after administration of 14C_IAP, the experiment was terminated by 
decapitation and the torso was immediately immersed in liquid nitrogen. The torso was 
then slightly thawed in a water bath (37°C) and a vertical incision was cut in the chest 
wall to expose the heart. An incision was made in the left ventricle of the heart and 3 
samples of frozen blood were collected on to pre-weighed filter paper discs placed 
inside glass scintillation vials. The glass vials containing the filter paper discs with heart 
blood samples were then re-weighed to determine the exact weight of the blood sample. 
Colour was bleached from the blood sample by addition of O.4ml hydrogen peroxide 
directly on to the filter disc. Iml distilled water was similarly added and the via1left at 
room temperature overnight. The following day, lOmI scintillant (EcoScint) was added 
to the vial and left to stand at room temperature for at least 2h. To determine 14C activity 
in the blood sample, the vial was placed in a liquid scintillation counter and the number 
of disintegrations per minute (dpm) was counted during a IOmin period. This was 
repeated twice and the mean number of dpm was calculated from the three 
measurements of 14C radioactivity. The activity of the blood sample can be expressed in 
standard units (Curie, Ci) using the following conversion: 
InCi = 2220dpm 
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The concentration of 14C_IAP (nCilml) in the tenninal blood sample was then calculated 
by dividing the activity of the blood sample by its volume (calculated from the weight 
of the blood sample by assuming a specific gravity of 1.05g/ml for blood). 
2.11.4 Measurement of local brain tissue 14C_IAP concentration 
2. 11.4.1 14C autoradiography 
Upon tennination of the experiment by decapitation, the brain was immediately 
removed from the skull and immersed in chilled isopentane (-42°C) for 2min. 
Concurrently, the torso was immersed in liquid nitrogen (section 2.11.3). The frozen 
brain was then embedded in cryomatrix and covered with a thin film of cryoprotectant. 
20J.lm coronal brain sections were cut on a cryostat at -22°C. Three of every ten sections 
were mounted on glass coverslips and dried on a hot plate at 60°C. Sections were then 
enclosed in an X-ray cassette along with a set of 13 pre-calibrated 14C plastic resin 
standards with increasing 14C concentration. Autoradiograms of the plastic standards 
and coronal brain sections were generated by exposure to 14C sensitive X-ray film 
(Kodak Biomax MRI film) for 5 days. Following 5 days exposure, autoradiograms 
were developed in a dark room using an automated processor. 
2. 11.4.2 Densitometric analysis of autoradiograms 
Measurement of 14C_IAP concentration in discrete brain regions was carried out on an 
MCID image analysis system. An autoradiogram was placed on a light box with stable 
light intensity, covered with a Perspex block to prevent curling and a digitised image 
was produced on screen. A standard curve was then generated by measuring the relative 
optical densities (RODs) of each of the 14C plastic standards. Additionally, the ROD of 
a background area of the film was measured; essentially acting as standard zero (i.e. the 
ROD reading when the concentration of 14C is zero). In general, the concentration of 
standard 1 was too low to darken the X-ray film during a 5 day exposure period and 
therefore was not used to generate the standard curve. Furthennore, the typical range of 
14C concentrations in the mouse brain was between those represented by standards 2 to 
5 (44 - 271nCilg). Consequently, the standard curve was generated from the ROD 
measurements of film background and 14C standards 2 to 5 (Figure 11). Linear 
interpolation was used to fit a line to the standard curve. 
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Figure 17. Representative standard curve of relative optical density readings 
from 14C standards 
The standard curve was generated from a background reading and standards 2 to 5 
(44,70, 179 and 271 nCi/g respectively). 
Local tissue concentrations of 14C_IAP were detennined from ROD measurements 
in 12 neuroanatomically-defined regions: frontal cortex; motor cortex; somatosensory 
cortex; insular cortex; dorsolateral caudate; ventromedial caudate; hippocampus (CAl); 
dorsolateral thalamus; ventromedial thalamus; hypothalamus; auditory cortex; and 
cerebellum. RODs were detennined in the 12 regions of interest ipsilateral and 
contralateral to occlusion by computing the mean of the measurements from 6 adjacent 
coronal sections at each anatomical locus. 
2.11.5 Calculation of local cerebral blood flow 
Calculation of local cerebral blood flow (LCBF) using the 14C_IAP method requires the 
detennination of three variables: 
1. brain tissue:blood partition coefficient for 14C_IAP (0.8) (Sakurada et ai., 
1978) 
2. local brain tissue 14C_IAP concentration at the end of the experiment 
3. profile of 14C_IAP concentration in arterial blood during the experiment 
Detennination of the second of the above variables is relatively straight-forward and is 
achieved as described previously (section 2.11.4). However, in the mouse, ascertaining 
the history of 14C_IAP arterial blood concentration is more challenging. In larger 
animals, such as rats and cats, cannulation of blood vessels for intravenous infusion of 
14C_IAP and repeated arterial blood sampling during the experimental period is 
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practicable. In the mouse, however, cannulation of multiple vessels is technically very 
demanding and substantially extends the period of anaesthesia. Furthermore, due to the 
small blood volume of the mouse, repeated arterial blood sampling may initiate 
inadvertent systemic hypotension. To avoid these difficulties, Maeda et aZ. (2000) 
described a method that combined intraperitoneal administration of 14C_IAP with 
sampling of arterial heart blood at the end of the experiment. Using this method, the 
concentration of 14C_IAP in the heart sample did not differ significantly from that 
measured from the terminal arterial blood sample obtained by repeated sampling. Since 
arterial blood 14C_IAP concentration rises linearly during the experiment, knowledge of 
terminal arterial blood 14C_IAP concentration can be used to construct a time-course of 
14C_IAP concentration in arterial blood during the experiment. 
Absolute values of local cerebral blood flow were computed by MClD image 
analysis software based on the operational equation (Figure 18). An arterial input curve 
was generated using the known 14C_IAP radioactivities (in dpm) in blood at the 
beginning (Os) and end (120s) of the experiment and assuming that concentration of 
14C_IAP at 60s was halfthat measured at 120s. 
Generation of an arterial input curve followed by determination of local brain tissue 
14C_ lAP concentrations (section 2.11.4) then enabled calculation of local cerebral blood 
flow (mVI00glmin) using the operational equation (Sakurada et aZ., 1978) (Figure 18). 
Figure 18. Operational equation for calculation of cerebral blood flow 
Operational equation as described by Sakurada et al. (1978) for determination of the 
rate of cerebral blood flow. Ci(T) is the tissue concentration of tracer at time T after 
administration of the tracer; A is the brain tissue:blood partition coefficient; K is a 
constant equal to fm/AW where flW is the flow rate f (mllmin) divided by the tissue 
mass W (9) and m is a constant equal to 1 that reflects unrestricted diffusion of tracer 
from the blood compartment to brain tissue compartment. t is the variable time. The 
rate of cerebral blood flow per unit mass of tissue (flW) is calculated from the local 
brain tissue concentration of tracer at time T [Ci(T)] determined from densitometric 
analysis of autoradiograms. the concentration of tracer in arterial blood from times 0 -
T. and the brain tissue:blood partition coefficient for the tracer (0.8 for 14C_IAP). 
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2.12 Adenoviral vectors 
Procedures involving adenoviral vectors were approved by the Health and Safety 
Executive and had local approval from the Advisory Committee on genetically modified 
work. Second generation recombinant adenoviral vectors containing the gene encoding 
human apolipoprotein E3 (Ad-APOE) or the gene encoding green fluorescent protein 
(GFP) (Ad-GFP) were obtained through collaboration with Dr Andy Baker (University 
of Glasgow, UK) and Dr George Dickson (Royal Holloway University, UK). Vectors 
were constructed at Royal Holloway and have been described in detail previously 
(Harris et ai., 2002). These second generation viral vectors were generated using 
adenovirus serotype 5 and had the Eland E3 regions of the viral genome and the 
adenovirus DNA polymerase (E2b) gene deleted. Deletion of these viral elements 
underlies the principal advantage of second generation (El -, E3-, polymerase-) vectors 
compared to conventional first generation vectors, which is the reduced potential for 
viral gene expression and diminished risk of an immune response. The transgene was 
located in the E 1 region and expression was driven by the full human cytomegalovirus 
(CMV) promoter/early enhancer (Figure 19). Adenoviral vectors were stored in viral 
storage buffer (10% glycerol in PBS) at -80°C until use when they were thawed on ice 
prior to injection. 
CMV enhancerl SO/SA H E3 promoter uman apo eDNA pA 
5' ITR E1 
region Ad-apoE: 31,471 bp 
3' ITR 
Figure 19. Schematic representation of adenoviral vector containing APOE gene 
The transgene expression cassette is located in the E1 region of the viral genome and 
contains the human CMV promoter/early enhancer driving expression of the human 
apoE eDNA followed by an SV40 polyadenylation signal (pA). Figure adapted from 
Harris et al., 2002. 
2.13 Statistical analysis 
Details of statistical tests used are given in individual results chapters. 
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Chapter 3 
Endocytic pathway alterations in 
human temporal lobe after global cerebral 
ischaemia and association with 
APOE genotype 
3.1 Introduction and aims 
Endocytosis is integral to the cellular uptake and trafficking of apoE. Endocytic 
pathway alterations may be central to mechanisms which could mediate APOE 
genotype-dependent differences in susceptibility to acute brain injury. The specific aims 
of the present study were to determine, in human post-mortem temporal lobe brain 
sections, if: 
1. alterations in the endocytic pathway occur after global ischaemia 
2. there is an association between differences in endocytic pathway alterations and 
APOE genotype after global ischaemia 
3.2 Materials and methods 
This study was carried out at the Wellcome Surgical Institute, University of Glasgow. 
All experiments were performed unaware of control or global ischaemia status and 
APOE genotype. 
3.2.1 Post-mortem human brain tissue 
Paraffin-embedded sections of medial temporal lobe (section 2.1) from 43 patients who 
died after an episode of global ischaemia (and subsequent reperfusion) due to cardio-
respiratory arrest and from 38 control patients, were studied. Cohort clinical details are 
given in Appendix C. The control and global ischaemia groups were matched for age 
and male/female ratio: control patients (25 males, 13 females; mean age 51 years); 
global ischaemia patients (27 males, 16 females; mean age 50 years). In the global 
ischaemia group, the survival period after the initial ischaemic episode (cardiac arrest) 
ranged from llh to 3 months. APOE genotype of controls and global ischaemia cases 
was determined from paraffin-embedded sections as described in section 2.1.2. 
3.2.2 Immunohistochemistry 
Adjacent sections were immunostained (peroxidase protocol) with rabaptin-5 and rab4 
antibodies (section 2.9.3). 
3.2.2.1 Semi-quantification of rabaptin-5 and rab4 immunostaining 
Semi-quantitative assessment of rabaptin-5 and rab4 immunoreactivity within specific 
regions of the hippocampus and neocortex of the temporal lobe was performed at x200 
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magnification. The degree of neuronal rabaptin-5 and rab4 immunoreactivity was 
graded according to a scoring system (section 2.9.6.2) in five regions of the temporal 
lobe (hippocampus CAl sector, hippocampus CA2 sector, hippocampus CA3/4 sector, 
dentate gyrus and neocortex). The degree of glial rabaptin-5 and rab4 immunoreactivity 
in the same regions was similarly scored. An average degree of neuronal and glial 
rabaptin-5 and rab4 immunoreactivity for the temporal lobe in each control and global 
ischaemia case was calculated from the sum of the degree of neuronal/glial 
immunoreactivity in CAl + CA2 + CA3/4 + dentate gyrus + neocortex divided by 5. 
Reproducibility of semi-quantitative assessment was tested (Appendix D). 
3.2.2.2 p-amyloid deposition and neurofibrillary tangles 
All controls and global ischaemia cases were screened for the presence of ~-amyloid 
(A~) deposits (diffuse and neuritic) and neurofibrillary tangles in paraffin-embedded 
sections previously immunostained by Dr Karen Horsburgh with anti-A~ (to detect A~ 
deposits) and anti-tau (to detect neurofibrillary tangles) antibodies. In each case, the 
presence or absence of diffuse A~ deposits and neuritic plaques and neurofibrillary 
tangles was determined. 
3.2.3 Ischaemic neuronal damage 
Semi-quantification (as above) of the degree of ischaemic neuronal damage in the five 
regions had previously been performed in haematoxylin and eosin-stained sections 
adjacent to those immunostained with rabaptin-5 and rab4 by Dr Karen Horsburgh 
(Horsburgh et al., 1999a). An average degree of ischaemic neuronal damage for the 
temporal lobe in each control and global ischaemia case was previously calculated as 
above. 
3.2.4 Statistical analysis 
Mann-Whitney U-statistic was used to assess statistical differences in the degree of 
neuronal and glial rabaptin-5 and rab4 immunoreactivity and ischaemic damage in each 
area within the temporal lobe between the control and global ischaemia groups. 
Spearman Rank correlation analysis was used to assess the association between the 
average degree of neuronal rabaptin-5 or rab4 immunoreactivity and the average degree 
of ischaemic neuronal damage. In the global ischaemia group, Spearman Rank 
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correlation analysis was used to assess the association between the average degree of 
neuronal rabaptin-S and rab4 immunoreactivity and also to assess the association 
between neuronal rabaptin-S or rab4 immunoreactivity and patient survival time. 
Two-way analysis of variance (ANOY A) was used to assess the association 
between APOE genotype and the average degree of neuronal rabaptin-5 or rab4 
immunoreactivity in response to global ischaemia. Two-way ANOY A tested for an 
interaction between the effects of possession of an APOE £4 allele and of an episode of 
global ischaemia on the average degree of neuronal immunoreactivity of the endocytic 
markers. Use of two-way ANOY A assumes a normal distribution of data. Assumption 
of normality was reasonable when the average response per subject was calculated 
(Kolmogorov-Smirnov test, P > 0.05). Fisher's exact test was used to assess the 
association between APOE genotype and A~ deposition. All data are presented as mean 
±SEM. 
3.3 Results 
3.3.1 Ischaemic neuronal damage 
Cardio-respiratory arrest is the most common cause of global ischaemia, which induces 
neuronal damage in selectively vulnerable regions of the brain (see section 1.1.2.2). In 
the present cohort of individuals, ischaemic damage was previously assessed by Dr 
Karen Horsburgh (Horsburgh et ai., I 999a). There was extensive neuronal damage in 
the hippocampus and neocortex after global ischaemia whereas there was minimal 
neuronal damage in controls. In global ischaemia cases, there was a characteristic 
pattern of selective neuronal damage in vulnerable regions of the temporal lobe. In 
affected areas, neurons were shrunken with densely stained nuclei and intensely 
eosinophilic cytoplasm (Figure 20). The degree of neuronal damage was significantly 
greater in global ischaemia cases compared to controls (P < 0.0005) in all regions of the 
temporal lobe (Figure 20). 
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Figure 20. Ischaemic neuronal damage after global ischaemia 
Ischaemic damage was assessed previously by Dr Karen Horsburgh (Horsburgh et al., 
1999a). (a) Example of ischaemic neuronal damage in a control individual and a patient 
who died after an episode of global ischaemia. Neuronal damage is absent in the 
control whereas neurons displaying the histological features of ischaemic cell change 
are evident in the global ischaemia patient. Photomicrographs are from the 
hippocampal CA1 sector. (b) There was a significant increase in the degree of neuronal 
damage after global ischaemia compared to controls in each region of the temporal 
lobe examined. ***P < 0.0005, Mann-Whitney U-statistic. n = 38 (control); n = 43 
(global ischaemia). Data are presented as mean ± SEM. 
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3.3.2 Rabaptin-5 immunostaining 
3.3.2.1 Neuronal immunostaining 
The majority of controls displayed minimal (semi-quantitative score = 1) or no neuronal 
rabaptin-5 immunoreactivity. In the dentate gyrus and neocortex, there was no neuronal 
rabaptin-5 immunostaining in the majority of controls. In hippocampus sectors CAl, 
CA2 and CA3/4 the majority of controls displayed a minimal amount of neuronal 
rabaptin-5 immunoreactivity which was predominantly confined to the pyramidal cell 
layer. A moderate amount (semi-quantitative score = 2) of dense rabaptin-5 
immunoreactivity was observed in only 3 of 38 controls. After global ischaemia, dense 
neuronal rabaptin-5 immunostaining was observed in the majority of cases; there was 
no evidence of neuronal staining in only 2 of 43 cases. As in controls, neuronal 
immunostaining after global ischaemia was predominantly confined to the pyramidal 
cell layer of hippocampus sectors CAl, CA2 and CA3/4, in particular CAl, but was 
also evident in the dentate gyrus granule cell layer and in the neocortex. Dense 
intraneuronal rabaptin-5 immunostaining was granular in nature and localised to the 
cytoplasm of cell bodies and neurites, indicative of its endosomallocation (Figure 21). 
In some global ischaemia cases, neuronal immunostaining appeared particularly intense 
adjacent to the plasma membrane. In addition to pyramidal and granule cell layer 
staining, a diffuse pattern of rabaptin-5 immunostaining was also detected in the 
molecular layer of the hippocampus in four global ischaemia cases. 
Semi-quantification revealed significant increases in the degree of neuronal 
rabaptin-5 immunoreactivity in hippocampal sectors CAl (P < 0.0005), CA2 (P < 
0.0005) and CA3/4 (P < 0.0005) and in the neocortex (P < 0.05) after global ischaemia 
(Figure 22). There was also a trend towards an increase in neuronal immunoreactivity 
in the dentate gyrus, although this did not reach statistical significance (P > 0.05). After 
global ischaemia, rabaptin-5 immunoreactivity was observed in both non-ischaemic and 
ischaemic neurons. There was a weak correlation between the average degree of 
neuronal rabaptin-5 immunoreactivity and the average degree of ischaemic neuronal 
damage in the temporal lobe (P = 0.024, r = 0.34) (Figure 23). There was no correlation 
between neuronal rabaptin-5 immunoreactivity and ischaemic neuronal damage in 
controls (P > 0.05). There was also no association between the extent of neuronal 
rabaptin-5 immunoreactivity and survival time after the global ischaemic episode (P > 
0.05) (Figure 24). 
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3.3.2.2 Glial immunostaining 
Glial rabaptin-5 immunostaining was detected in both controls and after global 
ischaemia. In both groups, the degree of immunoreactivity was less than that observed 
in neurons. The majority of controls displayed only minimal or no glial rabaptin-5 
immunostaining and, when present, immunostaining was predominantly confined to the 
neocortex. After global ischaemia, only 7 of 43 cases showed a moderate or greater 
level of glial rabaptin-5 immunoreactivity. As in controls, glial immunostaining was 
primarily observed in the neocortex, but in addition, was also observed in the 
hippocampal CA3/4 sector. In the hippocampus, glial immunostaining displayed a less 
laminar pattern than the neuronal staining. 
Semi-quantification revealed a significant increase in the degree of glial rabaptin-5 
immunoreactivity in only the CA3/4 sector of the hippocampus (P < 0.05) after global 
ischaemia compared to controls (Figure 22). 
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Figure 21. Rabaptin-5 immunostaining 
Representative examples of neuronal rabaptin-5 immunoreactivity from a patient who 
experienced an episode of global ischaemia (b,c) and a control individual (a). In the 
control (a), there is minimal neuronal rabaptin-5 immunoreactivity. After global 
ischaemia (b,c), there is markedly increased neuronal rabaptin-5 immunoreactivity in 
neurons displaying the features of ischaemic cell change. Photomicrographs are from 
the hippocampal CA1 sector. Scale bar (a,b), 251lm; (c,e), 10llm. 
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Figure 22. Semi-quantitative assessment of rabaptin-5 immunoreactivity 
There was a significant increase in the degree of neuronal rabaptin-5 immunoreactivity 
after global ischaemia compared with controls in all regions examined except the 
dentate gyrus. Only in CA3/4 was there a significant change in the degree of glial 
rabaptin-5 immunoreactivity after global ischaemia. *P < 0.05, ***P < 0.0005, Mann-
Whitney U-statistic. n = 38 (control); n = 43 (global ischaemia). Data are presented as 
mean ± SEM. 
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Figure 23. Association between Ischaemlc neuronal damage and neuronal 
rabaptin-5 Immu noreactivity 
There was a significant correlation between the average degree of ischaemic neuronal 
damage and the average degree of neuronal rabaptin-5 immunoreactivity in temporal 
lobe after global ischaemia (P = 0.024; r = 0.34, Spearman Rank). There was no 
correlation in controls (P> 0.05, Spearman Rank). 
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Figure 24. Association between survival time after global ischaemia and 
neuronal rabaptin-5 immunoreactivity 
There was no correlation between survival time after an episode of global ischaemia 
and the average degree of neuronal rabaptin-5 immunoreactivity in temporal lobe (P > 
0.05, Spearman Rank). 
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3.3.3 Rab4 immunostaining 
3.3.3.1 Neuronal immunostaining 
Neuronal rab4 immunoreactivity (Figure 25) was detected in both controls and after 
global ischaemia. In both groups, immunostaining was observed throughout the 
temporal lobe, although was most prominent in the hippocampus, in particular the CA 1 
sector. In the hippocampus and dentate gyrus, neuronal rab4 immunostaining was 
primarily restricted to the pyramidal cell layer and granule cell layer respectively. The 
majority of controls displayed a minimal (score = 1) degree of neuronal rab4 
immunoreactivity, however, in 8 of 38 controls there was a moderate (score = 2) or 
greater (score = 3) degree of neuronal immunoreactivity, particularly in the 
hippocampus. It was noted that the level of neuronal rab4 immunoreactivity in controls 
was greater than the level of neuronal rabaptin-5 immunoreactivity in all regions of the 
temporal lobe. In the majority of global ischaemia cases, the greatest extent of neuronal 
rab4 immunoreactivity was observed in the hippocampal sectors whereas in the dentate 
gyrus and neocortex, a minimal and moderate level, respectively, were observed most 
frequently. Neuronal rab4 immunoreactivity was evident in all global ischaemia cases. 
Similar to rabaptin-5, intraneuronal rab4 immunostaining was localised to the cytoplasm 
of cell bodies and proximal neurites, however, a diffuse pattern of rab4 immunostaining 
in the neuropil was not observed in any controls or global ischaemia cases. 
Semi-quantification revealed significant increases in the degree of neuronal rab4 
immunoreactivity after global ischaemia in hippocampal sectors CAl (P < 0.05), CA2 
(P < 0.05), CA3/4 (P < 0.05) and in the dentate gyrus (P < 0.05) and neocortex (P < 
0.005) (Figure 26). As observed with rabaptin-5, rab4 immunoreactivity was evident in 
both non-ischaemic and ischaemic neurons after global ischaemia. However, correlation 
analysis showed that there was no association between the average degree of neuronal 
rab4 immunoreactivity in temporal lobe and the degree of ischaemic neuronal damage 
after global ischaemia (P > 0.05) (Figure 27). There was also no association between 
neuronal rab4 immunoreactivity and neuronal damage in controls (P > 0.05) (Figure 
27). In addition, there was no association between neuronal rab4 immunoreactivity and 
survival time after global ischaemia (P > 0.05) (Figure 28). 
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3.3.3.2 Correlation between neuronal rab4 and rabaptin-5 immunostaining 
In adjacent sections immunostained for rab4 and rabptin-5 it was evident that similar 
areas were immunoreactive for both antibodies after global ischaemia. It was also noted 
that the average degree of neuronal rab4 and rabaptin-5 immunoreactivity were similar 
after global ischaemia. Correlation analysis indicated a moderate association between 
the average degree of neuronal rab4 and rabaptin-5 immunoreactivity in temporal lobe 
after global ischaemia (P = 0.003, r = 0.48) but no association in controls (P > 0.05) 
(Figure 29). 
3.3.3.3 Glial immunostaining 
As observed in neurons, glial rab4 immunoreactivity was evident in both controls and 
after global ischaemia. However, in both groups, the degree of immunoreactivity was 
less than that observed in neurons. Minimal (score = 1) or no (score = 0) glial rab4 
immunoreactivity was observed in the majority of controls in the hippocampus and 
neocortex; in the dentate gyrus there was almost complete absence of glial rab4 
immunostaining. After global ischaemia, minimal or moderate (score = 2) levels of glial 
rab4 immunoreactivity were predominantly detected in the hippocampus and neocortex 
although as in controls, glial rab4 immunostaining was generally not observed in the 
dentate gyrus. 
Semi-quantification revealed a significant increase in the degree of glial rab4 
immunoreactivity after global ischaemia in only the CA2 sector of the hippocampus (P 
< 0.05) (Figure 26). It was noted that, in both controls and after global ischaemia, the 
degree of glial rab4 immunoreactivity was greater than the degree of glial rabaptin-5 
immunoreactivity. 
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Figure 25. Rab4 immunostaining 
Representative examples of neuronal rab4 immunoreactivity from a patient who 
experienced an episode of global ischaemia (b,c) and a control individual (a). In the 
control (a), there is minimal neuronal rab4 immunoreactivity. After global ischaemia 
(b,c), there is markedly increased neuronal rab4 immunoreactivity in neurons 
displaying the features of ischaemic cell change. Photomicrographs are from the 
hippocampal CA1 sector. Scale bar (a,b), 25f..I.m; (c,e). 10llm. 
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Figure 26. Semi-quantitative assessment of rab4 immunoreactivity 
There were significant increases in the degree of neuronal rab4 immunoreactivity after 
global ischaemia in all regions of temporal lobe examined. A trend toward an increased 
degree of glial rab4 immunoreactivity was revealed in all regions after global 
ischaemia, however, only in the hippocampal CA2 sector did the increase reach 
statistical significance. *P < 0.05, **P < 0.005, Mann-Whitney U-statistic. n = 38 
(control); n = 43 (global ischaemia). Data are presented as mean ± SEM. 
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Figure 27. Association between ischaemlc neuronal damage and neuronal rab4 
immunoreactivity 
There were no correlations between the average degree of ischaemic neuronal 
damage and the average degree of neuronal rab4 immunoreactivity in temporal lobe 
after global ischaemia (P> 0.05, Spearman Rank) or in controls (P> 0.05, Spearman 
Rank). 
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Figure 28. Association between survival time after global Ischaemia and 
neuronal rab4 immunoreactivity 
There was no correlation between survival time after an episode of global ischaemia 
and the average degree of neuronal rab4 immunoreactivity in temporal lobe (P> 0.05, 
Spearman Rank). 
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Figure 29. Association between neuronal rabaptin-5 and rab4 Immunoreactivity 
There was a significant correlation between the average degree of neuronal rabaptin-5 
and rab4 immunoreactivity after global ischaemia (P = 0.003; r = 0.48, Spearman 
Rank). There was no association in controls (P> 0.05, Spearman Rank). 
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3.3.4 Association between APOE genotype and alterations in neuronal 
rabaptin-5 and rab4 immunostaining after global ischaemia 
To determine if APOE genotype was associated with alterations in the degree of 
neuronal rabaptin-5 and rab4 immunoreactivity after global ischaemia, controls and 
global ischaemia cases were separated according to those individuals who possessed at 
least one APOE E4 allele and those without an E4 allele. The success rate for 
determination of APOE genotype was high; APOE genotype was undetermined in only 
three control patients. Consequently, 35 controls were used for APOE genotype 
analysis. The frequency of the APOE E4 allele was similar in the control and global 
ischaemia groups. In the control group, 11 individuals possessed at least one APOE £4 
allele (7 males, 4 females; mean age 49 years) and 24 individuals were without an E4 
allele (18 males, 6 females; mean age 52 years). In the global ischaemia group, 15 
patients possessed at least one APOE £4 allele (9 males, 6 females; mean age 49 years) 
and 28 patients were without an E4 allele (18 males, 10 females; mean age 52 years). 
The number of individuals homozygous for the APOE E4 allele was too low to evaluate 
if the effects of this genotype (two controls and two global ischaemia cases were APOE 
E4 homozygotes). Likewise, the frequency of the APOE E2 allele was too low to 
determine any impact of this genotype (two controls and three global ischaemia cases 
possessed one APOE E2 allele; there were no controls or global ischaemia patients 
homozygous for the E2 allele). An average degree of neuronal rabaptin-5 and rab4 
immunoreactivity for the temporal lobe was calculated from the individual scores in 
each of the five regions - hippocampal sectors CAl, CA2, CA3/4, the dentate gyrus and 
neocortex. 
Two-way ANOV A showed that the average degree of neuronal rabaptin-5 
immunoreactivity was not significantly different between the APOE £4 and non-APOE 
E4 groups (P> 0.05) but was significantly greater after global ischaemia compared to 
control (P = 0.001). There was no significant interaction between possession of the 
APOE E4 allele and an episode of global ischaemia (P > 0.05) (Figure 30). Two-way 
ANOV A revealed that the average degree of rab4 immunoreactivity was not 
significantly different between the APOE E4 and non-APOE E4 groups (P > 0.05) and 
was also not significantly different after global ischaemia compared to control (P > 
0.05). However, there was a significant interaction between possession of the APOE E4 
allele and an episode of global ischaemia (P = 0.017) (Figure 31). The mean increase in 
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the average degree of neuronal rab4 immunoreactivity after global ischaemia was 0.9 
units lower on the semi-quantitative score in APOE e4 carriers than in individuals 
without an APOE e4 allele (95% confidence interval of 0.2 to 1.6 units lower). 
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Figure 30. Effect of APOE genotype on alterations in neuronal rabaptin-5 
immunoreactivity after global ischaemia 
The average degree of neuronal rabaptin-5 immunoreactivity in temporal lobe was not 
significantly different between the APOE e4 and non-APOE e4 groups (P > 0.05. two-
way ANOVA) but was significantly greater after global ischaemia compared to control 
(P = 0.001, two-way ANOVA). There was no interaction between possession of an 
APOE e4 allele and an episode of global ischaemia (P> 0.05, two-way ANOVA). n = 
24 (control without e4); n = 11 (control with e4); n = 28 (global ischaemia without e4); n 
= 15 (global ischaemia with e4). Data are presented as mean ± SEM. 
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Figure 31. Effect of APOE genotype on alterations in neuronal rab4 
immunoreactivity after global ischaemia 
The average degree of neuronal rab4 immunoreactivity in temporal lobe was not 
significantly different between the APOE £4 and non-APOE £4 groups (P> 0.05, two-
way ANOVA) and was also not significantly different after global ischaemia compared 
to control (P > 0.05, two-way ANOVA). There was a significant interaction between 
possession of an APOE £4 allele and an episode of global ischaemia on the average 
degree of neuronal rab4 immunoreactivity (P = 0.017, two-way ANOVA). n = 24 
(control without 84); n = 11 (control with £4); n = 28 (global ischaemia without 84); n = 
15 (global ischaemia with £4). Data are presented as mean ± SEM. 
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3.3.5 p-amyloid deposition and neurofibrillary tangles 
Previous studies have shown that there are marked alterations in the endocytic pathway 
in individuals with AD and also in patients with Down syndrome (with early AD) 
(Cataldo et aI., 1997; Cataldo et al., 2000). The present work clearly indicated that there 
were marked endocytic pathway alterations in response to global cerebral ischaemia and 
that these were APOE genotype-dependent. In order to assess if these alterations may 
have been influenced by the presence of AD-type pathology, temporal lobe sections 
from all brains were screened for the presence of diffuse and neuritic p-amyloid (AP) 
deposits and neurofibrillary tangles, which are the neuropathological hallmarks 
(required for diagnosis at post-mortem) of AD. Neuritic (or senile) plaques are 
extracellular deposits of fibrillar AP protein closely associated with dystrophic axons 
and dendrites, activated microglia and reactive astrocytes (Selkoe, 1991). 
Neurofibrillary tangles are composed of abnormal bundles of paired helical filaments 
(hyperphosphorylated tau) most often located in the perinuclear cytoplasm and apical 
dendrites (Mirra and Hyman, 2002). In addition, diffuse Ap-containing plaques are 
composed of amorphous AP which is in a non-fibrillar state (rarely associated with 
dystrophic neurites) and may represent immature lesions which are thought to occur at 
an earlier stage in AD than fibrillar neuritic plaques (Dickson et al., 1995; Lemere et al., 
1996; Morris et al., 1996). 
A minority of controls and global ischaemia cases displayed AP deposits and 
neurofibrillary tangles. AP deposits were present in 3 of 38 controls (one with diffuse 
plaques and two with neuritic and diffuse plaques) and 5 of 43 global ischaemia cases 
(four with diffuse plaques only and one with neuritic and diffuse plaques). Only 1 of 38 
control and 2 of 43 global ischaemia cases displayed neuritic plaques and neurofibrillary 
tangles (indicative of AD), therefore suggesting that endocytic alterations after global 
ischaemia were unlikely to be the result of AD-type pathological processes. 
The APOE £4 allele is associated with increased susceptibility to AD and a greater 
number of Ap-containing plaques in AD patients (Berr et al., 1994; Gearing et al., 
1995b; Polvikoski et ai., 1995; Marz et ai., 1996; Kraszpulski et ai., 2001). In the 
present study, AP deposition was not associated with possession of an APOE e4 allele 
in the control or global ischaemia groups (P > 0.05). Ap deposits were present in 1 of 
11 controls with an APOE e4 allele and 3 of 24 controls without an APOE e4 allele. In 
the global ischaemia group, AP deposits were present in 3 of 15 individuals with an 
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APOE E4 allele and 4 of 28 individuals without an APOE E4 allele. Thus, APOE-
genotype dependent alterations in endocytic pathway alterations after global ischaemia 
are unlikely to be the result of genotype-related differences in susceptibility to AD. 
3.4 Discussion 
The results from the present study demonstrate alterations in the endocytic pathway in 
human hippocampus and neocortex after global ischaemia. Immunoreactivity of the 
endocytic pathway markers, rabaptin-5 and rab4, was markedly increased in neurons 
and to a lesser degree in glia of patients who had experienced an episode of global 
ischaemia compared to controls, indicative of an up-regulation of endocytic pathway 
function. Furthermore, APOE genotype-dependent differences in endocytic pathway 
alterations after global ischaemia were also demonstrated. 
3.4.1 Global ischaemia and ischaemic neuronal damage 
The patients in this study experienced an episode of global cerebral ischaemia caused by 
cardio-respiratory arrest. Patients were subsequently resuscitated and, accordingly, the 
ischaemic episode was followed by a defined period of reperfusion (survival). In 
humans, and in animal models, an episode of global ischaemia with subsequent 
reperfusion produces a relatively stereotyped pathology in which there is selective and 
delayed neuronal damage in selectively vulnerable areas of the brain, including the 
hippocampus, cerebral cortex and striatum (Auer and Sutherland, 2002). Within each 
region, a hierarchy of vulnerability also exists. For example, in the hippocampus of the 
human brain, the pyramidal neurons of the CAl sector are particularly susceptible to 
ischaemic injury (Auer and Sutherland, 2002). It is pertinent to note that individuals 
included in the control group may also have experienced some degree of terminal 
hypoxia and/or hypotension since cardiac arrest is an inevitable consequence of death, 
although this would also be true of the global ischaemia cases. Crucially, however, 
control individuals would not have experienced any cerebral reperfusion. In a previous 
study using the present cohort, the extent of neuronal damage throughout the temporal 
lobe was markedly increased after global ischaemia compared to controls, with only 
minimal neuronal damage in control brain (Horsburgh et al., 1 999a). It is likely, 
therefore, that controls did not experience a significant level of ischaemic insult to the 
brain. 
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3.4.2 Endocytic pathway alterations 
Alterations in the neuronal endocytic pathway have previously been observed in post-
mortem brain from patients with Alzheimer's disease (AD) (Cataldo et al., 1997; 
Cataldo et aI., 2000). Akin to global ischaemia, selective neuronal damage in vulnerable 
regions of the brain (e.g. hippocampus, entorhinal cortex) is a predominant feature of 
AD. This suggests that the cascade of events associated with neuronal damage may 
include changes in intracellular trafficking activity through the endocytic system. In 
post-mortem AD brain, early endosomal volume in cortical pyramidal neurons was 
significantly increased as detected with antibodies to rab5 and rabaptin-5 (Cataldo et ai., 
2000). In addition, elevated rab4 immunoreactivity was also observed in cortical 
pyramidal neurons. These observations are believed to indicate an increase in endocytic 
pathway activity since overexpression of rabS, rabaptin-5 and rab4 have all been shown 
to promote increased endocytosis (Bucci et ai., 1992; van der Sluijs et al., 1992; de 
Hoop et al., 1994; Daro et al., 1996). In the present study, neuronal rabaptin-5 and rab4 
immunoreactivity was markedly increased in all regions of temporal lobe examined in 
global ischaemia patients. It is interesting to note that, in controls and global ischaemia 
cases, highest levels of neuronal rabaptin-5 and rab4 immunoreactivity were observed in 
the hippocampal CAl sector, the most susceptible area to ischaemic damage in humans. 
These data suggest that ischaemic neuronal damage caused by an episode of global 
ischaemia may induce increases in endocytic pathway activity similar to the alterations 
previously described in AD. In support of this, there was a significant association 
between the extent of ischaemic damage and the degree of neuronal rabaptin-S 
immunoreactivity after global ischaemia, although no association was evident between 
ischaemic neuronal damage and rab4 immunoreactivity. Minimal neuronal rabaptin-5 
and rab4 immunoreactivity was detected in control brain. It is possible that some 
controls may have experienced a mild ischaemic insult for reasons discussed above and 
that this may have affected the endocytic pathway, although there was no correlation 
between the extent of ischaemic neuronal damage and neuronal rabaptin-5 or rab4 
immunoreactivity in controls. Intense rabaptin-5 and rab4 immunoreactivity was 
observed extensively in neurons displaying the characteristic morphological features of 
ischaemic damage in global ischaemia cases, which is consistent with the theory that 
endocytic pathway alterations are involved in the response to ischaemic neuronal 
damage. In addition, intense rabaptin-5 and rab4 immunoreactivity was also observed in 
some morphologically "normal" neurons. A possible explanation for these observations 
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is that rabaptin-5 and rab4 in morphologically normal neurons reflect endocytic 
pathway alterations involved in the early response of the neuron to an ischaemic insult 
and prior to the appearance of morphological evidence of ischaemic damage. Similar 
findings were found previously in this cohort with 4-hydroxynonenal (4-HNE), a 
marker of oxidative stress-induced lipid peroxidation. 4-HNE immunoreactivity was 
also present in morphologically normal and ischaemic neurons after global ischaemia 
and it was proposed that 4-HNE in normal neurons indicated the early effects of free 
radical damage on lipids that would likely culminate in neuronal damage (McCracken et 
aI., 2001). In addition, neuronal endosomal alterations have been observed in post-
mortem brain from young individuals with Down syndrome (Cataldo et ai., 2000). 
Individuals with Down syndrome invariably develop AD by age 50, and therefore these 
endocytic pathway changes precede other classic neuropathological markers of AD such 
as neuronal damage and loss, amyloid deposition and neurofibrillary tangle formation. It 
is conceivable, therefore, that endocytic pathway alterations may occur at an early stage 
in response to a neuronal insult but prior to the appearance of morphological evidence 
of damage. 
The results from this study suggest that overall endocytic pathway activity is 
increased after global ischaemia. Furthermore, the two distinct stages of endocytosis 
that rabaptin-5 and rab4 are involved in enable separation of the response of these two 
phases of endocytosis after global ischaemia. Rabaptin-5 is specifically localised to 
early endosomes where it participates in their fusion during endocytic intemalisation. 
Accordingly, an increase in neuronal rabaptin-5 immunoreactivity is indicative of 
elevated intemalisation and trafficking of material from the plasma membrane to early 
endosomes. In contrast, rab4 is explicitly localised to recycling endosomes that are 
returning to the plasma membrane. Consequently, elevated neuronal rab4 
immunoreactivity after global ischaemia implies that endosomal recycling and transport 
of material back to the plasma membrane is also enhanced after global ischaemia. 
Therefore, in the present study there is evidence of a parallel response of the 
intemalisationlearly trafficking and recycling stages of endocytosis in neurons after 
global ischaemia. This is supported by the present finding of a significant association 
between neuronal rabaptin-5 and rab4 immunoreactivity in global ischaemia cases. 
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3.4.3 APOE genotype and endocytic pathway alterations 
When individuals were separated into groups according to APOE genotype (with or 
without an APOE £4 allele), there were two notable findings. First, there was a 
significant interaction between the effects of APOE genotype and an episode of global 
ischaemia on the alterations in degree of neuronal rab4 immunoreactivity in response to 
global ischaemia. In contrast, there was no interaction between the effects of APOE 
genotype and an episode of global ischaemia on alterations in the degree of neuronal 
rabaptin-5 immunoreactivity. These data indicate that there is a differential response of 
the intemalisationlearly trafficking and recycling phases of endocytosis in APOE &4 
carriers and individuals without an APOE &4 allele after global ischaemia. Rabaptin-5 
immunoreactivity was similarly increased in both APOE genotype groups after global 
ischaemia, reflecting comparable increases in endocytic intemalisationlearly trafficking. 
In contrast, there was a trend toward increased rab4 immunoreactivity in response to 
global ischaemia in individuals without an APOE &4 allele, whereas an opposite trend 
was evident in APOE &4 carriers. These data suggest an increase in the number of 
endosomes following a recycling route back to the plasma membrane after global 
ischaemia in non-APOE &4 individuals compared to APOE &4 carriers in which there 
may be a reduction in the number of endosomes trafficked along the recycling pathway. 
Second, the data indicate marked APOE genotype differences in the degree of neuronal 
rab4 immunoreactivity in control brain. The degree of neuronal rab4 immunoreactivity 
was approximately 50% greater (not statistically significant) in APOE &4 controls 
suggestive of underlying differences in endocytic pathway activity in non-ischaemic 
control brain. Since endocytic activation has previously been demonstrated in AD and 
in view of the association between APOE &4 and development of AD, elevated 
endosomal recycling activity in APOE &4 controls may be related to the presence of 
early AD in some individuals. This is unlikely, however, since all brains were screened 
for the presence of AJ3 deposits and neurofibrillary tangles which were only evident in a 
minority of controls and global ischaemia cases. Furthennore, the presence of AJ3 
deposits and/or tangles was not associated with APOE genotype. Significantly, in the 
control group, one APOE &4 individual displayed neuritic and diffuse AJ3 deposits and 
tangles but only minimal rabaptin-5 and rab4 immunoreactivity. Thus, it is possible that 
greater rab4 immunoreactivity in the control APOE &4 group may reflect APOE 
genotype specific intrinsic differences in endosomal trafficking in uninjured brain. 
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Previously, APOE genotype has been associated with differences in aspects of general 
brain function in uninjured brain, such as cerebral blood flow and glucose metabolism 
(Small et al., 1995; Scarmeas et al., 2003). In vitro studies have shown isofonn-specific 
differences in endocytic trafficking and localisation of apoE in uninjured neurons 
(DeKroon and Annati, 2001) and apoE3 and apoE4 have been shown to accumulate in 
different parts of cultured neurons (Nathan et al., 1994; Nathan et al., 2002). Isofonn-
specific effects influencing neuronal physiology in nonnal brain may therefore underlie 
the discrepancy in endocytic recycling activity between the APOE E4 and non-APOE E4 
control groups. 
In a previous study using this cohort of individuals, there was no association 
between the degree of neuronal damage after global ischaemia and APOE genotype 
(Figure 32) (Horsburgh et al., 1999a). Therefore, in this cohort, APOE genotype-
dependent differences in the endocytic response to global ischaemia are not linked to 
differences in pathological outcome. However, inability to control for important 
variables such as the duration and severity of the ischaemic insult in human subjects 
may preclude the detection of APOE genotype differences in neuronal damage. In 
addition, as discussed earlier, endocytic pathway alterations may reflect changes 
occurring early in the cascade of cellular processes triggered by the ischaemic insult. 
The majority of global ischaemia cases survived for 3 days or less and in view of the 
involvement of delayed neuronal damage in global ischaemia it is unclear if ischaemic 
damage matures further beyond this time-point. Thus, it is conceivable that APOE 
genotype differences in endocytic alterations could precede pathological differences. 
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Figure 32. Effect of APOE genotype on ischaemic neuronal damage 
Ischaemic damage was assessed previously by Dr Karen Horsburgh (Horsburgh et al., 
1999a). There was no significant difference in the degree of neuronal damage in 
individuals with and without an APOE e4 allele in controls or after global ischaemia. P> 
0.05, Mann-Whitney U-statistic. n = 24 (control without e4); n = 11 (control with e4); n = 
28 (global ischaemia without e4); n = 15 (global ischaemia with e4). Data are presented 
as mean ± SEM. 
The APOE genotype dependent differences in endocytic pathway alterations after 
global ischaemia evident in the present study raise the possibility that differences in the 
response of this pathway may contribute to the mechanisms underlying APOE genotype 
differences in susceptibility to acute brain injury shown previously. Since the endocytic 
pathway is integral to intracellular processing of apoE, these results suggest that there 
may be isoform-specific differences in the way that apoE (and other molecules) is 
trafficked through neurons after injury. The potential importance of interactions 
between the endocytic pathway, apoE trafficking and other processes involved in the 
response to cerebral ischaemia are discussed later (sections 5.4.6 and 5.4. 7). 
3.4.4 Conclusions 
In summary, the aims stated at the outset of this study have been achieved: 
1. upregulation of endocytic activity was evident in human post-mortem temporal 
lobe tissue after an episode of global ischaemia 
2. APOE genotype was associated with differences In endocytic pathway 
alterations after global ischaemia 
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Chapter 4 
Characterisation and validation of the 
intraluminal filament model of focal cerebral 
ischaemia in C57BI/6J mice 
4.1 Introduction and aims 
The intraluminal filament occlusion (sustained anaesthesia) model of focal ischaemia 
was established and characterised to enable further evaluation of the roles of APOE 
genotype and endocytic pathway alterations in the response to cerebral ischemia. The 
model was established in C57BV6J mice, the background strain of APOE transgenic 
mice used in the following study (chapter 5). The specific aims of the present study 
were to: 
1. establish and validate the reproducibility of an intraluminal occlusion model of 
focal cerebral ischaemia in the mouse 
2. determine the occlusion-duration effects of intraluminal occlusion on the extent 
and distribution of ischaemic damage and local cerebral blood flow 
3. determine the effects of focal cerebral ischaemia on the response of the 
endocytic pathway 
4.2 Materials and methods 
This study was carried out at the Wellcome Surgical Institute, University of Glasgow. 
Measurement of ischaemic damage and local cerebral blood flow was performed 
unaware of occlusion duration. 
4.2.1 Mice 
Adult male C57BV6J strain mice obtained from Charles River, UK, were used. 
4.2.2 Development of model 
4.2.2.1 Development of surgical technique 
Prior to characterising the model, preliminary work was required to gain competence in 
general surgical protocols and to establish the best surgical approach for intraluminal 
occlusion (section 2.3.2.1). 
4.2.2.2 Comparison of 5-0 and 6-0 filament 
Previous reports of focal cerebral ischaemia induced by a heat-blunted filament 
employed either a 5-0 or thinner 6-0 nylon monofilament. Once competence was gained 
in the surgical approach, experiments were performed to establish the most suitable size 
of filament to use. Cerebral blood flow was assessed qualitatively using the 14C 
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autoradiography technique (section 2.11.2) after 15min intraluminal occlusion induced 
with either a 5-0 or 6-0 filament (n = 5 in each group). 14C_IAP was administered 2min 
prior to the end of occlusion (i.e. at 13min). Clear evidence of hypoperfusion in core 
MCA territory (see section 4.3.1.1) ipsilateral to occlusion indicates a successful 
occlusion. Therefore, autoradiograms were assessed to determine if hypoperfusion 
(relative to the contralateral hemisphere) was present in two core MCA regions: (1) 
dorsolateral caudate nucleus, and (2) somatosensory cortex. 
4.2.2.3 Measurement of ischaemic damage - validation of method 
An adaptation of the technique developed by Osborne et al. (1987) was used for 
volumetric measurement ofischaemic damage as described (section 2.8). As the present 
study was the first to use the adapted technique, it was also necessary to test and verify 
the accuracy of the technique prior to full volumetric analysis. Two important features 
distinguished the adapted method from the original: (1) the modified technique used 
scale diagrams derived from a stereotaxic mouse atlas (Hof et al., 2000) compared to 
scale drawings of rat stereotaxic levels in the original technique, (2) mouse scale 
diagrams are overlayed on a stereotaxic grid which allows direct calibration of distance 
on the MCID image analyser and accounts for magnification from actual brain size; in 
contrast, the rat scale drawings are not on a stereotaxic grid therefore indirect calibration 
using a graticule and incorporation of a known magnification factor is required during 
volumetric calculations to account for enlargement of scale drawings from actual brain 
size. 
To test the accuracy of the adapted technique, the volume ofischaemic damage was 
compared in five mice using direct calibration of distance from the stereotaxic grid with 
that obtained using the previously established system of indirect calibration of distance 
using a graticule with incorporation of a magnification correction factor (as in original 
Osborne technique). 
4.2.3 Characterisation of model 
4.2.3.1 Effect of occlusion duration on ischaemic damage 
To assess the effects of occlusion duration on the volume of ischaemic damage, mice 
(29 ± 0.9g) were randomly assigned to one of three groups: 15min occlusion (n = 8); 
30min occlusion (n = 8); 60min occlusion (n = 7). After the appropriate duration of 
occlusion, the filament was withdrawn to allow reperfusion for 24h at which point mice 
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were anaesthetised and sacrificed by trans-cardiac perfusion fixation. Sections (6Jlm) 
were cut from paraffin embedded brain and the volume of ischaemic damage was 
measured as described (section 2.8). For brains to be included for volumetric analysis 
the following criteria had to be met: (I) clear evidence of ischaemic damage in the 
striatum, and (2) absence of haemorrhage as observed in haematoxylin and eosin-
stained tissue. Reproducibility of measurement of ischaemic damage was tested 
(Appendix E). 
4.2.3.2 Effect of occlusion duration on cerebral blood flow 
The occlusion-duration effects of intraluminal occlusion on local cerebral blood flow 
(LCBF) were assessed in groups of mice undergoing 15min (n = 6) or 60min 
intraluminal filament occlusion (n = 6) and 15min (n = 4) or 60min (n = 4) sham 
occlusion. LCBF was measured as described (section 2.11). 14C_IAP was administered 
2min prior to the end of occlusion (at 13min or 58min). Reproducibility of LCBF 
measurement was tested (Appendix F). 
4.2.3.3 Effect of occlusion duration on blood pressure 
The temporal profile of mean arterial blood pressure (MABP) during intraluminal 
occlusion was monitored in separate groups of mice subjected to 60min intraluminal 
filament occlusion (n = 8) or 60min sham occlusion (n = 6) as described (section 2.3.3). 
MABP was recorded at 5 minute intervals until the animal was sacrificed. 
4.2.4 Examination of cerebrovascular anatomy 
In a separate group of mice (n = 10), the major arteries of the circle of Willis were 
examined as described (section 2.3.4). 
4.2.5 Operational definition of MeA territory 
In order to assess the spatial distribution of ischaemic damage, an independent 
definition of "MCA territory" was required. The operational definition ofMCA territory 
used in the present study was derived from a series of detailed and systematic 
experiments by Scremin examining the rodent cerebral vascular system (Scremin, 
1995). At nonnal levels of perfusion pressure and in the absence of vascular 
abnonnalities, the MCA and its major branches supply the striatum and the majority of 
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the cerebral cortex (including motor, somatosensory, piriform, auditory cortex). The 
hippocampus and thalamus do not receive their blood supply from the MCA or its 
collaterals; these structures derive their blood supply from the posterior cerebral artery 
and its major branches and therefore lie outside MCA territory. 
4.2.6 Immunohistochemistry 
To assess the effects of focal ischaemia on the endocytic pathway, paraffin-embedded 
sections (6J.1m) were immunostained (peroxidase protocol) with antibodies to rabaptin-5 
and rab4 (section 2.9.3). 
4.2.7 Statistical analysis 
One-way analysis of variance (ANOY A) followed by Student's unpaired t-test 
(incorporating Bonferroni correction factor of 3) was used to assess statistical 
differences in the volume of ischaemic damage among the three occlusion groups. 
Student's unpaired t-test was used to assess statistical differences in LCBF between the 
15min occlusion and 60min occlusion groups. Student's unpaired t-test was used to 
assess statistical differences in MABP after 60min occlusion between sham occlusion 
and intraluminal occlusion groups. All data are presented as mean ± SEM. 
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4.3 Results 
4.3.1 Development of model 
4.3.1.1 Comparison of 5-0 and 6-0 filament 
To detennine the most appropriate type of filament to use for occlusion in the full study, 
the pattern of cerebral blood flow was assessed on 14C autoradiograms following 
occlusion with either a 5-0 (thicker) or 6-0 (thinner) filament (Table 4 and Figure 33). 
Hypoperfusion (relative to contralateral hemisphere) was observed in the dorsolateral 
caudate nucleus in 2 of 5 mice after occlusion with a 6-0 filament and in 4 of 5 mice 
after occlusion with a 5-0 filament. In the somatosensory cortex, hypoperfusion was 
observed in 1 of 5 mice after occlusion with a 6-0 filament and in 3 of 5 mice after 
occlusion with a 5-0 filament. Since clear hypoperfusion in MCA core territory 
(particularly the dorsolateral caudate nucleus) reflects a successful occlusion, these 
results demonstrate that a successful occlusion was achieved more consistently with a 
5-0 filament. In addition, the 5-0 filament moved along the lumen of the carotid vessels 
more smoothly and was more easily manipulated and directed. Accordingly, less time 
was required to correctly place the 5-0 filament, an important factor in the application of 
this technique. In consideration of the above findings, the 5-0 filament was chosen as 
the more suitable for this model and was used subsequently for all occlusions. 
Table 4. Hypoperfusion associated with intraluminal occlusion with a 5-0 and 
thinner 6-0 filament 
Filament size 
5-0 
6-0 
No. of mice with hypoperfusion in MeA territory 
Dorsolateral 
caudate nucleus 
4 of 5 
2 of 5 
Somatosensory cortex 
3 of 5 
1 of 5 
More consistent hypoperfusion in core MeA regions was produced by occlusion with 
the 5-0 filament indicating that this filament size was more suitable for achieving 
successful occlusion. 
122 
somatosensory 
cortex 
a 
dorsolateral caudate 
nucleus 
b 
Figure 33. Effect of filament size on hypoperfusion in MeA territory 
Representative autoradiograms illustrating (a) absence of hypoperfusion in MCA 
territory after occlusion with a 6-0 filament, indicating an unsuccessful occlusion, and 
(b) illustrating clear hypoperfusion (relative to contralateral hemisphere) in core MCA 
territory of occluded hemisphere after occlusion with a 5-0 filament, indicating a 
successful occlusion. 
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4.3.1.2 Measurement of ischaemic damage - validation of method 
To confinn the accuracy of the method adapted for use in mice, the volume of 
ischaemic damage was compared in a group of mice (n=5) using either direct (from 
mouse atlas stereotaxic grid) or indirect (from graticule with magnification correction) 
calibration of distance. Linear magnification of the mouse scale diagrams was measured 
under a dissecting microscope and detennined to be 9.25. The results shown in Figure 
34 demonstrate that the adapted method of volumetric measurement of ischaemic 
damage using direct distance calibration produced values that strongly correlated with 
those obtained using indirect distance calibration from a graticule (P = 0.0003, .; = 
0.98). This confirmed the accuracy of the adapted technique adapted for measuring the 
volume of ischaemic damage after intraluminal occlusion in mice. 
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Figure 34. Validation of adapted method for measurement of Ischaemlc damage 
The volumes of ischaemic damage obtained with the adapted method (direct 
calibration of distance from mouse atlas) strongly correlated (P = 0.003, I- = 0.98) with 
volumes obtained using a previously characterised method (Osborne et al., 1987) 
involving indirect calibration from a graticule. 
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4.3.2 Characterisation of model 
4.3.2.1 Post-operative recovery 
Post-operative recovery was closely monitored in mice undergoing 24h reperfusion. In 
general, animals adopted a hunched posture and displayed a reduction in normal 
exploratory behaviour throughout the recovery period. Circling (during spontaneous 
movement) and/or leaning (at rest) to one side were observed regardless of occlusion 
duration. In mice that experienced 15min occlusion, mobility and grooming behaviour 
was largely preserved. In contrast, minimal spontaneous movement was generally noted 
in mice that experienced 30min or 60min occlusion, although the response to tactile 
stimulation was not diminished. Normal grooming behaviour was generally absent in 
these mice. Sporadic episodes of spinning (barrel-rolling) were observed infrequently 
irrespective of occlusion duration. Subsequent histological analysis revealed that, in all 
mice, barrel-rolling during recovery corresponded to the presence of an intracranial 
haemorrhage. In addition, normal feeding was absent in all mice during the recovery 
period. 
4.3.2.2 Haemorrhage rate, mortality rate and absence of ischaemic damage 
Prior to full neuropathological analysis, haematoxylin and eosin-stained tissue from 
each brain was examined to determine if the criteria for proceeding to analysis were met 
(Table 5). 
Table 5. Mice excluded prior to measurement of ischaemic damage 
Duration of occlusion Number of mice excluded 
(min) Mortality Haemorrhage No ischaemic damage 
15 (n = 8) 0 1 (12.5%) 1 (12.5%) 
30 (n = 8) 1 (12.5%) 1 (12.5%) 1 (12.5%) 
60 (n = 7) 2 (28%) 0 0 
Combined (n = 23) 3 (13%) 2 (9%) 2 (9%) 
Criteria for inclusion included 24h recovery, absence of haemorrhage and clear 
histological evidence of ischaemic damage. 
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4.3.2.3 Effect of occlusion duration on ischaemic damage 
Areas of tissue displaying ischaemic pathology were identified on coronal haematoxylin 
and eosin-stained sections. With 15min occlusion, areas of ischaemic pathology were 
characterised by ischaemic damage to neurons and glial cells. There was minimal 
damage to vascular cells. Pallor and vacuolation of the neuropil were also features of 
these areas of ischaemic damage. With 30min occlusion and 60min occlusion, areas of 
ischaemic damage displayed similar pathology to that observed with 15min occlusion, 
although vascular pathology was more marked with these durations of occlusion. 
The volume of ischaemic damage increased markedly with increasing duration of 
occlusion: 15min occlusion (9 ± 2mm3); 30min occlusion (56 ± 6mm3); 60min 
occlusion (69 ± 2mm3) and was highly reproducible in all groups (co-efficient of 
variance, 3% with 60min occlusion) (Figure 35). 
The spatial distribution of ischaemic damage was highly sensitive to the duration of 
occlusion (Table 6). With 15min occlusion, ischaemic damage was restricted to MCA 
territory (striatum and cortex). Increasing the duration of occlusion beyond 15min 
resulted in ischaemic damage both within and outside (e.g. hippocampus, thalamus) 
MCA territory. 
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Figure 35. Effect of occlusion duration on ischaemic damage 
(a) There were significant increases in the volume of ischaemic damage with 
increasing duration of occlusion. Bars show mean. (b) The area of ischaemic damage 
at each coronal level was markedly increased when occlusion duration was increased 
beyond 1Smin. -P < 0.01; ***P < 0.001, one-way ANOVA followed by Student's 
unpaired t-test with Bonferroni correction factor. 1Smin (n=6); 30min (n = 5); 60min (n = 
5). Data are presented as mean ± SEM. 
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Table 6. Frequency of ischaemic damage in specific brain regions 
Duration of occlusion Number of mice with ischaemic damage in specific brain regions 
(min) Striatum Cerebral cortex Hippocampus Thalamus Hypothalamus 
15 60f6 10f6 o of6 o of6 o of6 
30 50f5 50f5 50f5 40f5 1 of 5 
60 50f5 50f5 50f5 50f5 50f5 
Ischaemic damage was confined to MCA territory (striatum, cortex) after 15min occlusion. Increasing the duration of 
occlusion to 30min resulted in consistent involovment of regions outside MCA territory including the hippocampus and 
thalamus but only infrequent involvement of the hypothalamus. 60min occlusion produced a similar pattern of ischaemic 
damage to 30min occlusion but with more frequent involvement of the hypothalamus . 
4.3.2.4 Effect of occlusion duration on cerebral blood flow 
To assess the effects of increasing the duration of occlusion on cerebral hypoperfusion, 
local cerebral blood flow (LCBF) was measured in distinct neuroanatomicalloci within 
and outside MCA territory and in an area exempt from the ischaemic insult 
(cerebellum). In sham-occluded mice, LCBF could not be measured fully quantitatively 
as the values were above the measurable limit of the image analysis system 
(200Om1l100glmin). The potential reasons for the excessively high values are discussed 
later (section 4.4.1.3). Therefore, in sham animals, the local tissue concentration of 14C_ 
lAP at each anatomical locus was normalised to the concentration of 14C_IAP in the 
cerebellum, an area exempt from the ischaemic insult. The normalised values were used 
as indices of cerebral blood flow in each locus. There were no hemispheric asymmetries 
in local brain tissue 14C concentration observed after sham occlusion indicating that 
surgical manipulation did not contribute to hypoperfusion in the occluded hemisphere 
(Figure 36). There were no significant differences in relative 14C_IAP concentration 
after 60min occlusion compared to 15min occlusion in any anatomical locus suggesting 
that surgical manipUlation did not contribute to the more severe hypoperfusion observed 
in some areas after 60min occlusion (Table 7). 
LCBF was reduced after both 15min occlusion and 60min occlusion in the 
occluded hemisphere (Figure 37). However, the severity of hypoperfusion was 
significantly different in these two groups. In 9 of 12 regions examined LCBF was 
significantly lower after 60min occlusion compared to 15min occlusion (P < 0.05) 
(Table 8 and Figure 38). In core MeA territory, such as the dorsolateral caudate 
nucleus, there was marked hypoperfusion after both 15min occlusion and 60min 
occlusion. In contrast, outside the territory of the MCA (e.g., hippocampus, dorsolateral 
thalamus, hypothalamus), marked hypoperfusion was apparent after 60min occlusion 
but not 15min occlusion. LCBF was not significantly different in the cerebellum, motor 
cortex and ventromedial thalamus after 60min occlusion compared to 15min occlusion 
(P > 0.05) (Figure 39). 
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Figure 36. Representative 14C-IAP autoradiograms after 15min and 60min sham occlusion 
Visual inspection of autoradiograms revealed that sham occlusion did not result in any hemispheric 
asymmetries in local brain tissue 14C concentration indicating that sham surgery did not result in cerebral 
hypoperfusion in the ipsilateral hemisphere. This observation was made after both 1Smin and 60min 
occlusion. Scale bar, Smm. 
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Table 7. Effect of sham occlusion duration on local brain tissue 14C concentration 
Local tissue concentration of 14C_IAP (normalised to cerebellum) 
Ipsilateral to occlusion Contralateral to occlusion 
15min Dec. 60min Dec. 15min Dec. 60min Dec. 
Cerebellum (cortex) 1.00 1.00 1.00 1.00 
Frontal cortex 1.06 ± 0.03 1.05 ± 0.03 1.05 ± 0.03 1.00 ± 0.02 
Caudate nucleus (dorsolateral) 1.07 ± 0.05 1.09 ± 0.10 1.08 ± 0.04 1.07 ± 0.06 
Caudate nucleus (ventromedial) 1.02 ± 0.04 1.07 ± 0.11 1.04 ± 0.04 1.03 ± 0.11 
Motor cortex 1.06 ± 0.04 1.02 ± 0.09 1.07 ± 0.04 1.04 ± 0.06 
Somatosensory cortex 1.09 ± 0.05 1.08 ± 0.08 1.09 ± 0.04 1.04 ± 0.08 
Insular cortex 1.04 ± 0.06 1.08 ± 0.07 1.05 ± 0.04 1.03 ± 0.01 
Hippocampus (CA1) 1.03 ± 0.05 1.05 ± 0.05 1.05 ± 0.04 1.03 ± 0.06 
Thalamus (dorsolateral) 1.12 ± 0.05 1.18 ± 0.03 1.12 ± 0.03 1.16 ± 0.01 
Thalamus (ventromedial) 1.14 ± 0.03 1.18 ± 0.01 1.15 ± 0.03 1.17 ± 0.02 
Hypothalamus 0.90 ± 0.04 1.01 ± 0.05 0.88 ± 0.04 1.04 ± 0.03 
Auditory cortex 1.00 ± 0.04 1.04 ± 0.04 1.00 ± 0.04 1.01 ± 0.02 
The local tissue concentration of 14C-IAP at each anatomical locus was normalised to the concentration of 14C-IAP in the cerebellum, an 
area exempt from the ischaemic insult, and used as an index of LCBF. There were no significant differences in the normalised 14C 
concentrations after 60min occlusion compared to 15min occlusion in any locus examined (P > 0.05). Unpaired Student's (-test for the 
comparison between 60min occlusion and 15min occlusion. Occ. (occlusion). n = 4 (each group). Data are presented as mean ± SEM. 
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Figure 37. Representative 14C-IAP autoradiograms after 15min and 60min intraluminal occlusion 
After 1Smin occlusion, marked cerebral hypoperfusion was restricted to MeA core territory (e.g. dorsolateral 
caudate nucleus). After 60min occlusion , in addition to core MeA areas, marked cerebral hypoperfusion was 
observed in regions outside MeA territory such as hippocampus and dorsolateral thalamus. Scale bar, Smm. 
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Table 8. Effect of intraluminal filament occlusion duration on local cerebral blood flow 
Local cerebral blood flow (mI/100g/min) 
Cerebellum (cortex) 
Frontal cortex 
Caudate nucleus (dorsolateral) 
Caudate nucleus (ventromedial) 
Motor cortex 
Somatosensory cortex 
Insular cortex 
Hippocampus (CA 1 ) 
Thalamus (dorsolateral) 
Thalamus (ventromedial) 
Hypothalamus 
Auditory cortex 
Ipsilateral to occlusion 
15min Occ. (% contralateral) 60min Occ. (% contralateral) 
123 ±6(103%) 115±3 (97%) 
57 ± 9 (41%) 14 ± 4** (11%) 
33 ± 5 (26%) 9 ± 2*** (8%) 
51 ± 7 (43%) 12 ± 2*** (11%) 
57 ± 8 (45%) 36 ± 6 (32%) 
46 ± 8 (32%) 12 ± 2** (9%) 
45 ± 10 (36%) 12 ± 3* (10%) 
61 ± 7 (55%) 16 ± 6*** (16%) 
64 ± 12 (48%) 23 ± 8* (17%) 
119 ± 11 (84%) 86 ± 17 (60%) 
68 ± 7 (70%) 36 ± 10* (37%) 
43 ± 11 (39%) 8 ± 3* (7%) 
Contralateral to occlusion 
15min Occ. 
121 ± 5 
138 ± 12 
127 ± 6 
119 ± 7 
128 ± 14 
143 ± 8 
124 ± 11 
111 ± 3 
133 ± 6 
141 ± 8 
97 ± 7 
111 ± 6 
60min Occ. 
119 ± 3 
122 ± 6 
119 ± 7 
109 ± 7 
114 ± 5 
128 ± 6 
116 ± 7 
103 ± 5 
133 ± 4 
143 ± 6 
98 ± 5 
109 ± 4 
LCBF was significantly lower after 60min intraluminal filament occlusion compared to 15min occlusion in 9 of 12 anatomical loci examined in 
the occluded hemisphere. There were no statistically significant differences in LCBF between 60min and 15min occlusion at any loci 
examined contralateral to the occluded hemisphere. *P < 0.05; **P < 0.01; ***P < 0.001, unpaired Student's t-test for the comparison between 
60min occlusion and 15min occlusion. Occ. (occlusion). n = 6 (each group). Data are presented as mean ± SEM . 
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Figure 38. Effect of occlusion duration on local cerebral blood flow in the dorsolateral caudate nucleus and hippocampus (CA1) 
LCBF was significantly lower after 60min occlusion compared to 15min occlusion in the dorsolateral caudate nucleus (MCA core territory) 
and in the CA 1 region of the hippocampus (outSide MCA territory). There were no statistical differences in LCBF in either region in the 
contralateral hemisphere after 60min occlusion compared to 15min occlusion. Data extracted from Table 1. ***P < 0.001, unpaired 
Student's t-test. n = 6 (each group). Data are presented as mean ± SEM . 
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Figure 39. Effect of occlusion duration on local cerebral blood flow in the ventromedial thalamus and cerebellum 
In the hemisphere ipsiateral to occlusion, significant reductions in LCBF were not observed in all loci examined. For example in the 
ventromedial thalamus, LCBF was reduced after 6amin compared to 15min occlusion, however, this did not reach statistical 
significance (P > 0.05). In the cerebellum, which is exempt from the direct ischaemic episode, LCBF was similar after 6amin and 
15min occlusion both ipsilateral and contralateral to occlusion suggesting that general physiological decline was not responsible for 
more severe cerebral hypoperfusion in other areas after 60min occlusion. Unpaired Student's t-test for the comparison between 
6amin occlusion and 15min occlusion. n = 6 (each group). Data are presented as mean ± SEM . 
4.3.2.5 Effect of occlusion duration on blood pressure 
Mean arterial blood pressure (MABP) remained stable during surgical manipulation in 
both the sham and intraluminal occlusion groups (Figure 40). Immediately following 
placement of the filament tip, a transient increase in MABP was observed in both 
groups, followed by a return to pre-occlusion levels at which blood pressure stabilised. 
In the sham occlusion group, MABP remained stable throughout the occlusion. In the 
occlusion group, MABP declined progressively from 25min after the onset of occlusion 
and was significantly lower after 60min occlusion compared to sham occlusion (61 ± 2 
mmHgvs.77±2mmHg,P<0.0001). 
4.3.3 Cerebrovascular anatomy 
The vascular anatomy of the circle of Willis and its associated arteries was examined 
under a dissecting microscope. A complete circle of Willis was present in only 1 of 10 
mice examined (Figure 41). Of the remaining 9 mice, 6 had one posterior 
communicating artery absent and 3 were deficient for both posterior communicating 
arteries. All other major components of the circle of Willis appeared normal in these 
mIce. 
4.3.4 Immunohistochemistry 
To assess the response of the endocytic pathway to focal ischaemia, sections were 
immunostained with rabaptin-5 and rab4 antibodies. Several concentrations of primary 
antibodies were used with and without pre-treatment (microwaving, pepsin treatment) 
and with Standard and Elite ABC kits. However, with all combinations, staining was 
weak (mainly of background) and non-specific and therefore the endocytic response 
could not be assessed after focal ischaemia in C57B1I6J mice. Preliminary 
immunostaining on sections from APOE transgenic mice produced specific staining, 
indicating that these antibodies could be used to assess endocytic pathway activity in the 
following study in APOE transgenic mice (chapter 5). The reason for these 
discrepancies is unclear, but may be a result of processing of brains at different times. 
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Figure 40. Mean arterial blood pressure during 60min occlusion 
Mean arterial blood pressure (MABP) remained stable during the surgical procedure. In 
the sham occlusion group, MABP remained relatively stable throughout the entire 
procedure with only a small decline evident 4Smin after sham occlusion. In the 
occlusion group, a progressive decline in MABP was noted 2Smin after occlusion onset 
and MABP was significantly lower after 60min occlusion compared to sham occlusion. 
MABP recorded every Smin throughout the procedure. *-P < 0.0001, Student's 
unpaired t-test. n = 6 (sham occlusion): n = 8 (intraluminal occlusion). Data are 
presented as mean ± SEM. 
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Figure 41. Integrity of the circle of Willis in C57BI/6J mice 
(a) Diagram of major arteries in a complete circle of Willis. (b) 1 of 10 mice had a 
complete circle of Willis containing both PcomAs (arrows). (c) 6 of 10 mice had one 
PcomA present (arrow) and (d) 3 of 10 mice had both PcomAs absent. ACA (anterior 
cerebral artery); MCA (middle cerebral artery); PCA (posterior cerebral artery); PcomA 
(posterior communicating artery); SCA (superior cerebellar artery); SA (basilar artery); 
ICA (internal carotid artery). 
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4.4 Discussion 
The results from the present study demonstrate that a reproducible model of focal 
cerebral ischaemia induced by intraluminal filament occlusion was achieved in 
C57B1I6J mice. A steep increase in the extent of ischaemic damage, that included 
recruitment of tissue outside MCA territory, was observed with increasing occlusion 
duration and was likely related to increasing severity of hypoperfusion and PcomA 
hypoplasticity. 
4.4.1 Technical and methodological considerations 
4.4.1.1 Intraluminal occlusion 
Successful intraluminal occlusion requires that the tip of the intraluminal filament is 
placed at the correct position to block the origin of the MCA and therefore prevent 
blood entering this artery from the circle of Willis. Correct placement of the filament 
cannot be determined objectively but rather relies upon (1) knowledge of the 
approximate distance from the carotid bifurcation to insert the filament so that the tip 
reaches the origin of the MCA, and (2) resistance felt while gently pushing the filament 
along the internal carotid artery indicating that the tip is lodged in the proximal part of 
the anterior cerebral artery and therefore occluding the MCA. During preliminary 
experiments to learn and refine the technique, resistance was felt after advancement of 
the filament approximately IOmm distal to the carotid bifurcation. This was in 
agreement with previous studies describing intraluminal occlusion in the mouse in 
which the filament was inserted 9 - 11.5mm (Clark et al., 1997; Hata et al., 1998; 
Kitagawa et al., 1998c; Belayev et al., 1999; Mao et al., 1999). There are two major 
consequences arising from failure to achieve correct filament placement that are 
characteristic of the intraluminal occlusion technique in both mice and rats: (1) 
inadequate obstruction of the origin of the MCA caused by the filament not being 
advanced far enough along the internal carotid artery, and (2) rupture of the vessel wall 
as a result of the filament being advanced too far/with too much force. A consequence 
of the first of the above complications is absence of cerebral hypoperfusion and 
ischaemic pathology (Schmid-Elsaesser et al., 1998) whereas the latter is associated 
with bleeding from the punctured vessel and subarachnoid haemorrhage (Garcia, 1993; 
Clark et al., 1997; Tsuchiya et al., 2003 a). Previous studies have reported exclusion 
rates due to intracranial haemorrhage of up to 30% (Matsuo et al., 1994; Clark et al., 
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1997; Yanaka et al., 1997; Tsuchiya et al., 2003a). Perhaps related to the incidence of 
intracranial haemorrhage, high mortality rates (up to 80%) have also been reported 
following intraluminal occlusion in the mouse (Kitagawa et al., 1998c; Connolly et at., 
1996; Clark et al., 1997). In the present study, mortality rate and incidence of 
intracranial haemorrhage were both less than 15% and therefore within the range 
previously reported. The occurrence of intracranial haemorrhage did not appear to be 
associated with increasing duration of occlusion. This is not unexpected since 
haemorrhage is likely to occur due to incorrect filament placement regardless of 
occlusion duration. Examination of brains revealed that deaths during recovery were not 
due to intracranial haemorrhage. A particularly severe ischaemic insult may be the 
underlying cause since deaths occurred only after longer periods of occlusion (3Omin 
and 6Omin), consistent with previous reports (Connolly et at., 1996; Kitagawa et al., 
1998c). 
4.4.1.2 Measurement of ischaemic damage - validation of method 
The studies described in this thesis involved occlusion of the MCA in mice with an 
intraluminal filament. A rigorously tested method for volumetric assessment of 
ischaemic damage following focal cerebral ischaemia had previously been established 
and used extensively in the laboratory (Osborne et al., 1987). However, this method was 
set up in order to measure infarct volumes in rats following electro-coagulation of the 
MCA (Tamura et al., 1981) and therefore volume calculation was derived from area 
measurements on scale diagrams of the rat brain. It was necessary, therefore, to 
establish and validate the accuracy and reproducibility of a modified version of the 
Osborne method that would be pertinent to the mouse intraluminal occlusion model. 
Volumes of damage calculated from area measurements at eight corona1levels had been 
shown previously to provide a close approximation of the true infarct volume in rats 
(Osborne et al., 1987). Therefore, eight coronal levels for area measurement were 
chosen from a stereotaxic mouse atlas (Hof et al., 2000). Areas of ischaemic damage 
were delineated on to scale diagrams derived from the stereotaxic atlas representing the 
eight coronal levels. An advantage of the mouse scale diagrams was their 
superimposition on a stereotaxic grid which enabled direct calibration of distance from 
the grid for area measurements and accounted for magnification of the diagrams from 
true brain size. Previously, indirect calibration from a graticule measurement and 
subsequent use of a magnification factor was required with the rat scale diagrams. In the 
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present study, volumetric measurement of ischaemic damage using direct distance 
calibration from the mouse stereotaxic diagrams produced comparable values to those 
generated from indirect graticule distance calibration as used in the Osborne method. 
This confirmed that the adapted method using direct distance calibration from mouse 
atlas scale diagrams produced accurate measurements of the volume of ischaemic 
damage. 
It was also important to validate the reproducibility of volumetric measurement as 
there are a number of potential sources of error during the measurement process. These 
include selection of the appropriate sections for each coronal level, identification of 
areas of ischaemic damage, delineation of areas of damage on to scale diagrams and 
area measurement on the image analysis system. In the present study, measurement of 
the volume of ischaemic damage in two different sessions was highly reproducible 
(Appendix E) and therefore errors arising from the above sources were minimal. 
Overall, the refined technique for volumetric assessment of ischaemic damage in mice 
was considered to provide accurate and reproducible measurements. 
4.4.1.3 Measurement of local cerebral blood flow 
In the present study, LCBP was measured quantitatively using a modification of the 
method first described and validated by Maeda et al. (2000). This method was used to 
avoid some of the complications associated with LCBP measurement in mice using 
techniques originally developed and tailored for use in larger species that involve 
multiple blood vessel cannulations (Reivich et al., 1969; Sakurada et ai., 1978). In small 
rodents, such as mice, cannulation of multiple blood vessels for 14C_IAP infusion and 
arterial blood sampling is less practicable. Extensive and precise surgery under 
prolonged general anaesthesia is required. In addition, blood loss during repeated 
sampling of arterial blood may lead to systemic hypotension on account of the relatively 
small blood volume in the mouse. In the present study, these complications were 
avoided by intraperitoneal administration of 14C_IAP in conjunction with a single 
sampling of heart blood upon termination of the experiment. Sampling of blood samples 
from the frozen heart was readily attainable. 
A possible source of error in LCBP measurement, particularly applicable to the 
mouse, arises from the post-mortem diffusion of 14C_IAP. During the time required to 
remove the brain from the skull and freeze in isopentane, the tracer can diffuse from 
more highly perfused areas to tissue with lower levels of perfusion resulting in 
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distortion of autoradiograms. In larger species, such as the cat and rat, this may not 
present a major problem due to the relatively large structures and greater diffusion 
distances. However, in the mouse, structures are smaller and more tightly packed and 
diffusion distances are greatly reduced. Therefore, underestimation of LCBF in high-
flow areas and overestimation in low-flow areas may result. To minimise post-mortem 
diffusion of tracer it is necessary therefore to avoid any delay in removal and freezing of 
the brain. In the present study, it was possible to transfer the brain to the freezing 
medium (isopentane) 30 - 40s after decapitation. It has been shown previously that 
removal and freezing of the brain 1 - 2min following decapitation results in the loss of 
normal contrasts in optical densities among various structures observed on 
autoradiograms. Freezing of the brain in 30s, however, gave rise to structural 
heterogeneity approaching that observed in the rat although it was proposed that some 
degree of tracer diffusion still occurred (Jay et at., 1988). In the present study, structural 
heterogeneity was also observed although to a lesser extent than that observed in rat 
studies previously conducted in the department and elsewhere. It is likely, therefore, 
that some degree of tracer diffusion occurred in this study and that the magnitude of 
LCBF may be underestimated in high-flow areas and overestimated in low-flow areas. 
A further consideration in LCBF measurement is the exponential relationship that 
exists between local brain tissue 14C concentration and absolute CBF. At lower 14C 
tissue concentrations, the curve is linear and therefore a small change in 14C 
concentration will produce a proportional change in CBF. At higher concentrations of 
14C, however, the slope of the curve increases rapidly. In this region, a small increase in 
tissue 14C concentration would be reflected by a much larger increase in CBF. A 
consequence of this relationship is that in highly perfused areas (with high 14C 
concentrations), LCBF may be overestimated. This is in contrast to the effect discussed 
above in which underestimation of LCBF in high-flow areas may occur due to tracer 
diffusion. In the present study, such overestimation of LCBF is more likely to occur in 
the hemisphere contralateral to occlusion, particularly in high-flow areas which 
included somatosensory cortex and dorsolateral thalamus. In contrast, in ischaemic 
territory (ipsilateral to occlusion) tissue 14C concentration is relatively low and therefore 
LCBF measurement is less prone to overestimation. 
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4.4.2 Ischaemic damage after intraluminal occlusion 
4.4.2.1 Reproducibility of ischaemic damage 
In the present study it was important to establish if reproducible volumes of ischaemic 
damage were attainable using this model as previous reports in both mice and rats 
suggested that a significant limitation of the intraluminal occlusion model is variability 
in extent of ischaemic damage (Laing et al., 1993; Kuge et aI., 1995; Connollyet al., 
1996; Clark et at., 1997; Takano et al., 1997). The inherent variability of the model may 
be partly attributable to some of the technical complications described in section 
4.4.1.1. In the present study, the volume ofischaemic damage was highly reproducible 
after 15min, 30min or 60min intraluminal occlusion. 
Previously, strategies to minimise variability have included coating of the filament 
end with either silicon resin (Koizumi et al., 1986; Takano et al., 1997; Hata et al., 
1998) or poly-L-Iysine (Belayev et al., 1996; Belayev et at., 1999). The rationale behind 
these approaches is that coating the filament increases the adhesive forces between the 
filament and the vascular endothelium and so minimises the chances of residual flow 
past the filament. Although reproducibility has been demonstrated with these coated 
filaments, limitations include possible direct toxic effects of the coating substance on 
the endothelium and increased risk of haemorrhage as a result of excessive adhesion 
(Huang et at., 1998). In the present study, use of a heat-blunted uncoated filament 
produced a high level of reproducibility. Several important factors may underlie this 
consistency. First, mice within a narrow weight-range (29 ± O.9g) were used. It has been 
shown previously that the size of filament is an important determinant of a successful 
occlusion and that the appropriate diameter of filament varies with the animal's weight 
(Connolly et al. 1996; Hata et al., 1998). Consequently, if a uniform thickness of 
filament is employed, using mice within a narrow weight range should improve 
reproducibility. In the present study, the diameter of the heat-blunted filament tip was 
measured microscopically and therefore both filament size and animal weight were 
rigorously controlled. Second, to occlude the MCA, a technique that does not require 
interference with the pterygopalatine artery, a branch of the internal carotid artery 
(ICA), was used. In many studies, the pterygopalatine artery is ligated or electro-
coagulated. However, due to its small size, deep-lying position and proximity to the 
vagus nerve, gaining access to this artery may produce inadvertent damage to the vagus 
nerve or one of its smaller branches with detrimental effects on the cardiovascular 
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and/or respiratory system(s) during the surgical procedure. Third, to assess the volume 
of ischaemic damage, a well-established and characterised technique developed in rats 
(Osborne et al., 1987) was optimised and validated for use in mice. This method 
involves light microscopic examination of thin sections stained with haematoxylin and 
eosin to delineate areas of ischaemic damage at multiple coronal levels. Such a system 
affords greater accuracy and sensitivity of measurement than the frequently-employed 
2,3,5-triphenyltetrazoline chloride method in which relatively fewer and thicker tissue 
blocks are used to differentiate areas of viable and damaged tissue (Liszczak et al.,1984; 
Park et al.,1988a). 
4.4.2.2 Effects of occlusion duration on extent and spatial distribution of 
ischaemic damage 
Increasing the duration of occlusion resulted in progressively larger volumes of 
ischaemic damage. However, the increase in volume of damage was disproportionately 
steep, in particular between 15min and 30min occlusion; the volume of ischaemic 
damage with 30min occlusion was 5-fold greater than with 15min occlusion. The 
steepness of the relationship between duration of occlusion and volume of ischaemic 
damage differs from that described in other species (Jones et al., 1981) where the 
volume of damage increases markedly between 1 - 3h of occlusion (Kaplan et al., 
1991). In the present study in the mouse, this relationship was somewhat compressed 
with the occlusion-duration effect on extent of ischaemic damage most pronounced 
between 15min and 30min occlusion. 
Expansion of the ischaemic lesion from 15min to 30min occlusion groups was in 
part due to development of damage in MCA territory (e.g. cerebral cortex) but also to 
the involvement of regions of the brain outside MeA territory, such as the hippocampus 
and thalamus. This finding is in agreement with previous reports of the susceptibility of 
the C57B1I6J mouse to the effects of focal cerebral ischaemia. Using MAP2 
immunoreactivity as a marker of viable neurons, Kitagawa et al. (1998c) demonstrated 
the loss of MAP2-immunoreactive neurons in the caudoputamen, cerebral cortex and 
hippocampus after intraluminal filament occlusion, reflecting areas of damage 
extending outside MCA territory. Belayev et al. (1999) also observed ischaemic damage 
in areas outside MCA territory such as the hippocampus and thalamus. Additionally, 
Rata et al. (1998) reported that the incidence of infarction in regions such as the 
hippocampus, thalamus and hypothalamus may be up to 75% after intraluminal filament 
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occlusion. In contrast, in other strains of mice such as CBA and DBAl2 the ischaemic 
lesion was confined to the caudoputamen and cerebral cortex with hippocampal neurons 
remaining intact (Kitagawa et al., 1998c). The spatial distribution of damage in the 
C57BV6J mouse also appears to differ from that previously observed in the rat as 
structures not consistently damaged in rat (e.g. hippocampus, thalamus) are consistently 
involved in the mouse (Belayev et al., 1999). This suggests that PcomA deficiency in 
C57BV6J mice, as observed in this and previous studies (Kitagawa et al., 1998c; Kelly 
et al., 2001b), may be a contributory factor in damage observed outside MCA territory 
since rats and the CBA and DBAl2 mouse strains have an intact circle of Willis 
(Kitagawa et al., 1998c). Recently in the rat, however, cellular alterations indicative of 
direct ischaemic damage were observed in areas outside MCA territory following 
intraluminal occlusion but not electrocoagulation of the MCA prompting the authors to 
propose that this technique should not be viewed as a model of pure MCA occlusion 
(Kanemitsu et al., 2002). Thus, strain- and model-specific factors may underlie the 
distinctive spatial pattern of ischaemic damage induced by intraluminal occlusion and 
are likely mediated through effects on cerebral blood flow. 
The sensitivity of lesion volume/spatial distribution to intraluminal occlusion 
duration in the C57BV6J mouse has important practical implications, most notably the 
need for precise control over the duration of occlusion in order to minimise inter-animal 
variability. 
4.4.3 Cerebral blood flow during intraluminal occlusion 
In the present study, the intensity of ischaemia was most dense in the dorsolateral 
caudate nucleus and somatosensory cortex (e.g. 8 - 9% of contralateral value after 
60min occlusion). There is little published LCBF data in mouse models of focal 
cerebral ischaemia, although systematic measurement of LCBF has been previously 
reported in rats following intraluminal occlusion (Memezawa et al., 1992; Belayev et 
al., 1997). The topographical pattern of severity of CBF deficit in the present study is 
consistent with these previous reports using the same model in which ischaemia was 
also demonstrated to be most intense in the somatosensory cortex and lateral 
caudoputamen. These areas represent core MCA territory and therefore would be 
expected to be most severely affected by occlusion. In the hemisphere contralateral to 
occlusion, a gradient of LCBF was observed declining from high-flow areas such as the 
ventromedial thalamus through areas with intennediate flow (e.g. caudate nucleus) to 
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the relatively modestly perfused hypothalamus. This spectrum of LCBF is also in 
agreement with previous studies that have quantitatively measured LCBF in non-
occluded mice (Jay et ai., 1988; Maeda et ai., 2000). 
Increasing the duration of occlusion was associated with increases in the severity of 
cerebral hypoperfusion in the hemisphere ipsilateral to occlusion. The lower levels of 
CBF observed after 60min occlusion (compared to 15min occlusion) may be a 
reflection of the progressive decline in blood pressure and neurochemical events 
associated with cerebral ischaemia (e.g. release of vasoconstrictor substances such as 
endothelins, increase in tissue pressure and platelet aggregation obstructing collateral 
vessels). The hypotension observed with 60min occlusion in the mouse is likely to 
exacerbate the ischaemic insult as a result of autoregulatory disturbances. Cerebral 
autoregulation is the physiological regulatory mechanism that maintains constant blood 
flow in the face of changes in perfusion pressure (paulson et ai., 1990). Failure of this 
mechanism is a feature of cerebral ischaemia (Dirnagl and Pulsinelli, 1990). 
Consequently, when blood pressure declines, CBF will fall accordingly and wi11likely 
impact on the extent of ischemic damage. For example, after occlusion in the rat, 
transient hypotension of 40mmHg increased the volume of ischaemic damage by 45% 
(Osborne et ai., 1987). In the present study, in mice, blood pressure declined by 
25mmHg after 60min occlusion. Bilateral common carotid artery occlusion (BCCAo) 
also induced reductions in MABP in C57B1I6J mice but not MFI mice (Kelly et al., 
2001 b) suggesting a strain-specific effect perhaps linked to lack of PcomA integrity. 
Regions of the brain involved in the regulation of blood pressure, in particular the 
hypothalamus (Talman, 1985; Fontes et al., 2001; Dampney et ai., 2002), experience 
ischaemia during intraluminal filament occlusion or BCCAo when there is absence of a 
PcomA. 
With durations of occlusion in excess of 30min, hypoperfusion and ischaemic 
damage were consistently observed in the hippocampus, thalamus and hypothalamus. 
The blood supply of these areas is not derived from the MCA (Scremin, 1995). In rats, 
intraluminal filament placement occludes the anterior choroidal artery in addition to the 
MCA leading to ischaemic damage in the hypothalamus. A similar mechanism may be 
responsible for hypothalamic damage in the C57B1I6J mouse after intraluminal filament 
occlusion. Cerebral hypoperfusion and ischaemic damage observed in the hippocampus 
and thalamus in C57B1I6J mice may be a reflection of abnormalities observed in the 
posterior portion of the circle of Willis in this and other studies (Kitagawa et ai., 1998c; 
146 
Kelly et ai., 2001 b}. Absence or inadequacy of collateral supply via the PcomA when an 
intraluminal filament is introduced into the internal carotid artery and directed towards 
the anterior portion of the circle of Willis will also be exacerbated by hypotension. 
There have been few previous studies examining the temporal-spatial progression of 
CBF deficits during occlusion in ischaemia models, particularly in the mouse. However, 
there is some evidence to suggest that the severe decline in CBF observed in the present 
study may be specific to intraluminal occlusion in the C57B1I6J mouse. Kitagawa et ai. 
(l998c) observed cerebral hypoperfusion in areas outside MCA territory in C57B1I6 
mice but not DBAl2 mice indicating a possible C57B1I6 strain-specific effect, however, 
this study did not examine the temporal profile of CBF deficits. In the rat, there is 
minimal evidence of cerebral hypoperfusion in areas outside MCA territory following 
electro-coagulation (Hakim et ai., 1992) and clip occlusion (Takagi et ai., 1995) of the 
MCA. Most recently, in a thorough study using intraluminal occlusion, LCBF in areas 
outside MCA territory (hippocampus, thalamus) of the occluded hemisphere was not 
significantly different from levels in the non-occluded control hemisphere (Belayev et 
ai., 1997). The temporal profile of CBF deficits in rats has also been studied and has 
shown that the degree of hypoperfusion remains relatively stable with increasing 
occlusion duration (Hakim et ai., 1992; Memezawa et ai., 1992). Of particular relevance 
to the present study is the previous demonstration in rats experiencing intraluminal 
occlusion that CBF deficits in the occluded hemisphere remain constant after 20, 60 and 
120min of occlusion (Memezawa et ai., 1992). The current findings, which show a 
severe decline in CBF with increasing occlusion duration, are therefore in contrast to 
these previous studies. Thus, although distant changes in CBF have been reported in 
other rodent species, the magnitude, distribution and extreme duration-dependence are 
not in accord with the present report. Furthermore, the species/strain specific effects of 
intraluminal occlusion on the temporal-spatial pattern of CBF deficits parallels the 
pathological observations discussed above. Consequently, results from the previous 
studies outlined above in association with the present findings collectively suggest that 
intraluminal occlusion in the C57B1I6 mouse produces a distinctive occlusion duration-
dependent pattern of CBF deficits and ensuing ischaemic pathology that is not observed 
in other species (e.g. rat) or other strains of mice (e.g. DBAl2). 
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4.4.4 Implications for utility of model in further studies 
Elucidation of the above features of the intraluminal occlusion model has important 
implications for its application. In particular, the choice of occlusion duration requires 
particular consideration. Reproducibility was demonstrated after each occlusion 
duration and therefore 15min, 30min or 60min occlusion are all vindicated on the basis 
of acceptable inter-animal variability. However, 30min and 60min occlusion were 
associated with declining blood pressure and widespread hypoperfusion, factors that 
produce massive volumes of ischaemic tissue (approximately 60% of hemisphere after 
60min occlusion). Such large volumes of damage may represent the upper limit of 
damage and therefore are not appropriate for investigation of factors that may modulate 
the amount of ischaemic damage (e.g. genetics, pharmacotherapy). In addition, 30min 
and 60min occlusion were associated with greater mortality rate compared to 15min 
occlusion. Therefore, in view of the low mortality rate, high degree of reproducibility 
and avoidance of the effects of declining systemic blood pressure and widespread 
cerebral hypoperfusion, 15min occlusion was considered to be the most suitable 
occlusion duration for investigating the influence of APOE genotype on outcome and 
endocytic pathway activity in response to focal cerebral ischaemia as described in the 
following chapter. 
4.4.5 Conclusions 
In summary, the major objective of the present study - to characterise the intraluminal 
filament occlusion model of focal cerebral ischaemia in C57BV6J mice - has been 
accomplished. The aims stated at the outset of this study have been achieved: 
1. an intraluminal occlusion model was developed in C57BV6J mice and the 
reproducibility of ischaemic damage validated after three different durations 
(15min, 30min and 60min) of occlusion 
2. increasing the duration of occlusion resulted in a steep increase in the extent of 
ischaemic damage and widespread increases in the severity of cerebral 
hypoperfusion 
However, rabaptin-5 and rab4 immunostaining was unsuccessful in C57BV6J paraffin-
processed tissue after focal ischaemia. Thus, it was not possible to define if there were 
alterations in the endocytic pathway in response to focal ischaemia in C57BV6J mice. 
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Chapter 5 
Association between APOE genotype and 
differences in outcome and endocytic 
pathway alterations after focal cerebral 
ischaemia in mice 
5.1 Introduction and aims 
APOE transgenic mice expressing human APOE isoforms have been developed that 
display a human-like pattern of APOE expression and apoE immunoreactivity (Xu et 
al., 1996). The effects of APOE genotype on outcome and apoE and endocytic pathway 
alterations after focal ischaemia were investigated in these mice. The specific aims of 
the present study were to determine, in a mouse model of transient focal ischaemia, if: 
1. APOE genotype is associated with differences in outcome 
2. there are alterations in apoE that are APOE genotype-dependent 
3. there are endocytic pathway alterations that are APOE genotype-dependent 
5.2 Materials and methods 
This study was carried out at the Wellcome Surgical Institute, Glasgow. All 
experiments were performed unaware of APOE genotype. 
5.2.1 Mice 
Adult male human APOE transgenic mice (33 ± 1.8g), were used (section 2.2.2). 
5.2.2 Focal ischaemia and evaluation of neurological deficit 
Transient focal ischaemia (15min) was induced by intraluminal filament occlusion 
(sustained anaesthesia model) in APOE £3 (n = 17) and APOE £4 (n = 20) as described 
(section 2.3.2.1). After 15min occlusion, the filament was withdrawn to allow 
reperfusion for 24h. After 24h reperfusion, mice were assigned a neurological deficit 
score of 0 to 4 as described (section 2.4). Following neurological evaluation, mice were 
perfused transcardially (section 2.5) and paraffin-processed (section 2.6.1.1). Paraffin 
embedded brains were cut into 6J.llD sections (section 2.6.2) which were used for 
histological and immunohistochemical analysis. 
5.2.3 Measurement of ischaemic damage 
The volume of ischaemic damage was measured in haematoxylin and eosin-stained 
tissue as described (section 2.8). Criteria for inclusion were: (1) clear evidence of 
ischaemic damage in the striatum, and (2) absence of intracranial haemorrhage as 
observed in haematoxylin and eosin-stained tissue. 
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5.2.4 Immunohistochemistry 
Adjacent sections (6J.lm) were immunostained (peroxidase protocol) with apoE, 
rabaptin-5 and rab4 antibodies as described (section 2.9.3). Fluorescent double-labelling 
immunostaining was performed on selected sections as described (section 2.9.4). 
5.2.4.1 Volumetric measurement of apoE immunostaining 
Boundaries between areas of tissue containing numerous intensely stained apoE-
positive cells and areas with few and faintly stained cells (normally outside the 
ischaemic territory) could be defined. The distribution of clearly defined areas of apoE 
immunostaining could therefore be delineated at eight coronal levels. Areas were then 
integrated with the distance between each coronal level to calculate a volume in the 
same way as for ischaemic damage (section 2.9.6.1). Reproducibility of volumetric 
measurement was tested (Appendix G). 
5.2.4.2 Semi-quantification of apoE, rabaptin-5 and rab4 immunoreactivity 
Semi-quantification of apoE, rabaptin-5 and rab4 immunoreactivity was performed at 
the level of the caudate nucleus (coronal level 3, O.2mm anterior to bregma). In the 
hemisphere ipsilateral to occlusion, the degree of cellular immunoreactivity in the 
ischaemic caudate nucleus was semi-quantified in six fields, using a IOmm2 grid at 
x400 magnification, according to a scoring system as described (section 2.9.6.2). The 
average degree of immunoreactivity was then calculated. Reproducibility of semi-
quantification was tested (Appendix H). 
5.2.5 Statistical analysis 
All statistical comparisons were made between the APOE £3 and APOE £4 groups. 
Student's unpaired t-test was used to assess statistical significance of differences in the 
volume of ischaemic damage. Mann-Whitney V-statistic was used to assess statistical 
significance of differences in neurological deficit. Student's unpaired t-test was used to 
assess statistical significance of differences in the volume of apoE immunostaining. 
Pearson correlation was used to assess statistical significance of the association between 
the volume of ischaemic damage and the volume of apoE immunostaining. Mann-
Whitney U-statistic was used to assess statistical significance of differences in the 
degree of apoE, rabaptin-5 and rab4 immunoreactivity. Spearman correlation was used 
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to assess statistical significance of the association between the degree of apoE 
immunoreactivity and the degree of rabaptin-5 or rab4 immunoreactivity. All data are 
presented as mean ± SEM 
5.3 Results 
5.3.1 Mortality rate, haemorrhage rate and absence of ischaemic damage 
Prior to volumetric measurement of ischaemic damage, haematoxylin and eosin-stained 
tissue from each brain was examined to determine if the criteria for proceeding to 
analysis were met (Table 9). 
It was noted that mortality rate (11 %) and the percentage of brains without evidence 
of ischaemic damage (14%) in the present study were similar to the frequencies 
observed in the previous study (chapter 4) in C57B1I6J mice. In contrast, the 
haemorrhage rate in the present study was considerably higher in APOE transgenic mice 
(38%) than that observed in the previous study in C57B1I6J mice (9%). Putative reasons 
for this discrepancy are discussed later (section 5.4.1). There were no apparent 
differences between APOE 83 and APOE 84 mice in mortality rate (12% vs 10%), 
haemorrhage rate (35% vs 40%) or the percentage of mice with no ischaemic damage 
(12% vs 15%). 
Table 9. Mice excluded prior to measurement of ischaemic damage 
Number of mice excluded 
Genotype 
Deaths Haemorrhage No ischaemic damage 
APOE E3 (n = 17) 2 (12%) 6 (35%) 2 (12%) 
APOE E4 (n = 20) 2 (10%) 8 (40%) 3 (15%) 
Combined (n = 37) 4(11%) 14 (38%) 5 (14%) 
Criteria for inclusion included 24h recovery, absence of haemorrhage and clear 
histological evidence of ischaemic damage. A high exclusion rate due to intracranial 
haemorrhage was evident in both APOE 83 and APOE 84 mice. Mortality rate and the 
number of mice without histological evidence of ischaemic damage were relatively low 
and similar in both groups. 
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5.3.2 Effect of APOE genotype on Ischaemic damage 
.The volume of ischaemic damage was significantly greater in APOE E4 compared to 
APOE E3 mice (9 ± Imm3 vs. 7 ± Imm3, P = 0.006). The volume ofischaemic damage 
was also highly reproducible in both the APOE E3 and APOE E4 groups (Figure 42). 
The spatial distribution of ischaemic damage was similar in both the APOE E3 and 
APOE E4 groups (Table 10) and in general was restricted to the striatum. Thus, the 
distribution of ischaemic damage was similar to that observed after the same duration of 
occlusion in the previous study in C57B1I6J mice (chapter 4). In the hemisphere 
ipsilateral to occlusion, ischaemic damage was observed in the striatum in all mice. 
Ischaemic damage extended outside the striatum infrequently to include small areas of 
the somatosensory cortex overlying the striatum and the dorsolateral thalamus. No 
ischaemic damage was observed in the hippocampus and hypothalamus of any mice. In 
the hemisphere contralateral to occlusion, there was no evidence of ischaemic damage. 
Table 10. Frequency of ischaemic damage in specific brain regions 
Genotype 
APOE E3 
APOEE4 
Number of mice with ischaemic damage 
Striatum Cortex Thalamus 
7 of 7 
7of7 
2of7 
2 of7 
1 of 7 
1 of 7 
In general, 15min occlusion produced ischaemic damage restricted to the striatum with 
only infrequent involvement of cerebral cortex (somatosensory) and the thalamus 
(dorsolateral). The distribution of ischaemic damage was not related to APOE 
genotype. 
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Figure 42. Effect of APOE genotype on volume of ischaemic damage 
(a) The volume of ischaemic damage was significantly greater in APOE £4 mice. Bars 
show mean. (b) There was a trend toward larger areas of damage at coronal levels in 
APOE £4 mice. **P < 0.01 , Student's unpaired i-test. n = 7 (each group). Data are 
presented as mean ± SEM. 
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5.3.3 Effect of APOE genotype on neurological deficit 
There was a significantly greater neurological deficit score in the APOE £4 group 
compared to the APOE £3 group (2.0 ± 1.3 vs. 0.7 ± 0.5, P = 0.038) (Figure 43). 
Neurological deficit correlated with the volume of ischaemic damage (P = 0.034, r = 
0.82) (Figure 43). 
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(a) Significantly greater neurological deficits were observed in APOE 84 mice. Bars 
show mean. (b) There was a significant correlation between the neurological deficit 
score and the volume of ischaemic damage (P = 0.03; r = 0.82, Spearman Rank 
correlation co-efficient). *P < 0.05, Mann-Whitney U-statistic. n = 7 (each group). 
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5.3.4 ApoE immunostaining 
5.3.4.1 Control immunostaining in the non-ischaemic hemisphere 
In both APOE E3 and APOE E4 mice, faint apoE immunostaining of the neuropil was 
observed throughout the hemisphere. ApoE immunostaining of glial cells was also 
observed, most notably in cells displaying astrocytic morphology in the caudate nucleus 
(Figure 44). There was minimal evidence of neuronal apoE immunostaining in the 
caudate nucleus, thalamus and hippocampus, but in the cerebral cortex, neuronal apoE 
immunostaining was more readily observed, particularly in the parietal cortex. Glial 
apoE immunostaining was also observed in white matter tracts, including the internal 
capsule and corpus callosum. In the internal capsule, cells displayed small, spherical 
nuclei and cell bodies and in some areas were arranged in rows and orientated along the 
plane of the fibre tracts, characteristic of oligodendrocytes. In the corpus callosum, 
cellular staining appeared to be predominantly astrocytic. There were no observable 
differences in apoE immunostaining between APOE E3 and APOE £4 mice in the 
hemisphere contralateral to occlusion. 
5.3.4.2 Alterations in the ischaemic hemisphere 
In both APOE E3 and APOE E4 mice, marked alterations in the cellular localisation and 
intensity of apoE immunostaining were observed in areas of tissue displaying ischaemic 
damage in the occluded hemisphere (Figure 45). Most noticeably, there was a marked 
increase in neuronal apoE immunoreactivity compared to the non-ischaemic 
contralateral hemisphere. Intensely apoE-immunoreactive neurons exhibited the 
morphological features of ischaemic cell change (e.g. shrunken, triangular cell body). 
There were no observable differences in apoE immunoreactivity in ischaemic neurons 
between APOE E3 and APOE e4 mice. Double-labelling (apoE and neu-N antibodies) 
was performed, however, high background fluorescence and non-specific apoE 
immunoreactivity in areas of ischaemic damage precluded the detection of apoE/neu-N 
co-localisation. Increased apoE immunoreactivity in glial cells was also observed in 
areas of ischaemic damage, although the intensity of immunostaining was less than that 
observed in neurons. To a lesser extent, apoE immunostaining of the neuropil was 
increased compared to the contralateral hemisphere. 
In areas outside the ischaemic territory, (e.g. undamaged cerebral cortex) apoE 
immunostaining was similar to that observed in the non-ischaemic contralateral 
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hemisphere. However, faint apoE immunostaining of a few pyramidal neurons in the 
CA3 sector of the hippocampus was observed infrequently in both APOE £3 (1 of 7) 
and APOE £4 (1 of 7) mice in the occluded hemisphere. These neurons appeared 
morphologically nonnal. A similar pattern of glial apoE immunoreactivity in the 
internal capsule was observed to that detected in the contralateral hemisphere in both 
APOE £3 and APOE £4 mice. 
5.3.4.3 Volumetric measurement of apoE immunostaining 
As described above, in the ischaemic hemisphere, increased apoE immunoreactivity 
(compared to the non-ischaemic hemisphere) was localised to areas of ischaemic 
damage. Areas of tissue containing numerous intensely apoE-immunoreactive cells 
could be demarcated from tissue containing minimal apoE immunostaining. Thus, areas 
and volumes of tissue containing increased apoE immunoreactivity could be 
determined. The volume of tissue displaying increased apoE immunoreactivity was 
significantly greater in APOE £4 compared to APOE £3 mice (8 ± Imm3 vs. 6 ± Imm3, 
P = 0.013) and was similar to the volume of ischaemic damage [APOE £3 mice (6mm3 
vs. 7mm3); APOE E4 mice (8mm3 vs. 9mm3)]. There was a significant correlation 
between the volume of apoE immunoreactivity and the volume of ischaemic damage (P 
= 0.007,? = 0.89) (Figure 46). 
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Figure 44. Control apoE immunostaining in the non-ischaemic hemisphere 
In general, minimal glial and neuronal apoE immunostaining was observed in the non-
ischaemic hemisphere contralateral to occlusion of both APOE £3 and APOE £4 mice. 
(a,b) Glial apoE immunostaining (arrows) was predominantly observed in the caudate 
nucleus. (c,d) Faint neuronal apoE immunostaining (arrows) was detected in the 
cerebral cortex but was minimal in other areas including the caudate nucleus (a,b), and 
hippocampus (e,f). Scale bar, 251lm. 
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Figure 45. Alterations in apoE immunostaining in the ischaemic hemisphere 
Alterations in the intensity and cellular localisation of apoE immunostaining were 
observed in both APOE s3 and APOE s4 mice in the ischaemic hemisphere ipsilateral 
to occlusion. In ischaemic areas (e.g. caudate nucleus shown), intense apoE-
immunoreactive cells were observed (b,d). Neurons with ischaemic morphology were 
strongly immunoreactive for apoE (arrows). Glial apoE immunostaining in the 
contralateral hemisphere is shown for comparison (a,c). High-magnification 
photomicrographs illustrate the dense apoE immunostaining in the cytoplasm of 
ischaemic neurons (e,f) . In contrast, areas outside the ischaemic territory ipsilateral to 
occlusion (e.g. cerebral cortex shown) displayed only minimal glial and neuronal apoE 
immunostaining (g ,h). Scale bar (a-d, g,h), 25f..l1T1; (e,f), 10Jlm. 
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Figure 46. Effect of APOE genotype on volume of apoE immunoreactivity 
(a) The volume of apoE immunoreactivity was significantly greater in APOE 84 mice. 
Bars show mean (b) The volume of apoE immunoreactivity correlated with the volume 
of ischaemic damage (P = 0.007; 1= 0.89, Pearson correlation). *P < 0.05, Student's 
unpaired t-test. 
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5.3.4.4 Semi-quantification of apoE immunoreactivity 
Semi-quantification of apoE immunostaining was carried out in the caudate nucleus in 
the hemisphere ipsilateral to occlusion and thus provided an index of the degree of apoE 
in response to ischaemic damage induced by intraluminal occlusion. Semi-
quantification revealed that the degree of apoE immunoreactivity was similar in both 
APOE E3 and APOE £4 mice (2.04 ± 0.52 vs. 2.14 ± 0.50, P > 0.05) (Figure 47). 
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Figure 47. Semi-quantification of apoE immunoreactivity 
Semi-quantification was carried out in the caudate nucleus of the ischaemic 
hemisphere (ipsilateral to occlusion). The degree of apoE immunoreactivity was similar 
in both APOE E3 and APOE E4 mice (P > 0.05, Mann-Whitney U-statistic). n = 7 (each 
group). Data are presented as mean ± SEM. 
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5.3.5 Rabaptin-5 immunostaining 
5.3.5.1 Control immunostaining in the non-ischaemic hemisphere 
In both APOE e3 and APOE e4 mice, faint rabaptin-5 immunostaining of the neuropil 
was observed. Minimal rabaptin-5 immunostaining of neurons and glial cells was also 
observed in the non-ischaemic hemisphere in both APOE e3 and APOE e4 mice (Figure 
48). Cellular rabaptin-5 immunostaining was distributed throughout the hemisphere, 
including the caudate nucleus, cerebral cortex, hippocampus and thalamus. 
5.3.5.2 Alterations in the ischaemic hemisphere 
In both APOE e3 and APOE e4 mice, alterations in rabaptin-5 immunostaining were 
observed in the ischaemic hemisphere (Figure 48). In general, increased rabaptin-5 
immunoreactivity was observed in the neuropil and in neurons and glia of areas 
displaying ischaemic damage. The majority of neurons displaying increased rabaptin-5 
immunoreactivity exhibited the features of ischaemic cell change with minimal 
immunostaining of morphologically normal neurons. Intraneuronal rabaptin-5 
immunostaining was localised to the cytoplasm of cell bodies and proximal neurites, 
indicative of its endosomal location. Most intense rabaptin-5 immunostaining was 
observed adjacent to the plasma membrane. Glial cells with the morphology of reactive 
astrocytes occasionally exhibited increased rabaptin-5 immunoreactivity in ischaemic 
areas. 
Rabaptin-5 immunostaining In areas outside the ischaemic territory (e.g. 
undamaged cerebral cortex, hippocampus) was similar to that observed in the non-
ischaemic contralateral hemisphere in both APOE e3 and APOE e4 mice. 
162 
Contralateral 
('t") 
w 
ll.J 
o 
a.. 
<:( 
.q-
w 
LU 
o 
a.. 
<:( 
~ 
Q) 
+J 
co 
a 
caudate 
c 
en 9 
a. 
cortex 
APOEE3 
Figure 48. Rabaptin-5 immunostaining 
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Throughout the non-ischaemic hemisphere contralateral to occlusion (e.g. caudate 
nucleus shown), minimal neuronal and glial rabaptin-5 immunoreactivity was observed 
(a,c). In ischaemic areas of the occluded hemisphere (caudate nucleus shown), 
increased neuropil and cellular rabaptin-5 immunoreactivity was observed (b,d).These 
included cells with the morphology of ischaemic neurons (arrows) . High-magnification 
photomicrographs (e,f) illustrate rabaptin-5 immunostaining in the cytoplasm of 
ischaemic neurons (arrows). Areas outside the ischaemic territory in the hemisphere 
ipsilateral to occlusion (e.g. cerebral cortex shown) displayed faint neuronal and glial 
rabaptin-5 immunoreactivity. Scale bar (a-d, g,h), 251!m; (e,f), 10l!m. 
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5.3.5.3 Semi-quantification of rabaptin-5 immunoreactivity 
As with apoE, semi-quantification of rabaptin-5 immunostaining was carried out in the 
caudate nucleus in the hemisphere ipsilateral to occlusion to give an index of the degree 
of rabaptin-5 immunoreactivity in response to ischaernic damage induced by 
intraluminal occlusion. Semi-quantification revealed that the degree of rabaptin-5 
immunoreactivity was similar in both APOE 83 and APOE 84 mice (1. 76 ± 0.74 vs. 1.67 
± 0.47, P > 0.05) (Figure 49). 
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Figure 49. Semi-quantification of rabaptin-5 immunoreactivity 
Semi-quantification was carried out in the caudate nucleus of the ischaemic 
hemisphere (ipsilateral to occlusion). The degree of rabaptin-5 immunoreactivity was 
similar in both APOE £3 and APOE £4 mice (P > 0.05, Mann-Whitney U-statistic). n = 7 
(each group). Data are presented as mean ± SEM. 
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5.3.6 Rab4 immunostaining 
5.3.6.1 Control immunostaining in the non-ischaemic hemisphere 
Similar to rabaptin-5, minimal rab4 immunostaining of the neuropil, neurons and glia 
was observed in both APOE E3 and APOE E4 mice (Figure 50). Cellular 
immunostaining was distributed throughout the hemisphere, including the caudate 
nucleus, cerebral cortex, hippocampus and thalamus. 
5.3.6.2 Alterations in the ischaemic hemisphere 
Alterations in rab4 immunostaining were observed in the ischaemic hemisphere in both 
APOE E3 and APOE E4 mice. In general, increased neuronal and glial rab4 
immunoreactivity was observed in areas displaying ischaemic damage (Figure 50). In 
contrast to rabaptin-5, there was not an observable increase in rab4 immunostaining of 
the neuropil in ischaemic tissue. The majority of neurons displaying increased rab4 
immunoreactivity exhibited the morphological features of ischaemic cell change. 
Similar to rabaptin-5, neuronal rab4 immunostaining was localised to the cytoplasm and 
was particularly strong adjacent to the plasma membrane. 
Rab4 immunostaining in areas outside the ischaemic territory (e.g. undamaged 
cerebral cortex) was similar to that observed in the non-ischaemic contralateral 
hemisphere in both APOE E3 and APOE E4 mice. 
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Figure 50. Rab4 immunostaining (overleaf) 
Throughout the non-ischaemic hemisphere contralateral to occlusion (e.g. caudate 
nucleus shown), minimal neuronal and glial rab4 immunoreactivity was observed in 
both APOE £3 and APOE £4 mice (a,c). In ischaemic areas of the hemisphere 
ipsilateral to occlusion (caudate nucleus shown), increased cellular rab4 
immunoreactivity was observed (b,d). These included cells with the morphology of 
ischaemic neurons (arrows). The extent of rab4 immunoreactivity was markedly greater 
in APOE £3 mice (b) compared to APOE £4 mice (d). High-magnification 
photomicrographs illustrate intense rab4 immunoreactivity in the cytoplasm of 
ischaemic neurons (arrows) in a representative APOE £3 mouse brain and faint rab4 
immunoreactivity in a representative APOE £4 mouse brain. Areas outside the 
ischaemic territory in the hemisphere ipsilateral to occlusion (e.g. cerebral cortex 
shown) displayed minimal neuronal and glial rabaptin-5 immunoreactivity in both APOE 
£3 and APOE £4 mice. Scale bar (a-d, g,h), 25~m; (e,f). 10~m. 
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5.3.6.3 Semi-quantification of rab4 immunoreactivity 
Semi-quantification of rab4 immunostaining was carried out in the caudate nucleus in 
the hemisphere ipsilateral to occlusion (as for apoE and rabaptin-5 previously) to give 
an index of the degree of rab4 immunoreactivity in response to ischaemic damage 
induced by intraluminal occlusion. Semi-quantification revealed that the degree of rab4 
immunoreactivity was significantly greater in APOE £3 compared to APOE £4 mice 
(2.38 ± 0.76 vs. 1.19 ± 0.92, P = 0.021) (Figure 51). 
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Figure 51. Semi-quantification of rab4 immunoreactivity 
Semi-quantification was carried out in the caudate nucleus of the ischaemic 
hemisphere (ipsilateral to occlusion). The degree of rab4 immunoreactivity was 
significantly greater in APOE £3 mice compared to APOE £4 mice. *P < 0.05, Mann-
Whitney U-statistic. n = 7 (each group). Data are presented as mean ± SEM. 
168 
5.3.7 Correlations of apoE, rabaptin-5 and apoE immunoreactivity 
Rabaptin-5 (intemalisation) and rab4 (recycling) are markers of two different stages of 
the endocytic pathway. Correlation analysis of rabaptin-5 and rab4 immunoreactivity 
was performed to determine if there was a parallel response of these two endocytic 
processes to ischaemic damage. Endocytosis is integral to apoE trafficking, and may 
therefore be involved in the apoE response to ischaemic damage. Correlation analysis of 
apoE and rabptin-5 or rab4 immunoreactivity was also performed to determine if there 
was an association between the apoE and endocytic responses to ischaemic damage. 
Correlation analysis revealed that the degree of rabaptin-5 immunoreactivity 
correlated with the degree ofrab4 immunoreactivity in APOE £3 mice (P = 0.029, r = 
0.80) but not in APOE £4 mice (P > 0.05) (Figure 52). The degree of rabaptin-5 
immunoreactivity correlated strongly with the degree of apoE immunoreactivity in 
APOE 83 mice (P = 0.008, r = 0.89) and to a lesser extent in APOE £4 mice (P = 0.047, 
r = 0.76) (Figure 53). The degree of rab4 immunoreactivity also correlated with the 
degree of apoE immunoreactivity in APOE £3 mice (P = 0.045, r = 0.76) but not in 
APOE £4 mice (P > 0.05) (Figure 53). 
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Figure 52. Association between rabaptin-5 and rab4 Immunoreactivity 
The degree of rabaptin-5 immunoreactivity correlated with the degree of rab4 
immunoreactivity in APOE 83 mice (P = 0.029, r = 0.80) but not in APOE 84 mice (P > 
0.05, Spearman Rank correlation co-efficient). 
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Figure 53. Association between apoE and rabaptin-5 or rab4 immunoreactivity 
The degree of rabaptin-5 immunoreactivity correlated with the degree of apoE 
immunoreactivity in both APOE £3 (P = 0.008, r = 0.89) and APOE £4 mice (P = 0.047, 
r = 0.76, Spearman Rank correlation co-efficient). The degree of rab4 immunoreactivity 
correlated with the degree of apoE immunoractivity in APOE 83 mice (P = 0.045, r = 
0.76) but not in APOE £4 mice (P > 0.05, Spearman Rank correlation co-efficient). 
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5.4 Discussion 
The results from this study have demonstrated that transgenic mice expressing the 
human APOE E4 allele show a poorer pathological (greater volume of ischaemic 
damage) and neurological (greater neurological deficit score) outcome compared to 
mice expressing human APOE E3 after transient focal cerebral ischaemia. In both 
groups, ischaemic damage was closely associated with alterations in apoE 
immunostaining, most notably an Increase in neuronal apoE immunoreactivity in 
comparison to non-ischaemic tissue. In addition, alterations in immunostaining of the 
endocytic pathway markers, rabaptin-5 and rab4, were also associated with ischaemic 
damage and, furthermore, the nature of these alterations was dependent on APOE 
genotype. 
5.4.1 APOE genotype and outcome after focal ischaemia 
The present data indicate that the APOE E4 allele is associated with a poorer outcome in 
a mouse model of focal cerebral ischaemia. To date, studies investigating the influence 
of APOE genotype on outcome after focal ischaemic stroke in humans have produced 
conflicting results. Some studies did not find an association between APOE genotype 
and outcome (McCarron et a/., 1998; McCarron et a/., 1999; MacLeod et a/., 2001) 
whereas others have suggested a poorer prognosis in APOE E4 carriers after stroke (Liu 
et a/., 2002; Treger et a/., 2003). Conflicting findings may, in part, be related to the 
heterogeneity of human stroke and the inability to control for underlying confounding 
factors, such as pre-existing disease and lifestyle factors (e.g. smoking) and the location, 
severity and duration of the ischaemic insult, in human studies. For example, in one 
study which did not detect an APOE genotype-related difference in outcome, there was 
substantial variability in the location of the ischaemic lesion (MacLeod et a/., 2001). 
Only 24% of patients demonstrated a subcortical lesion with others displaying lesions in 
various other regions such as the cerebellum and brainstem. In contrast, in another study 
which analysed a more homogenous sample of stroke patients (infarcts limited to MCA 
territory), a poorer prognosis was indicated in APOE E4 carriers (Liu et a/., 2002). Such 
confounding variables can be overcome in animal models of cerebral ischaemia, as in 
the present study which incorporated a stringently controlled duration of focal 
ischaemia and reperfusion. A brief duration (15min) of occlusion followed by 24h 
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reperfusion produced a highly reproducible volume and distribution of ischaemic 
damage in both APOE E3 and APOE E4 mice. 
The findings that the extent of ischaemic damage and the neurological deficit were 
significantly greater in APOE E4 mice are consistent with and expand upon previous 
studies investigating the effects of APOE genotype on outcome in animal models of 
focal cerebral ischaemia. Using a similar transient focal ischaemia model, but with a 
substantially longer occlusion duration (6Omin) than in the present study (15min), 
Sheng et ai. (1998) found that mice expressing human APOE E4 displayed a larger total 
infarct volume than APOE £3 mice. However, in the study by Sheng et ai., the effects of 
brain oedema on measurements of ischaemic damage were not controlled for. In a 
recent study in which brain oedema was controlled for, Mori et ai. (2003) reported that 
total infarct volume was greater in APOE £4/4 knock-in mice compared to £3/3 and £2/2 
mice after 24h permanent focal ischaemia. In view of the primarily striatal distribution 
of ischaemic damage in the present study, it is of note that Sheng et ai. (1998) also 
found that the subcortical infarct volume was significantly greater in APOE £4 mice. 
This suggests that APOE genotype can influence the extent of ischaemic damage after 
focal ischaemia throughout the hemisphere. In the present study, the severity of the 
neurological deficit was greater in APOE £4 mice and neurological score also correlated 
with the volume of ischaemic damage. These data suggest that differences in the extent 
of ischaemic damage translate to varying degrees of functional impairment and that the 
more severe neurological deficit in APOE £4 mice is linked to the greater amount of 
ischaemic damage in this group. These data are also consistent with previous studies 
that reported more severe neurological deficits in APOE £4 mice (Sheng et ai., 1998; 
Mori et ai., 2003). In these studies, differences in functional outcome likely relate to 
variation in the extent of cortical and subcorticaVstriatal damage rather than striatal 
damage alone as in the current study. The present data and previous findings therefore 
demonstrate a consistent association between the APOE £4 allele and poorer outcome in 
animal models of focal ischaemia, which may reflect the ability to control important 
experimental conditions in such studies. In addition, poorer outcome in APOE £4 mice 
has been demonstrated in other models of acute brain injury, including global 
ischaemia, closed head injury and excitotoxic damage (Buttini et ai., 1999; Buttini et 
ai., 2000; Horsburgh et ai., 200Oc; Sabo et ai., 2000), suggesting that the APOE £4 
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allele may have common (detrimental) effects on the response to various types of acute 
brain injury. 
Previous studies have not found any differences in gross brain morphology in 
APOE transgenic mice at the ages (2 - 3 months) used in this study (Xu et al., 1996) 
and so gross neuroanatomical differences are unlikely to account for the differences in 
outcome observed in the present study. However, it is pertinent to consider that the 
C57BU6J strain provided the genetic background for these APOE transgenic mice. 
Cerebrovascular anatomical discrepancies in the circle of Willis, in particular 
hypoplasticity of the posterior communicating artery (PcomA), are an inherent feature 
of the C57BV6J mouse and are associated with increased susceptibility to ischaemic 
damage in this strain (chapter 4 in this thesis; Barone et al., 1993; Connolly et al., 1996; 
Fujii et al., 1997; Yang et aI., 1997a; Kitagawa et al., 1998c; Kelly et al., 2001b; Majid 
et al., 2001). The previous study in this thesis (chapter 4) demonstrated that PcomA 
hypoplasticity is likely associated with important downstream effects on blood pressure 
and cerebral blood flow that impact upon the distribution and extent of ischaemic 
damage. However, in this study a brief duration of occlusion (l5min) was used, which 
was previously determined to be exempt from the synergistic effects of PcomA 
hypoplasticity and declining blood pressure and cerebral blood flow (chapter 4). 
Assessment of histology in the present study revealed that ischaemic damage was 
absent in the hippocampus of all mice, which also suggests that PcomA hypoplasticity 
did not contribute to the differences in outcome. It is unclear, however, if the volume of 
tissue at risk of ischaemic damage was similar in both the APOE £3 and APOE £4 mice. 
Thorough analysis of cerebral blood flow would be required to provide such 
information. Previously, it was shown that the severity of blood flow reduction during 
focal ischaemia and vascular anomalies in the circle of Willis were similar in APOE-
deficient and wild-type mice (Bart et al., 1998). 
Transgenic mice used in this study were back-bred to a common genetic 
background (C57BV6J) at least six times in the USA before transport to the UK where 
several further back-crosses were carried out. These steps ensure that a level of 
homology in genetic background approaching 100% was achieved. In addition, the 
APOE £3 and APOE £4 lines selected from the original lines generated (Xu et al., 1996) 
were matched for the number of copies of the APOE gene (two copies). Differences in 
outcome are therefore not related to the APOE gene copy number. However, the sites of 
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APOE gene integration could differ in each line and affect other coding regions of the 
genome. Thus, subtle genetic differences may still exist between the APOE &3 and 
APOE &4 mouse lines. The extent to which such slight differences, if present, would 
impact upon the response to ischaemia is unknown. 
5.4.2 ApoE alterations after focal ischaemia 
The mechanism(s) underlying the association between APOE genotype and differences 
in outcome after focal ischaemia and other forms of acute brain injury are currently 
unclear. A role for apoE in modulating the neuronal response to damage in an isoform-
specific manner after acute brain injury has been proposed. Key to this proposal has 
been the demonstration that apoE is markedly upregulated and can accumulate in 
neurons under pathological conditions, thus providing a basis for putative interactions 
with pathways involved in neuronal death and/or survival. Previously, increased 
neuronal apoE has been observed following global ischaemia in rodents (Hall et al., 
1995; Kida et al., 1995; Ali et al., 1996; Horsburgh and Nicoll, 1996; Ishimaru et al., 
1996; Horsburgh et al., 200Oc) and humans (Horsburgh et al., 1999a), focal ischaemia 
(Kitagawa et al., 2001; Kamada et al., 2003; Nishio et al., 2003) and subdural 
haematoma (Horsburgh et al., 1997) in rats, spinal cord injury in the mouse (Haasdijk et 
al., 2002; Seitz et al., 2003), excitotoxin-induced injury in the mouse (Grootendorst et 
al., 2000), and after stroke in humans (Aoki et al., 2003). However, at the outset of this 
thesis, there was little information regarding the spatial distribution and cellular 
localisation of apoE following focal ischaemia in APOE transgenic mice. 
In the present study, marked increases in cellular (including neuronal) apoE 
immunoreactivity were observed in ischaemic tissue. Analysis of the distribution of 
elevated apoE immunoreactivity in the occluded hemisphere revealed that the volume of 
apoE immunoreactivity strongly correlated with the volume of ischaemic damage, 
suggesting an important role for apoE in the response to ischaemic damage. The close 
spatial relationship between ischaemic damage and increased apoE immunostaining 
may underlie the larger volume of apoE immunoreactivity observed in APOE 84 mice, 
since this group also displayed a greater volume of ischaemic damage. This pattern 
parallels that previously reported in a global ischaemia model in which increased 
neuronal apoE immunoreactivity was associated with increased ischaemic neuronal 
damage in the hippocampus of APOE &4 compared to APOE &3 mice after 17min global 
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ischaemia (Horsburgh et ai., 2000c). However, although the distribution of apoE 
immunoreactivity was significantly greater in APOE 84 mice in the present study, 
within the ischaemic territory, semi-quantitative assessment revealed no difference in 
the degree of apoE immunoreactivity between APOE E3 and APOE 84 mice. This is 
particularly interesting in view of previous studies which have shown baseline 
differences in apoE levels in the same lines of APOE E3 and APOE 84 mice as used in 
the present study. Western blot analyses showed that apoE levels in the brain were 
approximately 50% lower in APOE 83 mice (Sheng et ai., 1998; Horsburgh et at., 
2000c). This difference was maintained after global ischaemia, although to a lesser 
magnitude (approximately 15% lower in APOE E3 mice) (Figure 54). It was not 
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Figure 54. ApoE levels in APOE E3-437 and APOE 84·81 lines of mice 
In the lines of transgenic mice used in the present study, it was shown previously 
(Horsburgh et a/., 2000) that there were greater levels of apoE in APOE E4 mice after 
sham treatment and after global ischaemia (BCCAo), although differences were not 
significantly different. P> 0.05. Figure courtesy of Dr Karen Horsburgh. 
possible to assay apoE levels in the present cohort of mice, although since the same 
transgenic mouse lines were used as before, it may be speculated that baseline levels 
were greater in APOE fA mice. Thus, it might be expected that the degree of apoE 
immunoreactivity in ischaemic tissue in the present study would be greater in APOE E4 
mice given the greater amount of apoE available in these mice. It could be proposed that 
the mice used in the present were better matched for apoE levels than previously, 
although this is unknown since apoE levels could not be determined and would appear 
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unlikely based on the consistent findings in two previous studies (Sheng et al., 1998; 
Horsburgh et al., 2000c). A more plausible explanation is that the focal ischaemic insult 
was both of similar and sufficient severity in APOE E3 and APOE E4 mice to induce a 
similar, possibly maximal, upregulation of apoE and therefore preclude detection of 
genotype-dependent differences in the apoE response to ischaemic damage. The similar 
degree of apoE immunoreactivity in both APOE transgenic groups may therefore reflect 
this uniformity in severity of ischaemic damage. 
Within ischaemic areas, intense apoE immunoreactivity was evident in glial cells 
and ischaemic neurons. In addition to an upregulation of apoE, these observations also 
indicate an apparent redistribution of apoE in ischaemic tissue since minimal and 
predominantly glial apoE immunoreactivity was observed in non-ischaemic tissue. 
These findings are consistent with previous reports. After global ischaemia increased 
apoE immunoreactivity has been observed in pyramidal neurons of the selectively 
vulnerable hippocampus in rodents (Hall et a/., 1995; Kida et a/., 1995; Ali et al., 1996; 
Horsburgh and Nicoll, 1996; Ishimaru et a/., 1996; Horsburgh et a/., 2000c) and in 
humans (Horsburgh et al., 1999a). Moreover, increased neuronal apoE 
immunoreactivity in the ischaemic core has been demonstrated 24h and seven days after 
transient focal ischaemia in the rat (Kamada et al., 2003) and in human brain associated 
with areas of cerebral infarction (Aoki et al., 2003). 
The source of apoE that accumulates in neurons after an ischaemic insult in this and 
previous studies is unclear, although two main mechanisms have been proposed -
uptake of glial-derived apoE and/or neuronal synthesis of apoE. Since neurons express 
several receptors of the low density lipoprotein receptor family, notably the low density 
lipoprotein receptor-related protein (LRP), that are capable of intemalising apoE-
containing lipoproteins, it is possible that neuronal apoE is derived from uptake of apoE 
from the extracellular space. Astrocytes are believed to be the predominant source of 
apoE in the brain (Boyles et a/., 1985; Pitas et a/., 1987a) and it has been speculated that 
neuronal apoE is derived from intemalisation of astrocyte-secreted apoE. Recently, 
Nishio et al. (2003) observed increased apoE immunoreactivity in astrocytes, neurons 
and macrophages after focal ischaemia in the rat. In contrast, APOE mRNA was 
expressed in astrocytes and macrophages but not in neurons and is therefore compatible 
with an astrocytic origin for neuronal apoE. In the present study, increased glial apoE 
immunoreactivity was evident in ischaemic tissue. It is possible that apoE could initially 
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be upregulated in glial cells and subsequently sequestered by ischaemic neurons. 
Horsburgh and Nicoll (1996) demonstrated that after transient global ischaemia in the 
rat, apoE immunoreactivity was initially increased in astrocytes 24h after ischaemia and 
prior to evidence of neuronal damage and subsequent localisation of apoE to damaged 
neurons 72h after ischaemia. It is worth noting, however, that the development of 
neuronal damage follows a different time-course in focal and global ischaemia. Whether 
the temporal pattern of apoE redistribution observed after global ischaemia can occur 
within 24h after focal ischaemia is unclear. After acute subdural haematoma in the rat, 
neuronal accumulation of apoE was visible 30min after injury without evidence of 
increased glial apoE, suggesting a non-glial origin for apoE, such as from the circulation 
due to blood-brain barrier breakdown after injury (Horsburgh et al., 1 997). Another 
possibility is that apoE is produced within neurons. In contrast to the uninjured rodent 
brain, neuronal apoE immunoreactivity has been demonstrated in humans (Han et al., 
1994a; Han et ai., 1994b; Metzger et ai., 1996; Xu et ai., 1999) and apoE mRNA 
transcripts have also been localised to human brain neurons (Xu et ai., 1999), thus 
providing evidence that apoE can be synthesised locally within neurons. In the present 
study, transgenic mice expressing human APOE under the control of the human 
promoter were used. Accordingly, these mice display a human-like pattern of glial and 
neuronal apoE immunoreactivity in the uninjured brain (Xu et al., 1996). Detection of 
apoE immunostaining in some cortical neurons of morphologically normal tissue in this 
study is consistent with previous work and is suggestive of neuronal synthesis of apoE 
since this pattern of apoE immunostaining is not observed in wild-type mice (Xu et al., 
1996). Neuronal accumulation of apoE was demonstrated to occur in a neuroblastoma 
cell line in the absence of glial cells after an oxidative challenge, indicating upregulation 
of neuronal apoE synthesis (Aoki et al., 2003). In addition, increased APOE mRNA was 
observed in hippocampal neurons following kainic acid induced excitotoxicity 
(Boschert et al., 1999). Thus, the evidence described above suggests that neuronal 
uptake of glial-derived apoE is an important mechanism contributing to the 
accumulation of apoE in neurons after acute brain injury and that this may be 
augmented by increased synthesis of apoE within neurons. 
5.4.3 ApoE and mechanisms of neuroprotection in acute brain injury 
Marked upregulation of apoE after ischaemic brain injury suggests a role for apoE as an 
injury-response protein. A protective role for apoE in acute brain injury has been 
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highlighted by studies showing a poorer outcome in APOE deficient mice after focal 
ischaemia (Laskowitz et at., 1997), closed head injury (Chen et at., 1997) and global 
ischaemia (Horsburgh et at., 1999; Sheng et at., 1999; Kitagawa et at., 2002a; Kitagawa 
et at., 2002b). It has been proposed that apoE scavenges and redistributes cholesterol 
and lipids to damaged neurons where they are internalised by receptor-mediated 
endocytosis and used to promote neuronal survival and repair (Ignatius et at., 1987a; 
Poirier et at., 1993a; Poirier, 1994; Vance et at., 2000). Neuronal accumulation of apoE 
after injury may reflect this process. In addition, a number of mechanisms pertinent to 
cerebral ischaemia, that may be independent of the lipid transport-delivery properties of 
apoE, have been suggested to underlie the neuroprotective effects of apoE. 
ApoE and apoE-derived peptides can attenuate NMDA-mediated excitotoxicity in 
cell culture (Aono et at., 2002; Aono et at., 2003). Significantly, there is evidence that 
apoE3 provides more potent protection against excitotoxic injury than apoE4 (Buttini et 
at., 1999; Qiu et at., 2003). These differences may contribute to the worse outcome in 
APOE £4 mice in the acute phase (e.g. 24h after ischaemia). Putative interactions 
between the major neuronal apoE receptor, LRP, and the NMDA receptor via adaptor 
proteins such as PSD-95 have been described (Bacskai et at., 2000; Gotthardt et at., 
2000; Herz, 2001 a), and may provide a pathway through which apoE could alter 
glutamate receptor function and excitotoxic damage. Antioxidant properties of apoE 
have been shown in vitro (Lee et a/., 2004) and in vivo, in the uninjured brain 
(Ramassamyet at., 2001; Shea et at., 2002) and after global ischaemia (Horsburgh et 
at., 2000b). Furthermore, apoE3 (and apoE2) has been shown to provide greater 
neuroprotection against oxidative insults than apoE4 (Miyata and Smith, 1996; Pedersen 
et a/., 2000; Lauderback et at., 2002). Thus, an impaired ability to counteract oxidative 
stress may also contribute to porer outcome in APOE £4 mice. Similarly, relative 
neuroprotection in APOE £3 mice may result from a greater ability to attenuate the acute 
inflammatory response (Lynch et ai., 2003) and apoptotic cell death (DeKroon et at., 
2003). ApoE3 also binds with greater affinity to various cytoskeletal components, such 
as neurofilament proteins and the microtubule associated proteins, tau and MAP2 
(Huang et ai., 1994; Strittmatter et ai., 1994a; Strittmatter et ai., 1994b; Fleming et at., 
1996). This may promote greater cytoskeletal stability and neuronal survival after 
injury. In addition, evidence is accumulating of neurotoxic effects of apoE, in particular 
truncated apoE4 fragments, which can cause intracellular inclusions and elevations in 
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intracellular calcium levels as occurs during excitotoxicity (Tolar et ai., 1999; Huang et 
ai., 2001; Veinbergs et ai., 2002; Brecht et ai., 2004). However, the existence of toxic 
apoE fragments after cerebral ischaemia has not been investigated to date. In this 
regard, it is interesting to note that, in the present study, the volume of ischaemic 
damage in APOE E4 mice (9 ± lmm3) was similar to that observed previously (chapter 
4) in C57B1I6J mice (9 ± 2mm\ whereas the volume of damage in APOE E3 mice was 
reduced (7 ± lmm3). This suggests that the difference in extent of ischaemic damage in 
the present study is related to protective effects of apoE3 rather than toxic effects of 
apoE4 relative to endogenous mouse apoE. 
In addition to the above putative mechanisms for the effects of APOE genotype on 
outcome to cerebral ischaemia, results from the present study raise the possibility that 
endocytic pathway alterations may contribute to the effects of APOE genotype on the 
outcome to cerebral ischaemia. 
5.4.4 Endocytic pathway alterations after focal ischaemia 
Marked increases in rabaptin-5 and rab4 immunostaining were observed in areas of 
tissue displaying ischaemic damage in comparison to non-ischaemic areas such as the 
contralateral hemisphere and undamaged cerebral cortex of the ipsilateral hemisphere. 
Rabaptin-5 and rab4 are proteins integral to endocytic pathway function and the level of 
expression/immunoreactivity of these molecules has been shown to reflect endocytic 
pathway activity (see section 1.6.2.2). The observations in the present study would 
therefore indicate up-regulation of endocytosis in response to focal cerebral ischaemia. 
Moreover, rabaptin-5 and rab4 are involved in two distinct stages of the endocytic 
pathway and therefore enable separation of the response of these two phases of 
endocytic trafficking. Rabaptin-5 localises to early endosomes, and therefore an 
increase in rabaptin-5 immunoreactivity is indicative of elevated trafficking of material 
from the plasma membrane through coated vesicles that subsequently form early 
endosomes. In contrast, rab4 localises to recycling endosomes that are returning to the 
plasma membrane and, consequently, an increase in rab4 immunostaining suggests an 
increase in recycling activity. 
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5.4.5 APOE genotype-dependent differences in endocytic pathway 
alterations after focal ischaemia 
In the present study, APOE genotype was associated with differences in the extent of 
imunostaining of the endocytic recycling marker rab4 in ischaemic tissue. Although the 
degree of rabaptin-5 immunoreactivity was similar in both APOE E3 and APOE £4 
mice, the degree of rab4 immunoreactivity was significantly greater in APOE E3 mice. 
In view of the specific roles of rabaptin-5 and rab4 in distinct stages of endocytosis, 
these data suggest that there is a differential response of the intemalisationlearly 
trafficking and recycling phases of endocytosis in response to focal cerebral ischaemia 
in APOE E3 and APOE E4 mice (Figure 55). A similar degree of rabaptin-
5 immunoreactivity would indicate that endocytic intemalisation and trafficking to early 
(sorting) endosomes was comparable in both transgenic groups. However, a greater 
level of rab4 immunoreactivity in APOE £3 mice suggests that endocytic recycling 
activity was markedly increased in comparison to APOE E4 mice. Interestingly, there 
was a correlation between the degree of rabaptin-5 and rab4 immunoreactivity in APOE 
E3 mice but not in APOE E4 mice. These results suggest that there may be a parallel 
response of the intemalisation and recycling phases of endocytosis to ischaemic damage 
in APOE E3 mice whereas there may be uncoupling of these two processes in APOE £4 
mIce. 
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Figure 55, APOE genotype-dependent differences in the response of the 
endocytic pathway to cerebral ischaemia 
Solid arrows denote direction of transport. Thickness of broken arrows denote extent of 
activity in the particular phase of endocytosis. 
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5.4.6 Implications of elevated endocytic pathway activity after cerebral 
ischaemia 
The present results indicate enhanced endocytic pathway activity in ischaemic tissue 
following a focal ischaemic insult. This parallels the findings in human post-mortem 
tissue, in which increased endocytosis was observed after an episode of global 
ischaemia (chapter 3). Together, these results suggest that cerebral ischaemia may 
induce similar changes in the endocytic pathway irrespective of the type of ischaemic 
insult. The significance of enhanced endocytic internalisation and recycling activity 
after cerebral ischaemia is unclear. Endocytosis is an integral feature of all cell types 
and is essential for the uptake of important macromolecules such as trophic factors and 
nutrients (e.g. lipids) and internalisation of cell surface receptors, processes that support 
normal cellular function and integrity. As such, endocytic alterations may have various 
effects on the cellular response to an ischaemic insult. For example, a more active 
endocytic system following ischaemia may provide a mechanism for increased neuronal 
uptake of various neurotrophins that have neuroprotective effects and promote neuronal 
survival. Increased expression of several neurotrophins, such as nerve growth factor 
(NGF) and brain-derived neurotrophic factor (BDNF) and their receptors has been 
widely demonstrated in animal models of cerebral ischaemia and traumatic brain injury 
(for review see Abe et aI., 2000). It is conceivable that the beneficial effects of increased 
availability of growth factors after injury would be augmented by enhanced endocytic 
activity to promote their internalisation. Notably, increased endocytic recycling activity 
would provide a mechanism for more efficient recycling of neurotrophin receptors that 
could then be available for further neurotrophin uptake. 
Aside from its role in cellular internalisation of various molecules, endocytosis 
provides an important mechanism to regulate plasma membrane receptor availability 
(Mukherjee et al., 1997). Aggregation of membrane receptors in coated pits results in 
their rapid internalisation. Subsequent trafficking to degradative components of the 
endocytic system provides a mechanism for reducing membrane receptor availability. 
Alternatively, enhanced recycling of receptors via recycling endosomes can replenish 
receptor numbers on the cell surface. By regulating receptor availability, endocytosis 
can influence extracellular signalling pathways that are mediated by binding of ligands 
to plasma membrane receptors and endocytosis has been shown to be a well established 
way of down-regulating extracellular signals (Wi1lnow et al., 1999). Endocytic 
activation after cerebral ischaemia may therefore enable modulation of signalling 
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pathways associated with the response to ischaemia. For example, enhanced 
endocytosis may promote intemalisation of ionotropic glutamate receptors and provide 
a mechanism for attenuating excitotoxic pathways. Previously, glutamate receptor 
endocytosis has been demonstrated to be an important factor in the modulation of 
synaptic strength in neural plasticity paradigms (for reviews see Carroll et al., 2001; 
Malinow and Malenka, 2002; Gomes et al., 2003; Malenka, 2003). 
5.4.7 Alterations in the endocytic pathway • possible mechanism 
underlying APOE genotype differences in outcome to acute brain 
injury 
The present data indicate that the endocytic recycling response after focal ischaemia is 
attenuated in APOE £4 mice in comparison to APOE £3 mice. These findings are similar 
to those obtained in human post-mortem tissue in which an attenuated recycling 
response was evident in APOE £4 carriers after an episode of global ischaemia. A 
different response of the endocytic pathway provides a novel mechanism that may 
contribute to the APOE genotype-dependent differences in outcome to acute brain 
injury. Accumulation of apoE in ischaemic neurons was observed in this and previous 
studies and it has been proposed that apoE acts as a transport protein to deliver 
lipids/cholesterol to injured neurons for membrane repair and synaptic reorganisation. 
Endocytosis of apoE-containing lipoprotein particles via apoE receptors (e.g. LRP) is 
likely to be an important facet of neuronal accumulation of apoE after injury and 
therefore up-regulation of the endocytic pathway, as observed in this study, will 
enhance uptake of apoE and associated lipids. Following intemalisation, components of 
the lipoprotein-receptor complex dissociate and apoE and receptors can be directed to 
lysosomes for degradation or be recycled to the cell surface. Results fonn this study 
suggest that endocytic recycling is more active in APOE £3 mice after cerebral 
ischaemia. Accordingly, it is conceivable that recycling of apoE and its receptors are 
enhanced in APOE £3 mice. Significantly, this would replenish the pool of apoE 
available for mobilising lipids to injured neurons and would restore apoE receptors to 
the cell surface, processes that are likely to further promote neuronal uptake of apoE 
and allied lipids. Thus, the relative neuroprotective effects associated with the APOE £3 
allele may result from more pronounced endocytic recycling that in turn enhances apoE-
mediated delivery of vital cellular components (lipids, cholesterol) required for neuronal 
survival and repair. In this scenario, it may be expected that neuronal apoE 
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accumulation would be greater in APOE £3 mice, however, in the present study, the 
degree of apoE immunoreactivity in ischaemic tissue was similar in both APOE £3 and 
APOE £4 mice. There were also no observable differences in intensity of apoE 
immunoreactivity between APOE £3 and APOE £4 mice. A possible explanation for 
these findings is that the extent of endocytic internalisation and early trafficking (as 
indicated by rabaptin-5 immunoreactivity) was similar in both transgenic groups and 
that this stage of endocytosis is the principal determinant of apoE uptake. Subsequently, 
apoE may be trafficked along different routes with a recycling path more prominent in 
APOE £3 mice. Enhanced apoE recycling in APOE £3 mice may promote greater 
turnover of apoE such that the extent of neuronal apoE accumulation is similar in APOE 
£3 and APOE £4 mice at a given time. However, lipid/cholesterol delivery will be more 
efficient in APOE £3 mice due to the continued replenishing of the pool of apoE 
available for lipid/cholesterol delivery and uptake. 
Previous studies have provided evidence that apoE can escape lysosomal 
degradation and be recycled and re-secreted following internalisation. In vitro, 
incubating cells with apoE-containing lipoproteins resulted in their rapid internalisation 
and after 4h the release of significant amounts of endocytosed apoE (retroendocytosis) 
but not lipoprotein-derived cholesterol, suggesting that apoE escaped degradation 
(Rensen et al., 2000). Similar results were obtained in vivo, where only 15 - 20% of 
endocytosed apoE was degraded in contrast to hydrolysis of 75% of associated 
cholesterol (Rensen et al., 2000). ApoE may escape lysosomal degradation by following 
a recycling pathway. Pulse-chase experiments have demonstrated that approximately 
80% of internalised lipoprotein-associated apoE can escape the lysosomal pathway as a 
result of targeting to recycling endososmes (Heeren et al., 2001). Recently, it was 
shown that a significant proportion of internalised CSF-derived apoE is resistant to 
degradation and was localised to non-lysosomal vesicles (Ljungberg et al., 2003). 
Interestingly, isoform-specific differences of endocytic trafficking of apoE in primary 
human neuronal cultures have been shown. Using marker proteins specific for different 
endocytic compartments, progression of internalised apoE3 and apoE4 through these 
compartments differed. Although both isoforms were similarly trafficked to early 
endodosmes, apoE4 progressed to late endosomes/lysossomes whereas there was 
minimal evidence for apoE3 following this route (DeKroon and Armati, 2001). A likely 
explanation is that a significant proportion of apoE3 was directed to recycling 
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endosomes thus precluding its progressIon to late endosmes/lysosomes. 
Retroendocytosis of apoE3 would promote a continuous lipid delivery system and the 
finding in the present study of greater endocytic recycling activity in APOE £3 mice is 
consistent with this previous in vitro data. 
APOE genotype-dependent differences In endocytic pathway function and 
endocytic trafficking of apoE may also modulate the outcome to acute brain injury via 
mechanisms independent of the lipid transport/delivery properties of apoE. It has been 
proposed that apoE3 may exert neuroprotective effects by promoting increased stability 
of the neuronal cytoskeleton (Strittmatter et al., 1 994a; Strittmatter et al., 1 994b ). 
However, such a function would appear to require apoE to escape the endosomal-
lysosomal system and be available in the cytosol, an event lacking in conclusive 
evidence (DeMattos et al., 1999). Furthermore, cytosolic apoE has been shown to be 
cytotoxic (DeMattos et al., 1999). There is evidence to suggest that rab proteins, notably 
rab4, can interact with the cytoskeleton, in particular microtubule components where 
they can direct vesicle movement (Gonzalez and Scheller, 1999; Bielli et al., 2001). It 
may be speculated that the more prominent recycling pathway associated with apoE3 
could promote interactions with the cytoskeleton via rab4, a process that would not be 
dependent on the release of apoE into the cytosol. 
Generation of toxic apoE fragments may also be affected by endocytic pathway 
function. Evidence suggests that generation of truncated apoE fragments can have 
neurotoxic effects and that apoE4 in particular is more prone to truncation (Marques et 
al., 1996; Marques et al., 1997; Huang et al., 2001; Brecht et al., 2004). The lysosomal 
compartment is a likely location where apoE cleavage could occur in view of the 
proteolytic conditions that exist in these vesicles. After cerebral ischaemia the increased 
neuronal uptake of apoE and elevated endocytic pathway activity may accelerate the 
progression of apoE to the lysosomal system and promote apoE fragment production. 
Since previous studies have shown that apoE4 is preferentially trafficked to late 
endosomes/lysosomes (DeKroon and Armati, 2001), this may account for the greater 
tendency of apoE4 to be truncated. In contrast, apoE3 may be protected from truncation 
by following a recycling pathway. Lysosomal leakage has been demonstrated to be 
enhanced in the presence of apoE4 (Ji et al., 2002), which can promote apoptosis and 
could allow apoE to enter the cytosol where it can exert neurotoxic properties 
(DeMattos et al., 1999). Thus, APOE-dependent effects on endocytic trafficking could 
185 
modulate the propensity for apoE to develop neurotoxic properties via its fragmentation. 
Consequently, investigation of apoE fragmentation after cerebral ischaemia would be 
merited. 
Lastly, APOE-genotype differences in endocytic pathway behaviour may modulate 
outcome to acute brain injury through effects on signal transduction pathways involving 
apoE receptors. In view of the accumulating evidence that members of the LDL receptor 
family, such as LRP and apoER2, can function as signalling receptors in addition to 
their prototypic role as cell surface endocytic receptors (Willnow et ai., 1999; Herz, 
2001b), it is evident that these receptors lie at the "crossroads" of endocytic and signal 
transduction pathways. Endocytosis is an important mechanism for regulating 
transduction pathways elicited at the cell surface through its ability to intemalise and 
recycle receptors or target them for degradation (Willnow et aI., 1999). Ligand-binding 
to LRP has been shown to be capable of inducing NMDA receptor-mediated calcium 
influx (Bacskai et ai., 2000; Qiu et aI., 2002). It is evident that increased neuronal apoE 
intemalisation after injury would occur at the convergence of the endocytic and 
signalling pathways. Thus, endocytic pathway alterations may not only influence the 
trafficking of apoE but could also influence apoE receptor signalling cascades pertinent 
to cerebral ischaemia 
5.4.8 Conclusions 
In summary, the present study has demonstrated an association between APOE 
genotype and differences in outcome and endocytic pathway alterations after focal 
cerebral ischaemia in the mouse. The present results suggest a novel mechanism that 
may contribute to the deleterious effects on outcome to acute brain injury that are 
associated with possession of the APOE e4 allele. The aims stated at the outset of this 
study have been achieved: 
1. the volume of ischaemic damage and the neurological deficit score were 
significantly greater in APOE e4 mice compared to APOE e3 mice after transient 
focal cerebral ischaemia 
2. increased apoE immunoreactivity (including neuronal) was closely associated 
with areas of ischaemic damage in both APOE e3 and APOE e4 mice. The 
degree of apoE immunoreactivity in the ischaemic lesion was similar in APOE 
e3 and APOE e4 mice, however, the distribution of apoE immunoreactivity was 
significantly greater in APOE e4 mice 
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3. increased immunoreactivity of the endocytic pathway markers, rabaptin-5 and 
rab4, was observed in areas of ischaemic damage. The degree of rabaptin-5 
immunoreactivity was similar in APOE e3 and APOE e4 mice. The degree of 
rab4 immunoreactivity was significantly greater in APOE e3 mice. 
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Chapter 6 
Adenoviral-mediated gene transfer of APOE 
83 markedly reduces ischaemic brain 
damage after transient focal cerebral 
ischaemia in mice 
6.1 Introduction and aims 
The previous study (chapter 5) demonstrated that mice expressing human APOE E3 
have an improved outcome to transient focal ischaemia compared to APOE E4 mice. 
Augmenting apoE levels in the brain has also been shown to have neuroprotective 
effects after cerebral ischaemia in mice (Horsburgh et al., 2000b). This study 
investigated the effects of viral vector-mediated gene transfer of APOE E3 on outcome 
after transient focal ischaemia. The specific aims of the present study were to determine, 
in C57B1I6J mice, if adenovirus-mediated gene transfer of APOE E3: 
I. augments endogenous apoE levels in the brain 
2. attenuates isehaemie brain damage after transient focal ischaemia 
6.2 Materials and methods 
This study was carried out at the Division of Neuroscience, University of Edinburgh. 
All experiments were performed blinded to treatment. 
6.2.1 Mice 
Adult male C57B1I6J strain mice obtained from Charles River, UK., were used 
6.2.2 Adenoviral (Ad) vectors 
Second generation adenoviral vectors (viral EI, E2b, E3 genes deleted) with the APOE 
E3 eDNA (Ad-APOE) or GFP gene (Ad-GFP) inserted (section 2.12) were used. 
6.2.3 Preliminary characterisation of adenoviral transduction and 
transgene expression 
The class of adenoviral vector used in the present study ("second generation" with the 
viral EI, E2b and E3 gene deleted) had previously been administered to the periphery 
only (e.g. muscle, liver). Therefore, preliminary experiments involving stereotaxic 
injections of vectors (or vehicle) without subsequent focal ischaemia were performed 
initially, (1) to confmn that the vector transgene was expressed in the brain following 
intrastriatal injection, and (2) to provide an indication of the extent and distribution of 
transduction and tissue/cellular damage associated with vector administration. 
Vectors (and vehicle) were administered via stereotaxic injection into the caudate 
nucleus as described (section 2.3.1). Three mice received injection (O.5J.Ll) of Ad-APOE 
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(one each administered 3.4x1 09vp/ml, 3.4x101ovp/ml and 3.4xl011vp/ml), 3 mice 
received injection of Ad-GFP (one each administered 3.4xl09vp/ml, 3.4xl010vp/ml and 
3.4x1011vp/ml) and one mouse received injection of vehicle (10% glycerol in PBS). 
Three days after vehicle or vector administration, mice were sacrificed by transcardiac 
perfusion fixation. Adjacent sections around the level of the injection tract were stained 
with haematoxylin and eosin and immunostained for apoE. Sections from Ad-GFP 
injected mice were also mounted for inspection of GFP expression. Observations were 
made regarding the distribution and localisation of transgene expression, extent of 
tissue/cellular damage and apoE immunostaining. 
6.2.4 Effects of Ad-APOE administration on outcome and apoE 
immunostaining after focal ischaemia 
6.2.4.1 Vector and vehicle administration 
Mice (28 ± O.3g) were randomly assigned to three groups based on their treatment with 
vehicle (10% PBS in glycerol) (n = 5), Ad-GFP (n = 6) or Ad-APOE (n = 6). Vehicle 
and vectors were applied by stereotaxic infusion into the caudate nucleus (section 
2.3.1). Based on observations from the preliminary experiments (section 6.3.1), vectors 
were administered at a concentration of 3.4xl011vp/ml in 0.5~1 PBS containing 10% 
glycerol. An equal volume of vehicle was infused in vehicle-treated mice. 
6.2.4.2 Focal ischaemia and evaluation of neurological deficit 
Three days after stereotaxic injections, transient focal ischaemia (60min) was induced 
by intraluminal occlusion (recovery from anaesthesia model) as described (section 
2.3.2.2). This model of intraluminal occlusion was employed in the present study based 
on the hypothesis that application of Ad-APOE would reduce the amount of ischaemic 
damage. Accordingly, a model that produces a substantial volume of damage (striatal 
and cortical) was considered most appropriate. The results in chapter 4 demonstrated 
that the sustained anaesthesia model characterised in this thesis produced extensive 
volumes of ischaemic damage with 30 or 60min occlusion but was associated with 
declining MABP and widespread reductions in CBF outside MCA territory. These 
factors may render the brain unreceptive to neuroprotective strategies. In the recovery 
from anaesthesia model, mice are conscious during occlusion which should result in 
more stable MABP. Previous work also demonstrated that this model produces 
reproducible striatal and cortical ischaemic lesions with 45min occlusion. In the present 
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study, 60min occlusion was chosen since it was hypothesised that stereotaxic injection 
through a burr hole in the cranium may attenuate the ischaemic insult by reducing 
intracranial pressure. 
After 24h reperfusion, mice were assigned a neurological deficit score of 0 to 4 as 
described (section 2.4). Following neurological evaluation, mice were perfused 
transcardially (section 2.5) and paraffin-processed (section 2.6.1.2). Paraffin embedded 
brains were cut into 6J.lm sections (section 2.6.2) which were used for histological and 
immunohistochemical analysis. 
6.2.4.4 Measurement of ischaemic damage 
The volume of ischaemic damage was measured in haematoxylin and eosin-stained 
tissue as described (section 2.8). Criteria for inclusion were: (l) clear evidence of 
ischaemic damage in the striatum, and (2) absence of intracranial haemorrhage as 
observed in haematoxylin and eosin-stained tissue. 
6.2.4.5 ApoE immunohistochemistry 
Paraffin-embedded sections (6J.lffi) were immunostained (peroxidase protocol) with 
anti-apoE as described (section 2.9.3). 
Adjacent sections to those stained with haematoxylin and eosin were used to 
delineate the distribution of intense apoE immunostaining at eight coronal levels. 
Delineation of the areas of tissue displaying intense apoE immunostaining was 
performed at low magnification (x25). In doing so, apoE immunostaining in ischaemic 
neurons was not readily visible and therefore only areas of intense apoE 
immunostaining (mainly of neuropil) related to stereotaxic injection were quantified. 
Areas were then integrated with the distance between each coronal level to calculate a 
volume in the same way as for ischaemic damage (section 2.9.6.1). Reproducibility of 
volumetric measurement was tested (Appendix I). 
6.2.5 Effect of Ad-APOE administration on apoE levels 
ApoE levels were measured in mice receiving intrastriatal injections of vehicle, Ad-GFP 
or Ad-APOE without subsequent focal ischaemia. Mice were given bilateral injections 
(0.5J.lI) of vehicle (10% PBS in glycerol) or Ad-GFP (3.4xl011vp/ml) or Ad-APOE 
(3.4xlOllvp/ml) into the caudate nucleus (n = 2 mice per treatment group). Each 
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hemisphere was treated as an individual data point, therefore n = 4 for each treatment. 
Three days after injection, mice were perfused transcardially and brain tissue was 
harvested as described (section 2.10.1). Tissue samples were homogenised (section 
2.10.2) and total protein content was assayed (section 2.10.3). ApoE levels were then 
quantified by sandwich ELISA (section 2.10.4). 
6.2.6 Statistical analysis 
Two comparisons were made for areas and volumes of ischaemic damage, neurological 
deficit score, areas and volumes of apoE imrnunostaining and apoE levels: 1) vehicle vs. 
Ad-GFP; 2) Ad-GFP vs. Ad-APOE. To assess statistical differences, comparisons were 
perfonned using one-way ANOVA followed by Student's unpaired t-test incorporating 
a Bonferroni correction factor of 2. All data are presented as mean ± SEM. 
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6.3 Results 
6.3.1 Preliminary characterisation of adenoviral transduction and 
transgene expression 
6.3.1.1 GFP expression 
GFP expression was first examined in Ad-GFP injected mice without subsequent focal 
ischaemia. In all Ad-GFP injected mice, there was evidence of adenovirally transduced 
cells in the hemisphere ipsilateral to injection, as revealed by intense GFP fluorescence. 
The distribution of cells displaying intense GFP fluorescence was dependent on the 
concentration of Ad-GFP administered (Figure 56). With the lowest dose 
(3.4x109vp/ml), the distribution of intense GFP-Iabelled cells was limited to a small 
area of tissue immediately surrounding the injection tract. Increasing the vector dose to 
3.4xl010vp/ml resulted in a greater distribution of adenovirally transduced cells. The 
number of intense GFP-Iabelled cells in the caudate nucleus was markedly increased in 
comparison to the lower dose. In addition to GFP-Iabelled cells adjacent to the injection 
tract, there were also more distant cells labelled in the caudate nucleus and a few GFP-
positive cells in the external capsule. Administration of the highest dose of vector 
(3.4xlOllvp/ml) resulted in the most extensive distribution of GFP-Iabelled cells. The 
distribution of GFP-positive cells in the caudate nucleus was similar to that observed 
with injection of 3.4xl010vp/ml vector, however with the highest dose there was also 
extensive expression of GFP in cells of the subcortical white matter. 
The majority of intense GFP fluorescent cells in the caudate nucleus displayed 
large, round cell bodies with visible neurites of varying length (Figure 57). Many of the 
GFP expressing cells in subcortical white matter displayed small, elongated cell bodies 
and were orientated along the plane of the fibres suggesting that oligodendrocytes were 
the predominant cell type expressing GFP (Figure 51). It was not possible to confirm 
this, however, since a specific oligodendrocytic marker suitable for use in paraffin-
embedded tissue was not available. Double-labelling with the neuronal marker, neu-N, 
and the astrocytic marker, GFAP, was performed and did not show any co-localisation 
between GFP and either marker. However, the strong GFP signal may have masked the 
weak neu-N and GFAP signals. It should be noted that, although GFP expression 
provides an indication of adenoviral transduction, it is likely to be an underestimation 
since there may be additional cells and/or cell types transduced that are expressing GFP 
at undetectable levels or not at all. 
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Figure 56. Effect of adenoviral vector dose on distribution of GFP expression 
Increasing the titre of Ad-GFP resulted in an increase in the number and distribution of 
cells expressing GFP. At the lowest dose (3.4x109 vp/ml) GFP-Iabelled cells were 
confined to tissue immediately surrounding the injection tract. In contrast, at the highest 
dose (3.4x1011 vp/ml) GFP labelled cells were more widely distributed in the caudate 
nucleus and were also observed in the corpus callosum. ctx, cerebral cortex; cc, 
corpus callosum; en, caudate nucleus; IT, injection tract. Scale bar, 1 OO~m . 
194 
Figure 57. GFP expression in the caudate nucleus and subcortical white matter 
Intense GFP fluorescence, indicative of adenoviral transduction and transgene 
expression, was observed in cells in (a) the caudate nucleus and (b) the corpus 
callosum. GFP expression appeared to be localised mainly to oligodendrocytes. Scale 
bar, 25)lm. 
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6.3.1.2 Histology 
Sections from mice given vehicle, Ad-GFP or Ad-APOE without subsequent ischaemia 
were stained with haematoxylin and eosin to examine histological damage associated 
with the injection tract and/or adenoviral transduction. In all treatments groups, 
injections were associated with some distortion of tissue due to mechanical damage 
produced by the needle. In general, this was limited to a thin strip of tissue in the cortex 
and caudate nucleus (Figure 58). Mechanical disruption oftissue was also accompanied 
in most cases by a small amount of bleeding localised to the injection tract. There were 
no apparent differences in the extent of tissue disruption or bleeding among vehicle, 
Ad-GFP or Ad-APOE treated mice. Examination of tissue at higher magnification 
revealed that vehicle or vector injection without subsequent ischaemia resulted in only 
minimal cellular damage that was localised to mechanically disrupted tissue bordering 
the injection tract (Figure 58). No differences were observed in the extent of cellular 
damage in vehicle, Ad-GFP and Ad-APOE treated mice. In addition, there were no 
increases observed in the extent of cellular injury with increasing dose of Ad-GFP or 
Ad-APOE. Notably, in Ad-GFP treated mice, sections stained with haematoxylin and 
eosin adjacent to those examined for GFP revealed that, in areas of tissue containing 
GFP expressing cells, there was no histological evidence of cellular injury. These 
observations suggest that there were no significant direct cytotoxic effects of adenoviral 
transduction and trans gene expression and that mechanical damage was the primary 
factor underlying the minimal tissue and cellular injury localised to the injection tract.. 
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Figure 58. Tissue damage after vehicle or adenoviral vector injection 
(a-c) A small amount of tissue distortion caused by mechanical needle damage was observed regardless of treatment. (d-f) In addition, 
cellular injury was observed locally around the injection tract (arrows), however this did not extend far from the injection tract as indicated 
by the appearance of normal cellular morphology (block arrows). ctx, cortex; ee, corpus callosum; cn, caudate nucleus. Scale bar (a-c), 
~ 300~m; (d-f) , 50~. 
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6.3.1.3 ApoE immunostaining 
ApoE immunostaining was examined in vehicle, Ad-GFP and Ad-APOE treated mice 
that did not undergo focal ischaemia. ApoE immunoreactivity was observed in all mice, 
however, the intensity and distribution of apoE immunoreactivity varied markedly 
among the three groups (Figure 59). Faint apoE immunoreactivity of a few cells 
surrounding the injection tract was observed following administration of vehicle. 
Faintly stained cells appeared to have shrunken cell bodies and were located in the zone 
of damaged tissue observed in the adjacent section stained with haematoxylin and eosin. 
Similar observations were made in Ad-GFP treated mice regardless of the dose of 
vector given. Administration of Ad-APOE resulted in markedly greater intensity and 
distribution of apoE immunoreactivity. Increasing the dose of Ad-APOE also resulted in 
progressive increases in the intensity and distribution of apoE immunoreactivity. After 
administration of the highest dose of Ad-APOE (3.4xlO11vp/ml), extensive distribution 
of dense apoE immunoreactivity of the neuropil - encompassing most of the caudate 
nucleus and extending to the external capsule - was observed (Figure 59). In addition, 
intense apoE immunoreactivity of glial cells in the caudate nucleus and subcortical 
white matter was observed. Furthermore, dense neuropil apoE immunoreactivity in the 
deep layers of the cerebral cortex was observed after administration of the highest dose 
of Ad-APOE (Figure 60). These observations suggest that the greater intensity and 
distribution of apoE immunoreactivity following Ad-APOE injection is due to 
adenovirus-mediated delivery of the APOE gene since only minimal apoE 
immunoreactivity localised to the injection tract was observed after vehicle injection or 
adenovirus-mediated delivery of the GFP gene. Cellular apoE immunoreactivity 
adjacent to the injection tract is likely to be a response to tissue damage caused by 
mechanical disruption since this was observed in vehicle and Ad-GFP treated mice. 
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Figure 59. ApoE immunostaining after vehicle or vector administration without subsequent ischaemia 
(a) Vehicle and (b) Ad-GFP injection resulted in only minimal apoE immunostaining localised to the injection tract whereas (c) Ad-APOE 
injection produced dense apoE immunoreactivity around the injection tract and also distant to this in the caudate nucleus, corpus callosum 
and deep layers of the cerebral cortex. (d,e) Faint cellular apoE immunoreacivity (arrows) was evident around the injection tract in (d) vehicle 
and (e) AD-GFP treated mice. In contrast, injection of (f) Ad-APOE produced intense neuropil and cellular (arrows) immunoreactivity . 
Photomicrographs of Ad-GFP and Ad-APOE show immunostaining after injection of highest dose (3.4x1011vp/ml) of adenoviral vector. ctx, 
cortex; ee, corpus callosum; en, caudate nucleus; IT, injection tract. Scale bar (a-c), 500J..Lm; (d-f) , 50J..lm. 
Figure 60. ApoE immunostaining after Ad·APOE injection 
(a) Dense apoE immunoreactivity in the neuropil and a few cells with neuronal 
morphology (arrows) was observed in the caudate nucleus after administration of 
3.4x1011vp/ml Ad-APOE. (b) In addition, dense neuropil apoE immunoreactivity 
extended into the cerebral cortex and was also observed in a few glial cells (arrows) in 
the caudate nucleus. (c) Cellular apoE immunoreactivity was evident in subcortical 
white matter. Immunoreactive cells (arrows) displayed similar (oligodendrocytic) 
morphology to those expressing GFP after treatment with 3.4x1011vp/ml Ad-GFP. cn, 
caudate nucleus; cc, corpus callosum; ctx, cerebral cortex. Scale bar, 25J.l.m. 
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6.3.2 Effect of Ad-APOE administration on apoE levels 
ApoE levels were measured 3 days after injection in mice that did not undergo focal 
ischaemia (Figure 61). Administration of Ad-APOE resulted in significantly higher 
levels of apoE compared to treatment with Ad-GFP (50.7 ± 3.Ong apoE/mg total protein 
vs. 1.2 ± O.2ng apoE/mg total protein, P < 0.0001). There was no difference in the level 
of apoE following administration of vehicle or Ad-GFP (1.0 ± O.4ng apoE/mg total 
protein vs. 1.2 ± 0.2ng apoE/mg total protein, P> 0.05). 
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Figure 61. Quantification of apoE levels by ELISA 
*** 
Ad-A POE 
The level of apoE was Significantly greater in Ad-APOE compared to Ad-GFP treated 
mice. The level of apoE was similar in vehicle and Ad-GFP treated mice. **.p < 0.0001 
for the comparison between Ad-GFP and Ad-APOE, one-way ANOVA followed by 
Student's unpaired t-test with Sonferroni correction. n = 4 (each group). Data are 
presented as mean ± SEM. 
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6.3.3 Effect of Ad-APOE administration on ischaemic damage after focal 
ischaemia 
Administration of Ad-APOE significantly reduced the total volume of ischaemic 
damage in comparison to Ad-GFP treated mice (13 ± 3mm3 vs. 29 ± 4mm3, P = 0.013) 
(Figure 62). The total volume of ischaemic damage was similar in vehicle and Ad-GFP 
treated mice (27 ± 5mm3 vs. 29 ± 4mm3, P > 0.05). The volume of ischaemic damage 
was also similar in vehicle and Ad-GFP treated mice in the cortical (16 ± 4mm3 vs. 15 ± 
2mm3, P > 0.05) and striatal (9 ± Imm3 vs. 10 ± 0.5mm3, P > 0.05) components of the 
ischaemic injury. Administration of Ad-APOE significantly reduced the volume of 
ischaemic damage in comparison to Ad-GFP treated mice in both the cortex (6 ± 2mm3 
vs. 15 ± 2mm3, P = 0.012) and the striatum (7 ± Imm3 vs. 10 ± Imm3, P = O.OlO). In 
addition, there was a trend toward smaller areas of ischaemic damage at each coronal 
level in Ad-APOE treated mice compared to Ad-GFP treated mice. At coronal level 
three (injection level) the area of ischaemic damage was significantly reduced in Ad-
APOE compared to Ad-GFP treated mice (5 ± 0.9mm2 vs. 9 ± 0.5mm2, P = 0.003). 
There was no difference in the area of ischaemic damage between vehicle and Ad-GFP 
treated mice at the injection level (P> 0.05). 
The distribution of ischaemic damage predominantly involved the striatum and 
cerebral cortex (Table 11). There was no evidence of ischaemic damage in the 
hemisphere contralateral to occlusion. 
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Figure 62. Measurement of ischaemic damage 
(a) Administration of Ad-APOE significantly reduced the volume of ischaemic damage 
in the whole hemisphere (total), cerebral cortex and striatum in comparison to Ad-GFP 
treatment. (b) There was a trend toward reduced areas of ischaemic damage in Ad-
APOE treated mice compared to Ad-GFP treated mice at each coronal level. The area 
of ischaemic damage was significantly reduced at the level of injection in Ad-APOE 
compared to Ad-GFP treated mice. *P < 0.05 for the comparison between Ad-GFP 
and Ad-A POE, one-way ANOVA followed by Student's unpaired t-test with Bonferroni 
correction. Arrow denotes injection level. n = 5 (vehicle); n = 6 (Ad-GFP); n = 6 (Ad-
APOE). Data are presented as mean ± SEM. 
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Table 11. Frequency of ischaemic damage in specific brain regions 
Frequency of ischaemic damage in specific brain regions 
Treatment 
Striatum Cerebral cortex Hippocampus Thalamus Hypothalamus 
Vehicle 50f5 50f5 1 of 5 1 of 5 o of5 
Ad-GFP 6of6 6of6 o of6 1of6 Oof6 
Ad-A POE 6of6 4of6 1 of 6 1 of 6 o of6 
Ischaemic damage was generally observed in the striatum and cerebral cortex only with infrequent involvement of the 
hippocampus and thalamus. Hypothalamic damage was not observed in any mice. 
6.3.4 Effect of Ad·APOE administration on neurological deficit after focal 
ischaemia 
60min focal ischaemia provoked obvious neurological deficits in all mice except one 
treated with Ad-APOE in which there was no observable deficit. There was a trend 
toward a lower neurological deficit score in Ad-APOE treated mice, although this did 
not reach statistical significance (P > 0.05) (Figure 63). There was no association 
between neurological deficit and the volume of ischaemic damage (P> 0.05). 
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Figure 63. Neurological deficit after focal ischaemia 
50 
<> Vehicle 
Ad-GFP 
• Ad-APOE 
(a) There was a trend toward a lower neurological deficit score in mice receiving 
intrastriatal injection of Ad-APOE, however this was not statistically significant (P > 
0.05, one-way ANOVA). Bars show mean . (b) There was no correlation between 
neurological deficit and the volume of ischaemic damage (P> 0.05, Spearman Rank 
correlation co-efficient). 
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6.3.5 Effect of Ad-APOE administration on apoE immunostaining after 
focal ischaemia 
In all mice, in the hemisphere contralateral to injection and occlusion, there was 
minimal evidence of cellular apoE immunoreactivity regardless of vehicle, Ad-OFP or 
Ad-APOE treatment (Figure 64). ApoE immunoreactivity was present in a few cells 
with astrocytic morphology and was absent in neurons. Faint apoE immunostaining of 
the neuropil was observed in the majority of the contralateral hemisphere, including the 
striatum and cerebral cortex. 
In the hemisphere ipsilateral to occlusion, areas of ischaemic damage were 
associated with increased cellular apoE immunoreactivity (compared to non-ischaemic 
areas) regardless of treatment prior to ischaemia. ApoE immunoreactivity was observed 
in cells with the morphology of ischaemic neurons and to a lesser extent in cells with 
astrocytic morphology. Reactive glial cells displaying apoE immunoreactivity and 
localised to the injection tract were evident regardless of treatment (Figure 65). 
However, it was also evident that the nature of apoE immunoreactivity in the ipsilateral 
hemisphere was markedly different in Ad-APOE treated mice in comparison to those 
receiving vehicle or Ad-OFP as described below. 
In Ad-APOE treated mice, two major differences in apoE immunostaining in the 
ipsilateral hemisphere were observed in comparison to vehicle or Ad-OFP treated mice 
- increased intensity and distribution of neuropil and cellular immunoreactivity. First, in 
Ad-APOE treated mice, intense apoE immunostaining of the neuropil was evident at the 
injection level and also at coronal levels caudal to this. In 4 of 6 mice, such intense 
neuropil immunostaining was distributed throughout the entire striatum and also 
extended into the mid to deep layers of the frontal and parietal cortex at these levels 
(Figure 65). Notably, in 3 of 6 mice intense neuropil immunostaining was not only 
localised to ischaemic tissue but also extended to non-ischaemic tissue in the striatum 
and cerebral cortex. In contrast, apoE immunoreactivity was localised around the 
injection tract in vehicle and Ad-OFP treated mice (Figure 65). Second, the intensity of 
cellular apoE immunostaining, particularly in ischaemic neurons, was markedly greater 
in ischaemic tissue of Ad-APOE treated mice (Figure 65). Ischaemic neurons intensely 
immunoreactive for apoE were observed throughout the rostro-caudal extent of the 
striatum, including the coronal levels displaying intense neuropil immunoreactivity. 
Unlike vehicle and Ad-OFP treated mice, in which apoE immunoreactive ischaemic 
neurons were most apparent at the ischaemic border in the striatum, Ad-APOE treated 
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mIce displayed ischaemic neurons with similarly high apoE immunoreactivity 
throughout the striatum. In addition, intensely apoE-immunoreactive ischaemic neurons 
were also visible in the cerebral cortex of some animals, notably in areas with increased 
neuropil immunoreactivity (Figure 65). 
Vehicle 
Ad-GFP 
Ad-A POE 
/ 
/ 
Figure 64. ApoE staining in the contralateral hemisphere after focal ischaemia 
In the hemisphere contralateral to occlusion, apoE immunostaining was similar in all 
groups. Cellular immunostaining was confined to a few scattered apoE immunoreactive 
glial cells (arrows). In general, faint immunostaining of the neuropil was observed 
throughout the hemisphere. Photomicrographs show caudate nucleus. Scale bar, 
25~m. 
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Figure 65. ApoE immunostaining in the ipsilateral hemisphere after focal ischaemia 
(a,b) In vehicle and Ad-GFP treated mice, dense neuropil apoE immunoreactivity observed at low magnification was restricted 
to the injection tract. (c) In contrast, injection of Ad-APOE resulted in dense neuropil apoE distributed throughout the caudate 
nucleus and extending into the deep layers of the cerebral cortex. (d-f) In each treatment group, a small number of apoE 
immunoreactive cells with the morphology of reactive glial cells was observed adjacent to the injection tract (arrows). IT, 
injection tract; cn, caudate nucleus; cc, corpus callosum; ctx, cerebral cortex. Scale bar (a-c), 300j..l1ll ; (d-f) , 50~m . 
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Figure 65 (cont). ApoE immunostaining in the ipsilateral hemisphere after focal ischaemia 
(g-i) ApoE immunoreactivity was observed in neurons with ischaemic morphology (arrows) in the caudate nucleus of all mice. The 
intensity of apoE immunoreactivity was markedly greater in Ad-APOE treated mice (i). O-k) In the cerebral cortex, minimal or no 
apoE immunoreactivity was observed in ischaemic neurons of vehicle and Ad-GFP treated mice G,k), whereas intense 
immunoreactivity was observed in ischaemic neurons (arrows) of Ad-APOE treated mice (I) in cortical tissue also displaying dense 
neuropil immunoreactivity. Scale bar, 25J.lm. 
The distribution of intense apoE immunoreactivity was assessed at low 
magnification (x25). Cellular apoE immunoreactivity was not readily visible at this 
magnification and therefore intense neuropil apoE immunoreactivity related to 
vehicle/vector infusion could be differentiated from the apoE response to neuronal 
damage and quantified accordingly. Borders between areas of intensely immunoreactive 
neuropil and areas of pallor were readily identifiable therefore facilitating their 
delineation. 
Administration of Ad-APOE significantly increased the total volume of intense 
apoE immunoreactivity in comparison to Ad-GFP treated mice (5.4 ± 1.36mm3 vs. 0.6 ± 
0.13mm3, P = 0.006) (Figure 66). The total volume of intense apoE immunoreactivity 
was similar in vehicle and Ad-GFP treated mice (0.9 ± 0.04mm3 vs. 0.6 ± 0.13mm3, P > 
0.05). The volume of apoE immunoreactivity was also similar in vehicle and Ad-GFP 
treated mice in the cerebral cortex (0.2 ± 0.02mm3 vs. 0.1 ± 0.06mm3, P > 0.05) and 
striatum (0.7 ± 0.02mm3 vs. 0.5 ± 0.12mm3, P> 0.05). Administration of Ad-APOE 
significantly increased the volume of apoE immunoreactivity in comparison to Ad-GFP 
treated mice in both the cortex (1.1 ± 0.32mm3 vs. 0.1 ± 0.06mm3, P = 0.015) and the 
striatum (4.3 ± 1.09mm3 vs. 0.5 ± 0.12mm3, P = 0.005) (Figure 66). In addition, the 
area of apoE immunoreactivity was significantly larger in Ad-APOE treated mice 
compared to Ad-GFP treated mice at the level of the injection (3.5 ± 0.13 mm2 vs. 0.6 ± 
0.11mm2, P = 0.001) (Figure 66). There was no significant difference in the area of 
apoE immunoreactivity between vehicle and Ad-GFP treated mice (P> 0.05). 
In the Ad-APOE treated group, there was a trend toward smaller volumes of 
ischaemic damage in mice with larger volumes of apoE immunoreactivity (i.e. an 
inverse relationship) (Appendix J). 
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Figure 66. Volumetric measurement of apoE immunoreactivity 
(a) Administration of Ad-APOE significantly increased the volume of intense apoE 
immunoreactivity (as observed at low magnification) in the whole hemisphere (total), 
cerebral cortex and striatum in comparison to Ad-GFP treatment. (b) The area of 
intense apoE immunoreactivity was significantly greater at level of injection in Ad-
APOE compared to Ad-GFP treated mice. *P < 0.05 for the comparison between Ad-
GFP and Ad-APOE, one-way ANOVA followed by Student's unpaired t-test with 
Bonferroni correction. Arrow denotes injection level. n = 5 (vehicle); n = 6 (Ad-GFP); n 
= 6 (Ad-APOE). Data are presented as mean ± SEM. 
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6.4 Discussion 
The results from the present study have demonstrated that adenovirus mediated transfer 
of the human APOE E3 gene to the brain results in markedly increased levels of apoE 
compared to administration of control vector (Ad-GFP) or vehicle. Furthermore, the 
present data show that administration of Ad-APOE significantly reduced the volume of 
ischaemic damage by approximately 50% in comparison to treatment with AD-GFP or 
vehicle. 
6.4.1 Adenoviral vector transduction and transgene expression 
ApoE (and associated lipids) do not cross the blood-brain barrier and therefore 
modulation of apoE levels in the brain requires a direct intrathecal approach. In the 
present study, this was achieved by intrastriatal injection of an adenoviral vector 
carrying the APOE E3 eDNA. The integrity of adenoviral vector-mediated gene transfer 
to the brain has been shown previously for a number of genes by demonstration of 
cellular transduction and trans gene expression (jar review see Ooboshi et ai., 2003). 
However, these studies have utilised first generation adenoviral vectors (E 1- and/or E3-
deleted). In the present study, gene transfer to the brain was accomplished using a 
second generation adenoviral vector (E1, E2b, E3 deficient). 
This vector has been administered previously by intramuscular or intravenous 
injection (to target the liver) where it has been shown to promote regression of 
atherosclerotic pathology in susceptible APOE-deficient mice (Harris et ai., 2002). In 
this study, secretion of apoE into the circulation was evident for 70 days following 
intravenous administration. This contrasts with another study using a first generation 
adenoviral vector in which apoE expression was evident for 1 month only (Kashyap et 
ai., 1995). The key feature of the second generation vector that is thought to mediate 
persistent trans gene expression in the periphery is the deletion of the E2b region of the 
viral genome (Amalfitano et ai., 1998). Effectively, this removes the trigger that 
induces a cel1-mediated immune response against adenovirally-transduced cells and the 
potentially antigenic trans gene product (Amalfitano et ai., 1998; Hu et al., 1999). Prior 
to the present study, however, there was no information regarding the efficacy of the 
current vector as a gene transfer agent to the brain. It has been indicated that weaker 
trans gene expression may be a feature of second generation vectors (Dr Andy Baker, 
personal communication). Accordingly, preliminary experiments (adenoviral 
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application without subsequent ischaemia) were performed to assess the ability of this 
vector to mediate transgene expression in the brain. 
The ability of the vector to successfully transduce cells in the brain and mediate 
transgene expression was confinned in mice treated with an adenoviral vector 
containing the GFP reporter gene. At the dose of vector used in the focal ischaemia 
experiments, GFP expression was observed in cells distributed throughout a substantial 
part of the caudate nucleus and in overlying subcortical white matter. The extent ofGFP 
expression was similar to that observed in previous studies after intrastriatal injection of 
similar doses of first generation adenoviral vectors (Hermann et aI., 2001 b; Kilic et ai., 
2002). It is also possible that additional cells were transduced but not expressing GFP at 
the time-point examined and therefore the number of GFP expressing cells is likely to 
under-represent the extent of adenoviral transduction. Cells expressing GFP displayed 
oligodendrocytic morphology and transduction of this cell type is supported by the 
observation of numerous GFP expressing cells in subcortical white matter. The present 
observations are in accordance with both in vivo and in vitro studies analysing the 
cellular specificity of adenoviral gene transfer and transgene expression driven by the 
CMV promoter. Such studies have shown that, although adenoviral vectors transduce 
both neuronal and non-neuronal cells, transduction of glial cells occurs with greater 
efficacy (Elsharni et ai., 1997; Ambar et ai., 1999; Hermann et aI., 2001b; Kugler et at., 
2001). In addition, CMV promoter activity and transgene expression in glial cells may 
suppress promoter activity in neurons. Transgene expression in cultured hippocampal 
neurons was evident only if these cells were transduced in the absence of glia (Kugler et 
aI., 2001). In the present study, vectors were injected in the caudate nucleus (neuronal 
and glial popUlations present) therefore it is possible that transduction occurred in 
neurons and glia and that neuronal trans gene expression was suppressed resulting in the 
glial-specific nature of GFP expression. 
Immunohistochemical detection of apoE also provided confirmation of vector 
transduction and trans gene expression following Ad-APOE administration. At the dose 
of vector used in the ischaemia experiments, apoE was distributed throughout a large 
portion of the caudate nucleus, similar to GFP expression. Interestingly, apoE 
immunoreactivity was predominantly observed in the neuropil. These observations 
suggest that secretion of apoE occurs after adenoviral transduction and transgene 
expression, and may result in apoE being found in non-transduced areas, such as the 
deep layers of the cerebral cortex. In addition, there was evidence of a few apoE 
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immunoreactive glial cells in the caudate nucleus and in cells of the subcortical white 
matter displaying similar morphology to those expressing GFP indicating that APOE 
transgene expression is also likely to be glial in origin. It seems unlikely that apoE 
expression was the result of a response to adenoviral transduction since only minimal 
apoE immunoreactivity localised to the injection tract was observed after Ad-GFP 
injection. In support of this, apoE ELISA showed that apoE levels were minimal after 
Ad-GFP injection and were markedly increased after Ad-APOE injection. It is also 
unlikely that apoE expression was a response to injection-mediated cellular injury since 
histological damage was minimal in all groups. 
6.4.2 Adenoviral vector cytotoxicity 
The lack of a significant amount of cellular damage after adenoviral vector injection 
(without subsequent ischaemia) suggests there were no major direct cytotoxic effects of 
adenoviral transduction, in particular since areas of tissue containing GFP expressing 
cells did not display histological damage. Direct cytotoxicity following first generation 
adenoviral vector transduction has been reported when doses above 108 particles were 
injected into rat brain (Gerdes et al., 2000). Removal of additional viral genes in second 
generation vectors may attenuate this toxicity by preventing "leaky" expression of viral 
genes. This is supported by the finding that intracerebral injection of a gutless 
adenoviral vector, similar to the type used in the present study, resulted in greatly 
diminished toxicity (and immunogenicity) compared to a first generation vector (Zou et 
al., 2000). In the present study, tissue and cellular injury is likely to have been the result 
of mechanical disruption of tissue due to needle penetration, as indicated by the 
presence of (minimal) damage after vehicle injection. 
6.4.3 Neuroprotection by administration of Ad-APOE 
The present data demonstrate that adenoviral vector-mediated transfer of human APOE 
£3 was neuroprotective 24h after transient focal ischaemia and indicate the potential for 
gene transfer of APOE to be used as a therapeutic strategy in human stroke. The effects 
of administration of exogenous apoE have not previously been investigated in focal 
ischaemia, however the neuroprotective effects observed in the present study are 
consistent with those reported in a mouse model of transient global ischaemia. Human 
plasma-derived apoE (of mixed isoform complexed with very low density lipoprotein) 
214 
was continuously infused into a lateral ventricle prior, during and after the ischaemic 
insult and resulted in a reduction in the extent of ischaemic damage in selectively 
vulnerable regions (Horsburgh et al., 2000b). In another study, neurodegeneration and 
cognitive impairment in APOE-deficient mice was attenuated by intraventricular 
infusion of recombinant apoE (without lipids) (Masliah et al., 1997). Recombinant apoE 
and apoE-derived peptides have also been shown to attenuate excitotoxic damage in 
vitro (Aono et al., 2002; Aono et al., 2003). The present results also reinforce the 
greater neuroprotective effects associated with the apoE3 isoform and are consistent 
with the results in the previous chapter of this thesis showing that human APOE &3 
transgenic mice display less ischaemic damage after focal ischaemia than APOE &4 
mice. 
Intrastriatal administration of Ad-APOE significantly reduced the volume of 
ischaemic damage in both the striatum and cerebral cortex and by approximately 50% in 
the whole hemisphere. The preliminary experiments indicated that apoE was probably 
secreted into the extracellular space following adenoviral transduction. Since apoE is a 
diffusible molecule it is possible that apoE may be able to act remote to the 
injection/transduction sites and in this way may facilitate attenuation of the volume of 
ischaemic tissue. In support of this, neuropil apoE immunoreactivity was distributed 
throughout a large part of the caudate nucleus and extended into the deep layers of 
cerebral cortex (including non-ischaemic tissue) after focal ischaemia in Ad-APOE 
treated mice. There was also a trend toward smaller amounts of ischaemic damage in 
Ad-APOE treated mice with greater distribution of apoE immunoreactivity suggesting 
that increased availability of apoE may promote more robust neuroprotection. However, 
it cannot be excluded that greater ischaemic damage reduced the pool of apoE by 
inhibiting trans gene expression. Adenoviral transfer of genes encoding other diffusible 
proteins, such as GDNF and CNTF, to the brain parenchyma also resulted in reductions 
in infarct volume after focal ischaemia (Kitagawa et al., 1999; Hermann et al., 2001b). 
Similarly, attenuation of infarct volume after focal ischaemia was achieved by 
intraventricular application of adenovirus containing the interleukin-l receptor 
antagonist gene, facilitating diffusion of the vector via CSF pathways and transgene 
expression in ependymal cells (Betz et al., 1995; Yang et al., 1997b; Yang et al., 1999). 
In contrast, viral vector mediated overexpression of intraneuronal proteins that cannot 
diffuse through brain parenchyma (e.g. Bcl-XL' Bcl-2, calbindin D28K) have generally 
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failed to attenuate infarct volume after focal ischaemia, although have protected against 
neuronal loss in the striatum and infarct margin (Yenari et ai., 2001; Kilic et ai., 2002; 
Zhao et ai., 2003). Thus, it appears that diffusion of the transgene product or 
widespread vector transduction may be necessary for global alterations in ischaemic 
damage. 
Two principal explanations are suggested for the neuroprotective effects observed 
after administration of Ad-APOE in the present study, which may not be mutually 
exclusive. ELISA and immunohistochemical analysis indicated that Ad-APOE 
administration resulted in substantial elevations in the amount of apoE. It is possible 
that the concentration of available apoE is the key factor in determining the response to 
acute brain injury. In support of this, the neuroprotective effects observed in a model of 
global ischaemia followed intraventricular administration of human plasma-derived 
apoE of mixed isoform (Horsburgh et al., 20oob), although it is likely that apoE was 
primarily of the E3 isoform since the APOE &3 allele occurs with greatest frequency 
(-78%) in humans (Davignon et al., 1988). Similarly, intraventricular administration of 
recombinant apoE3 and apoE4 both reduced cognitive impairment and neuronal 
degeneration in aged APOE-deficient mice (Masliah et ai., 1997). In humans, some 
studies have shown lower plasma and brain levels of apoE in APOE &4 patients with 
AD (Bertrand et al., 1995; Beffert et al., 1999; Panza et ai., 2003) and it has been 
proposed that APOE &4 carriers are more susceptible to brain injury and disease as a 
result of reduced levels of apoE (poirier, 1994). Alternatively, the key factor underlying 
neuroprotection in the present study may be apoE isoform-related since the gene 
encoding the ''beneficial'' apoE3 isoform was administered. As described previously, 
there is substantial in vitro and in vivo evidence for the neuroprotective and 
neurotrophic properties of the apoE3 isoform in the brain that appear to be independent 
of the level of apoE present. Notably, APOE &4 transgenic mice displayed a poorer 
outcome after global ischaemia, despite this line of mice having greater levels of apoE 
than APOE &3 mice (Horsburgh et al., 2000c). In addition, using the same lines of mice 
for the previous study of this thesis, APOE &4 transgenic mice also demonstrated a 
poorer outcome after focal ischaemia. Other studies in human tissue have also shown 
higher levels of CSF -apoE in APOE &4 carriers (in both cognitively normal individuals 
and patients with AD) (Hesse et al., 2000) suggesting apoE isoform- rather than apoE 
level-specific effects. It is also conceivable that neuroprotection was mediated by both 
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mechanisms described above, i.e. increasing levels of apoE by adenoviral 
administration of the "beneficial" apoE3 isoform. Regardless of the mechanism of 
neuroprotection, however, the present data indicate the clinical potential of modulating 
apoE3 levels in acute brain injury. 
6.4.4 Inflammatory and immune responses to adenoviral vectors 
The need for long-term transgene expression in acute brain injury is perhaps less critical 
than that required for chronic neurodegenerative conditions such as Alzheimer's 
disease. Nonetheless, safe and stable prolonged expression of a therapeutic gene is 
likely to provide greater benefits for treatment of acute brain injury in the human CNS. 
For example, in the case of apoE3, which has demonstrated both neuroprotective and 
neurotrophic effects in experimental brain injury, long-term expression could promote 
both neuroprotection in the acute phase after injury and regeneration/plasticity over a 
longer period. Accordingly, the inflammatory and immune response (not assessed in the 
current study) and degree of cytotoxicity (section 6.4.2) provoked by adenoviral 
administration to the brain have important implications for gene transfer strategies in 
human acute brain injury. Despite the traditional belief that the brain is an immune-
privileged site, there remains the capability for significant inflammatory and immune 
responses directed against transduced cells, the adenovirus itself and the transgene 
product, which can limit the duration of transgene expression (Byrnes et al., 1995; 
Wood et al., 1996). Immunity to adenoviral-mediated gene transfer is believed to 
comprise an early innate inflammatory and cell-mediated response against transduced 
cells, followed by a later humoral response (Smith et al., 1997; Kajiwara et al., 2000). 
Early infiltration of macrophages and release of the pro-inflammatory cytokines IL-1J3, 
IL-6 and TNF-a have been demonstrated after adenoviral vector application in the brain 
(Cartmell et al., 1999; Zou et aI., 2000). In addition, T- and B-cell activation has been 
shown after intracerebral injection of first generation adenoviral vectors carrying the 13-
galactosidase reporter gene (Kajiwara et al., 2000; Zou et al., 2000). 
Significantly, second generation vectors have been shown to elicit diminished 
macrophage and T-cell responses and mediate longer trans gene expression (Zou, et al., 
2000). Furthermore, second generation vectors can sustain stable and long-term 
transgene expression even in the presence of an active peripheral immunisation with 
adenovirus that completely eliminates expression from first generation vectors within 
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60 days (Thomas et ai., 2000). Thus, reduced immunogenicity and minimal cytotoxicity 
offers promise of safer and more stable gene transfer with second generation adenoviral 
vectors. 
6.4.5 Potential for adenoviral vector administration post-ischaemia 
An important consideration in the present study (and previous studies) is that adenoviral 
application was performed prior to focal ischaemia in order that maximal transgene 
expression coincided with the onset of ischaemia. Such a scenario is evidently not 
possible clinically and so it will be necessary to establish if the neuroprotective effects 
of APOE gene transfer are also evident when vectors are administered in the post-
ischaemic phase. Encouragingly, adenovirus-mediated GDNF gene transfer 
immediately after focal ischaemia in rats significantly reduced infarct volume, although 
when administration was delayed until Ih post-ischaemia the protective effects were 
lost, indicating a very small therapeutic time window (Zhang et ai., 2002). 
An important issue to determine is the effect that protein synthesis inhibition, a well 
established feature of the ischaemic brain (Xie et ai., 1989; Mies, 1993; Hermann et ai., 
2001a), has on the efficacy of gene delivery after the ischaemic insult. At present, it is 
unclear whether the residual protein synthesis capability would support sufficient levels 
of trans gene expression to promote neuroprotection. It was previously shown that 
expression of an adenoviral vector reporter transgene (~-gal) delivered 90min after focal 
ischaemia was inversely related to the severity of cerebral hypoperfusion with a CBF 
threshold for transgene expression estimated at 40% of the resting value (Ooboshi et ai., 
2001). Other studies have shown that expression of the ~-gal reporter gene is possible, 
although to a lesser extent than in uninjured brain, when vectors are administered after 
ischaemic or traumatic insults (Abe et ai., 1997b; Abe et ai., 1997c; Kochanek et ai., 
2001a; Zou et ai., 2(02). It is pertinent to note that neurons contribute most strongly to 
the total protein synthesis rate of brain tissue and are most susceptible to protein 
synthesis inhibition after cerebral ischaemia (Thilmann et ai., 1986; Widmann et ai., 
1992; Mies, 1993). Thus, it is possible that adenoviral transductionltransgene expression 
predominantly in glial cells, as observed in this study, may promote more efficient 
transgene expression since glial protein synthesis after ischaemia is likely to be less 
severely inhibited than that in neurons. In the present study, the abundant apoE 
immunoreactivity observed in Ad-APOE treated mice after focal ischaemia suggests 
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preservation of trans gene expression and protein synthesis to a certain degree, at least in 
glial cells, although the extent to which apoE immunoreactivity represents apoE 
synthesised prior to the ischaemic insult is unknown. 
An additional consideration if vectors are to be administered after the ischaemic 
insult is the effect of the inflammatory and immune responses induced by the ischaemic 
insult itself. Increased production of pro-inflammatory cytokines (e.g. IL-l(3, TNF-a.) 
occurs rapidly after cerebral ischaemia and is associated with macrophage infiltration 
and microglial activation (Feuerstein et al., 1998; Stoll et al., 1998; del Zoppo et al., 
2000; Boutin et al., 2001). In view of the role of the inflammatory response in limiting 
the duration of adenoviral vector transgene expression (section 6.4.4), the presence of 
inflammatory mediators and cells in the ischaemic brain may hamper expression of 
transgenes introduced during or after the ischaemic insult. Furthermore, the 
inflammatory response to ischaemia may be compounded by additional reactions caused 
by vector application (Zou et al., 2002). In this regard, second generation adenoviral 
vectors administered after TBI in the rat were shown to induce a less pronounced 
immune response and a longer period of transgene expression (2 months) compared to 
first-generation vectors, despite the existence of an inflammatory response to TBI and a 
humoral immune response to the adenovirus (Zou et al., 2002). Anti-inflammatory 
agents that dampen the inflammatory response to ischaemia may support more effective 
adenoviral transduction and trans gene expression. Interestingly, pre-treatment with the 
anti-inflammatory agents cyclosporin A or flurbiprofen was shown to attenuate the 
inflammatory response and fever after adenoviral gene transfer (Geddes et al., 1996; 
Cartmell et al., 1999; Wilkinson and Euhus, 2001). 
6.4.6 ConclUSions 
In summary, the present study has demonstrated that adenovirus-mediated gene transfer 
of APOE E3 was neuroprotective in a model of focal cerebral ischaemia and indicates 
the potential of such an approach for human stroke therapy. The aims stated at the outset 
of the study have been achieved: 
1. adenovirus-mediated gene transfer of APOE £3 substantially increased the levels 
of apoE in the brain 
2. adenovirus-mediated gene transfer of APOE £3 significantly reduced ischaemic 
brain damage after transient focal ischaemia in mice 
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Chapter 7 
General discussion 
7. Human stroke therapy and the therapeutic potential of apoE 
Currently, there is no effective treatment for stroke (and other forms of acute brain 
injury) in widespread use. The only approved method for treatment of acute stroke is 
thrombolysis, and then only in patients who satisfy stringent criteria for treatment. For 
the vast majority of stroke patients such intervention is unavailable and, furthermore, in 
the majority of patients who do meet the criteria, thrombolytic treatment is ineffective 
(Report of the Stroke Progress Review Group, 2002). In addition, several 
neuroprotective agents that have proved efficacious in animal models have failed to 
produce similar results in clinical trials (Green, 2002). The need for novel approaches to 
the development of stroke treatment is therefore apparent. One reason that has been 
proposed for the failure to translate pre-clinical promise into clinical success is that 
most strategies have targeted individual mechanisms that lead to damage (Green, 2000; 
Leker and Shohami, 2002). For example, blocking excitotoxic-mediated necrotic cell 
death may only serve to divert cells along an apoptotic pathway (Choi, 1996; Lee et al., 
1999). Two strategies for overcoming this problem have been suggested. The first is the 
use of combination drug therapy with each agent active against a different individual 
mechanism. In support of this, a number of studies have shown synergistic 
neuroprotective effects when drug combinations have been used in in vitro and in vivo 
models of ischaemia (Schulz et al., 1998; Arias et al., 1999; Schabitz et al., 1999; Chen 
et al., 2002; Zausinger et al., 2003a; Zausinger et al., 2003b; Culmsee et al., 2004). The 
second strategy would be to use a single agent active against multiple mechanisms of 
damage. In this regard, apoE may be a candidate molecule since there is evidence that 
apoE, in particular the E3 isoform, can counteract the damaging effects of several 
pathophysiological mechanisms implicated in cerebral ischaemia, including 
excitotoxicity, oxidative stress, inflammation and apoptosis (section 1.5). In support of 
this, results from this thesis and previous studies suggest that restoring and/or increasing 
apoE levels can promote neuroprotection in the ischaemic brain. 
Increasing apoE levels in the brain would therefore appear to be a tempting strategy 
to pursue. Several approaches could be used to augment endogenous apoE levels: (1) 
direct intrathecal administration of apoE in lipid-conjugated form (Horsburgh et al., 
2000b) or via viral vector (chapter 6); (2) intrathecal or systemic administration of apoE 
mimetic peptides (that could cross the blood-brain barrier) (Aono et al., 2003); (3) 
administration of agents that can increase apoE expression levels. A key consideration 
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of any approach, however, would be the potential systemic side effects of increasing 
apoE levels given the fundamental role of apoE in lipid and cholesterol homeostasis in 
the periphery. In this regard, restricting increased apoE expression to the brain would be 
an important advantage. Since there is no clear evidence that apoE crosses the blood-
brain barrier, direct intrathecal administration/viral vector-mediated delivery of apoE 
could achieve brain-specific increases in apoE. However, even with these approaches, 
blood-brain barrier disruption in the injured brain could result in leakage of apoE into 
the systemic circulation. Systemic administration of apoE mimetic peptides (containing 
the receptor binding region) could traverse the blood-brain barrier, although it is highly 
likely this approach would have systemic actions. 
Another key issue relates to APOE polymorphism. Although the precise 
mechanism(s) responsible for APOE genotype-dependent responses to brain injury are 
not fully understood, there is evidence that differences may be due to beneficial 
properties of the apoE3 (and apoE2) isoform (that are absent in the apoE4 isoform) but 
also to direct toxic properties of apoE4 (section 1.5.4). These divergent effects of apoE 
isoforms could preclude development of a single drug that would benefit patients of all 
APOE genotypes. For example, a drug that indiscriminately enhances apoE expression 
in the brain may be beneficial in APOE £3 (and £2) carriers (promotes beneficial 
apoE31E2 effects) but have mixed effects in APOE £4 carriers (compensates for effects 
due to apoE4 deficiency but also promotes toxic apoE4 effects). Significantly, in the 
periphery, increasing apoE levels could have contrasting implications to those in the 
brain. APOE £4 carriers (who have a lower plasma apoE concentration) may benefit 
from increased apoE reducing plasma cholesterol and risk of atherosclerosis whereas in 
APOE £2 carriers (who have a higher apoE concentration) there would be a greater risk 
of hyperlipoproteinaemia (Mahley and RaIl, 2000). Again, this highlights the 
advantages of restricting the effects of an apoE-based therapeutic approach to the brain. 
In view of the above pharmacogenomic issues, specifically enhancing apoE3 
effects could be advantageous. This approach was employed in this thesis by indirectly 
increasing brain apoE3 levels via viral vector administration and resulted in a 50% 
reduction in ischaemic damage after focal ischaemia. Alternatively, promoting apoE3-
specific effects could be achieved by administration of the apoE3 isoform (in 
protein/mimetic form) alone. It would be interesting to investigate the effects of 
administration/viral vector mediated expression of apoE3 on the response to cerebral 
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ischaemia in APOE t4 transgenic mice. Another strategy for specifically promoting the 
effects of apoE3 over apoE4 is based on the structural differences of these isoforms that 
are believed to underlie their different biochemical properties (Dong and Weisgraber, 
1996; Raffai et al., 2001). Small molecule compounds (e.g. GIND-25, GIND-I05) have 
been discovered that can disrupt apoE4 domain interactions and convert the 
confonnation of apoE4 to apoE3. Significantly, such domain alterations in apoE4 can 
induce apoE4 to acquire biochemical features akin to those of apoE3 in vitro (Xu et al., 
2004). 
A third consideration with an apoE-based therapeutic approach would be the 
duration of apoE expression that could be achieved. The ability to mediate prolonged 
apoE expression after acute brain injury, while less important than in neurodegenerative 
disease, could provide more long-term benefits than a transient period of expression 
(although there may also be limitations to high-level long-term apoE expression, see 
below). For example, apoE (particularly apoE3) has been shown to have both 
neuroprotective and neurotrophic properties, which could promote neuroplasticity and 
long-term functional recovery. In this regard, a viral vector-mediated APOE gene 
transfer approach, as used in this thesis, would be most suitable. In the uninjured brain, 
there is evidence that adenoviral-mediated trans gene expression can persist for months 
after administration, even with a subsequent immune challenge against the virus 
(Thomas et al., 2000). It is unclear as yet if this could be achieved when the vector is 
administered after an ischaemic insult, although continued improvements in vector 
design are likely to further reduce the induction of inflammatory and immune responses 
that can restrict transgene expression. 
Conversely, it should be considered that uncontrolled long-term overexpression of 
apoE could also have deleterious effects in the brain via its putative interactions with 
AJ3. It has been proposed that apoE can promote the conversion of diffuse, non-fibrillar 
AJ3 deposits to the fibrillar form found in neuritic plaques (jor review, see Bales et al., 
2002). Mice that overexpress mutant APP and are APOE deficient display substantially 
less neuritic plaques than mutant APP mice expressing wild-type apoE despite similar 
brain AJ3 levels, indicating that apoE expression facilitates AJ3 fibrillogenesis and 
amyloid plaque formation (Bales et at., 1997; Bales et al., 1999; Holtzman et al., 1999; 
Holtzman et al., 2000a; Holtzman et al., 2000b). This is particularly relevant in stroke 
therapy since most strokes occur at an advanced age when AJ3 deposition is more 
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prevalent. Thus, a system to permit regulated apoE expression would have major 
benefits. 
Several systems with the potential to regulate viral vector-mediated trans gene 
expression are being explored and are based on the idea that transgene expression can 
be regulated by an inducible, co-expressed transcription factor. Induction should be 
reversible and should not activate other genes. The most widely explored regulation 
system is based on bacterial tetracycline resistance regulation (Tet system). The 
bacterial protein, TetR binds to its target DNA, the tet operator (tetO) only in the 
absence of tetracycline. Bujard and colleagues (Gossen and Bujard, 1992) engineered 
TetR and attached it to a eukaryotic transcription activator (tTA). In the presence of 
tetracycline (or a derivative) tT A cannot bind tetO and expression of the trans gene, 
which is downstream of tetO is prevented. Conversely, in the absence of tetracycline, 
transgene expression can be activated. Significantly, the level of transgene expression 
can also be regulated with this system by modulating the dose of tetracycline 
administered. Studies have shown that adenoviral vector-mediated temporally 
controlled trans gene expression in the brain can be achieved by incorporation of the Tet 
system (Harding et ai., 1997; Harding et ai., 1998; Ralph et ai., 2000; Smith-Arica et 
ai., 2000; Block et ai., 2003). Furthermore, cell-specific inducible transgene expression 
has been achieved by expressing Tet elements under the control of the NSE and GF AP 
promoters (Ralph et ai., 2000; Smith-Arica et ai., 2000). 
Thus, it would seem that, in future, using such systems to temporally, spatially and 
quantitatively regulate viral vector-mediated apoE overexpression would otTer the 
greatest clinical potential for an apoE-based therapeutic approach in human stroke. 
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Appendices 
Appendix A. Stock solutions 
Phosphate buffer (50mM, pH7.4) 
lOx stock solution 
• In 900ml distilled H20 dissolve: 
- 2.57g sodium dihydrogen orthophosphate (NaH2P04) 
- 11.95g disodium hydrogen orthophosphate (Na2HP04) 
• Add IOOmI distilled H20 and pH to 7.4 
• Filter and store at 4°C 
• Dilute 1: lOin distilled H20 as required 
Phosphate buffered saline (50mM, pH7.4) 
lOx stock solution 
• In 900ml distilled H20 dissolve: 
- 2.57g sodium dihydrogen orthophosphate (NaH2P04) 
- 11.95g disodium hydrogen orthophosphate (Na2HP04) 
- 86.67g sodium chloride (NaCI) 
• Add lOOmI distilled H20 and pH to 7.4 
• Filter and store at 4°C 
• Dilute 1: lOin distilled H20 as required 
Paraformaldehyde fixative (4%, pH7.4) 
• Heat 900m1 phosphate buffer to 65°C 
• Add 40g paraformaldehyde and maintain temperature at 65°C until completely 
dissolved 
• Add IOOmI phosphate buffer and pH to 7.4 
• Filter and store at 4°C 
'I 
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Appendix B. Summary of mouse numbers for all experiments 
Experiment Groups n Deaths Excluded* n for analysis 
Chapter 4 
Comparison of 5-0 and 6-0 filament 5-0 5 0 0 5 
6-0 5 0 0 5 
Effect of occlusion duration on 15min 8 0 2 6 
ischaemic damage 30min 8 1 2 5 
60min 7 2 a 5 
Effect of occlusion duration on cerebral 15min 6 a a 6 
blood flow 6amin 6 a a 6 
15min (sham) 4 a a 4 
6amin (sham) 4 0 0 4 
Effect of occlusion duration on blood occlusion 8 a a 8 
pressure sham 6 a a 6 
Examination of cerebrovascular 10 a a 1a 
anatomy 
Chapter 5 
All experiments APOE 3 17 2 8 7 
APOE 4 2a 2 11 7 
Chapter 6 
Characterisation of adenoviral vehicle a 0 1 
transduction and transgene expression Ad-GFP 3 a a 3 
Ad-APOE 3 a a 3 
Effect of Ad-APOE administration on vehicle 5 
outcome and apoE immunostaining Ad-GFP 6 
after focal ischaemia Ad-APOE 6 
Effect of Ad-APOE administration on vehicle 2 0 a 2 
apoE levels Ad-GFP 2 a a 2 
Ad-A POE 2 a a 2 
*Reasons for excluding mice are given in individual Results chapters. 
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Appendix C. Control and global ischaemia cohort: clinical 
details 
Controls 
Gender Age Clinical event APOE genotype 
1 F 42 mycosis fungoides 2,4 
2 M 72 carcinoma of lung/stomach 3,4 
3 M 55 stomach lymphoma/pulmonary embolism 3,3 
4 M 43 Hodgkin's lymphoma/ventricular failure 3,3 
5 F 50 carcinoma of breast 3,3 
6 M 47 septicaemia 3,3 
7 F 64 carcinoma of breast 3,3 
8 M 71 bronchopneumonia 4,4 
9 F 69 renal failure 4,4 
10 M 56 electrocution ? 
11 M 64 hepatic failure 3,3 
12 M 63 unknown progressive debilitating disease 3,3 
13 F 48 pulmonary oedema ? 
14 M 74 cervical myelopathy/cardiac arrest 3,4 
15 F 62 volvolus of sigmoid colon 3,3 
16 M 45 myocardial infarction 3,3 
17 M 57 non-Hodgkin's lymphoma 2,3 
18 M 59 bronchopneumonia 3,3 
19 F 70 pulmonary thrombo-embolism 3,3 
20 F 44 cervical lesion/sudden death 3,3 
21 M 20 drug overdose 3,4 
22 M 35 bronchopneumonia 2,3 
23 M 52 ischaemic heart disease 3,3 
24 F 24 pulmonary oedema and congestion 3,3 
25 M 82 bronchopneumonia 3,3 
26 F 46 septicaemia 3,4 
27 M 69 acute cardiac failure 3,3 
28 M 33 Crohn's disease/GI tract adenocarcinoma 3,4 
29 M 60 carcinoma of lung/pulmonary thrombo-embolism 3,3 
30 F 33 sudden cardiac death 3,3 
31 M 62 pulmonary congestion and oedema 3,3 
32 M 33 acute tracheobronchitis 3,3 
33 M 62 rhabdomyolysis-hyperkalaemic cardiac arrest 3,3 
34 F 21 septicaemic shock 3,4 
35 M 20 inhalation of gastric contents ? 
36 F 56 systemic sclerosis/cardiac failure 3,4 
37 M 38 congestive cardiac failure 2,4 
38 M 18 Hodgkin's lymphoma 3,3 
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Global ischaemia 
Gender Age Survival Clinical event APOE genotype 
1 F 73 3d cardiorespiratory arrest 3,3 
2 F 21 4d cardiorespiratory arrest 3,3 
3 M 30 2.5d cardiorespiratory arrest 3,3 
4 M 64 4d arterial occlusion 3,3 
5 F 48 6d cardiorespiratory arrest 3,4 
6 F 68 19d cardiorespiratory arrest 3,3 
7 M 17 3d cardiorespiratory arrest 3,3 
8 M 53 10h cardiorespiratory arrest 3,3 
9 F 50 6 weeks cardiorespiratory arrest 3,3 
10 F 50 3d cardiorespiratory arrest 3,3 
11 M 49 18h cardiorespiratory arrest 3,4 
12 M ? 3 months cardiorespiratory arrest 3,4 
13 M 73 <24h cardiorespiratory arrest 3,3 
14 M 66 1d hypoxia-CA 3,3 
15 F 62 1d cardiorespiratory arrest 2,4 
16 M 53 1d cardiorespiratory arrest 3,4 
17 M 46 10d hypoxia 3,3 
18 F 39 4d cardiorespiratory arrest 3,3 
19 M 62 9d cardiorespiratory arrest 3,3 
20 M 54 2d cardiorespiratory arrest 3,3 
21 M 25 2d bilateral carotid artery occlusion 4,4 
22 M 81 34h cardiorespiratory arrest 3,3 
23 M 68 4d cardiorespiratory arrest 3,4 
24 F 37 <1d cardiorespiratory arrest 3,3 
25 F 35 ? hypoxia 3,4 
26 M 85 3h cardiorespiratory arrest 2,3 
27 M 43 3d cardiorespiratory arrest 3,3 
28 M 56 1d cardiorespiratory arrest 2,3 
29 F 38 9d cardiorespiratory arrest 3,4 
30 F 53 22d hypoxia 3,3 
31 M 23 5d hypotension 3,3 
32 M 57 10d hypotension 3,4 
33 M 43 24h hypotension 3,3 
34 M 35 36h cardiorespiratory arrest 3,3 
35 M 54 3d hypoxia/aspiration 3,4 
36 M 69 2d cardiorespiratory arrest 3,3 
37 F 62 8d cardiorespiratory arrest 3,4 
38 F 48 1d asphyxia 3,3 
39 M 47 5d cardiorespiratory arrest 4,4 
40 M 65 13d cardiorespiratory arrest 3,3 
41 F 53 36h cardiorespiratory arrest 3,3 or 2,3 
42 F 38 2d cardiorespiratory arrest 3,4 
43 F 23 11 h cardiorespiratory arrest 3,4 
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Appendix D. Semi-quantification of immunoreactivity in 
human temporal lobe: validation and 
reproducibil ity 
Validation 
To validate my semi-quantitative analysis of immunoreactivity, my semi-quantitative 
scores were compared to scores assigned by Dr Karen Horsburgh who had previously 
used the same scoring system in this tissue. This showed that my scores were 
comparable to those obtained by Dr Horsburgh as shown below. 
Degree of neuronal rabaptin-5 Degree of glial rabaptin-5 
immunoreactivity immunoreactivity 
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Reproducibility 
To test the reproducibility of my semi-quantification, scores were compared from two 
separate scoring sessions. Semi-quantitative scores were comparable in both sessions 
indicating consistency in semi-quantification. 
Degree of neuronal rabaptin-5 Degree of glial rabaptin-5 
immunoreactivity immunoreactivity 
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Appendix E. Volumetric measurement of ischaemic damage: 
reproducibility 
Potential errors in quantification of ischaemic damage can arise from several sources: 
selection of sections at appropriate coronal levels; microscopic identification of areas of 
ischaemic damage; transcription to line diagrams and image analysis assessment. To 
test reproducibility (which incorporated all potential sources of error indicated above), 
the volume of ischaemic damage was measured in C57B1I6J mice on two separate 
measurement sessions and compared. As shown below, reproducibility of volumetric 
measurement on two separate occasions was excellent (P < 0.001,';' = 0.99). 
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Appendix F. Measurement of local cerebral blood flow: 
reproducibility 
Densitometric measurement is a key component in the quantification of local cerebral 
blood flow (LCBF) (see section 2.11.4). Potential errors in densitometry (e.g. 
calibration of image analyser, discrimination of anatomical structures) will have a major 
impact on the calculation of LCBF. To test reproducibility, LCBF was calculated in the 
12 neuroanatomicalloci ipsilateral and contralateral to occlusion using densitometric 
measurements of 14C concentration acquired on two separate measurement sessions. As 
shown below, there was a high level of consistency (P < 0.001,? = 0.97). 
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Appendix G. Volumetric measurement of apoE 
immunostaining in APOE transgenic mice: 
reproducibility 
Similar sources of error to those encountered during volumetric measurement of 
ischaemic damage (see appendix C) can also arise during volumetric measurement of 
apoE immunostaining. To test reproducibility, the volume of apoE immunoreactivity 
was measured in APOE transgenic mice on two separate occasions. As shown below, 
there was a high level of reproducibility (P < 0.001,1- = 0.95; Pearson correlation) 
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Appendix H. Semi-quantification of immunoreactivity in APOE 
transgenic mice: reproducibility 
To test the reproducibility of semi-quantification of apoE, rabaptin-5 and rab4 
immunoreactivity, semi-quantification was performed on two separate occasions and 
scores compared. As indicated below, reproducibility of semi-quantification was 
excellent for apoE (P < 0.001, ? = 0.91; Pearson correlation), rabaptin-5 (P < 0.001, ? 
= 0.94; Pearson correlation) and rab4 (P < 0.001,? = 0.97; Pearson correlation). 
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Appendix I. Volumetric measurement of apoE immunostaining 
after viral vector or vehicle administration: 
reproducibility 
Reproducibility of volumetric measurement of apoE immunostaining was shown 
previously in APOE transgenic mice (see appendix D). However, in chapter 6 
volumetric measurement of apoE immunostaining was performed at lower 
magnification (x25) (see section 6.2.4.5). To test reproducibility, the volume of apoE 
immunoreactivity determined at low magnification (x25) was measured on two separate 
occasions. There was a high level of reproducibility (P < 0.001, .; = 0.99; Pearson 
correlation). 
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Appendix J. Association between ischaemic damage and apoE 
immunoreactivity after Ad·APOE administration 
Associations between (a) the volume of ischaemic damage and apoE immunoreactivity 
and (b) the area of ischaemic damage and apoE immunoreactivity at injection level were 
assessed. There was a trend toward an inverse relationship between the volume or area 
of ischaemic damage and apoE immunoreactivity. However, it was recognised that there 
were too few data points (not normally distributed) to test the statistical significance of 
this relationship. 
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